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ABSTRACT
This thesis describes the development and application of 
a PCR based method of typing HLA-DPB1 alleles. The 
technique, called amplified fragment length polymorphism 
(AFLP), is based on analysis of polymorphic restriction 
enzyme recognition sequences in the second exon of DPB1, 
which encodes the polymorphic ßl domain of the HLA-DP 
molecule. Polymorphic restriction sites were identified 
from published DPB1 allele sequences and predicted 
fragment sizes were calculated. The combination of four 
enzymes, Eco NI, Fok I, Mnl I and Rsa I, were found to 
give allele specific fragment patterns for the 19 
recognised DPB1 alleles. The restriction fragments 
could be detected by ethidium bromide staining following 
polyacrylamide gel electrophoresis.
This procedure permits all but two pairs of heterozygote 
allele combinations to be distinguished by the scheme. 
One of the two pairs of non-discriminated heterozygotes 
could be seperated with a further restriction digest, 
while the other pair, containing rare alleles, is also 
inseparable by sequence specific oligonucleotide (SSO) 
typing. A method of discriminating this pair using a 
combination of AFLP and SSO typing is described. The 
AFLP scheme was tested by the typing of 31 DNA samples 
from the 10th International Histocompatibilty Workshop 
(10IHW) cell line panal. The results agreed with those 
obtainded by other typing methods including SSOs. The
VII
AFLP technique was then applied to two healthy 
population samples and to samples of insulin-dependent 
diabetes mellitis (IDDM) and multiple sclerosis (MS)
7patients.
Population samples of White Australians and South 
Indians were typed by AFLPs. The White Australian 
allele distribution agreed with published DPB1 allele
frequencies obtained by SSO typing. Results of AFLP and 
restriction fragment length polymorphism (RFLP) typing 
were compared and it was discovered that the RFLP 
analysis may be inaccurate in non-European populations. 
Samples that were previously HLA-DR typed were used to 
investigate linkage disequilibrium between the HLA-DR and 
-DP loci. Two previously reported associations were 
observed in the White Australians sample; DR2 and 
DPB1*0401; DR7 with DPB1*0801 to *1901. One previously 
unreported association was observed in South Indians; 
DR6Dwl3 and DPB1*1301.
HLA-DP and IDDM associations were investigated in two 
ethnic groups. In White Australians there was a 
positive association with DPB1*0301, in agreement with 
previous RFLP studies. In the South Indian sample a 
previously unreported negative association between 
DPB1*1301 and IDDM was observed. Alleles with a luecine 
residue at amino acid position 65 were more closely 
associated with IDDM in both ethnic groups than were 
positions corresponding to 57 or 70, implicated as being 
involved in IDDM susceptibility in HLA-DQB1 and DRB1
VIII
alleles respectively. DPB1*1301 was found to have a 
strong negative association with IDDM, the protective 
effect could best be described by a specific second 
hypervariable region sequence rather than by a single 
amino acid position.
HLA-DPB1 and MS associations were investigated in White 
Australians, where it was observed that DPB1*0301 was 
associated with MS only in patients without DR2, an 
antigen associated with MS. DPB1*0401, an allele 
reported to be positively associated with MS showed a 
trend of increased occurence in DR2 positive patients, 
and can be explained by linkage disequilibrium with DR2. 
As DR2 is associated with the progressive form of MS, it 
is implied that DPB1*0301 may be associated with the 
less progressive form of the disease.
During the typing of the 10IHW cell lines a novel AFLP 
pattern was observed. The DPB1 second exon PCR product 
was sequenced by automated direct sequencing. Results 
using the heterozygote as sequencing reaction template, 
along with AFLP data allowed the identification and 
manufacture of a first hypervariable region specific PCR 
amplification primer that only amplified the novel 
allele in the heterozygote. The resulting sequence 
conforms to the expected pattern of variation seen 
amoungst the other DPB1 alleles. All heterozygote 
combinations containing the novel allele can be 
descriminated. The new allele has been observed in two 
Asian populations.
IX
The AFLP technique is shown to be a simple and accurate 
procedure for typing HLA-DPB1 alleles. It can be used 
to separate all but one of the 190 possible heterozygote 
combinations, and is able to identify novel sequence 
variation. The technique requires no radioactive 
isotopes or hybridization procedures and is cost 
effective compared to SSO typing over low to moderate 
sample sizes.
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Chapter 1
General Introduction
11.1. HISTORY
An understanding of the major histocompatibility complex 
(MHC) arose from two initially independent lines of inquiry 
which led to the discovery of the mouse MHC system.
Tumour tissue transplantation experiments performed on mice 
at the turn of the century (Loeb 1901) led to the 
conclusion that tissue rejection had a genetic basis and 
inheritance that could only be explained by the involvement 
of multiple genes (Little and Tyzzer 1916). In his search 
for tumour specific antigens, Gorer (1937) discovered an 
antigenic determinant which was shared between graft and 
host in successful tissue transplants. This determinant 
became known as histocompatibility 2, or H-2 (Gorer et al 
1948). It was later realised that alleles of H-2 existed 
in other mouse strains (Amos et al 1955), and that H-2 was 
in fact a complex, i.e. that it encoded multiple serologic 
specificities (Gorer and Mikulska 1959).
The second line of inquiry arose from the attempt to 
describe the immune response to foreign antigens. It was 
discovered that different synthetic polypeptides gave 
strain specific responses in the guinea pig (Levine et al 
1963), an observation repeated in other inbred laboratory 
animals including the mouse (McDevitt and Sela 1965). It 
was thought that the responsiveness to certain antigens was 
controlled by immune response (Ir) genes and in 1969, 
McDevitt and Chinitz showed that the H-2 type of a mouse
could predict its Ir type, implying that the two loci were 
linked.
Some Ir genes mapped to a region outside the Ir region, 
named the I region (McDevitt et al 1972), mouse strains 
that differed only at the I region were developed and led 
to the description of the immune associated (la), region 
(Klein and Huaptfeld 1976, McDevitt et al 1976). As the 
MHC systems of other animals were studied and the molecular 
biology of the H-2 complex became clearer the Ir and la 
regions became known as the class II region.
2
In 1958 the first human leucocyte associated (HLA) antigen, 
"Mac", was defined serologically (Dausset 1958), however it 
was some time before it was realised that "Mac" was in fact 
analogous to an H-2 molecule. As the study of the HLA 
system used specific antisera to define HLA antigens, an 
international standard of typing protocols and reagents had 
to be developed. This was achieved at the first 
International Histocompatibility Workshop (Amos 1965), and 
subsequent Workshops have resulted in the development of a 
system of nomenclature for HLA antigens as well as a better 
understanding of the structure and function of the HLA 
system.
HLA-DP was the last expressed class II locus identified. 
Positive MLC between HLA-A, B, C and DR matched individuals 
(Mawas et al 1978, Reisnmoen et al 1979) and serological 
studies (Charron and McDevitt 1979, and Nadler et al 1981)
3both suggested the existence of additional polymorphic 
genes within the class II region. In 1980, the so called 
secondary B cell (SB) antigens were described by primed 
lymphocyte typing (PLT). It was noted that the SB 
antigens did not stimulate a strong primary response, i.e. 
by the mixed lymphocyte reaction (MLR) but did stimulate a 
strong secondary response (Shaw et al 1980). In 1981 the 
SB locus was mapped between the HLA-DR and Glyoxalase I 
loci (Shaw et al 1981) and the genes first mapped and 
seguenced in 1984 (Gorski et al 1984). At the Ninth 
International Histocompatibility Workshop, the nomenclature 
of the class II system was revised and SB was renamed DP, 
and six PLT defined specificities (DPwl-6) were recognised 
(Hartzman et al 1984).
1.2. STRUCTURE OF HLA MOLECULES
1.2.1. Class I antigens
HLA-class I proteins are membrane bound cell surface 
antigens found on almost all nucleated cells. On a typical 
cell, class I proteins represent about 1% of the total 
membrane protein (Strachen 1987). The HLA class I molecule 
is 45 KDa transmembrane protein which is non-covalently 
associated with a 12 KDa non-polymorphic, highly conserved 
serum protein called ß2 microglobulin encoded on chromosome 
15 (Fig 1.1). The HLA class I antigen is made up of three
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5extracellular domains, al, ol2 and a3 , as well as 
transmembrane and cytoplasmic domains. Each extracellular 
domain is about 90 amino acids long, the polymorphic a2 and a3 
domains and ß2 microglobulin contain a disulphide bond, a 
conformation characteristic of immunoglobulin like domains. 
ß2 microglobulin associates with class I molecules in the 
Golgi complex. Three class I genes have been defined 
serologically, HLA-A, HLA-B and HLA-C, however there are at 
least 17-HLA like loci in the class I region (Roller et al, 
1988). Some of these loci are known to be pseudogenes 
(Strachan 1987), while other loci have been found to 
express class I chains and may be related to the murine 
non-classical class I gene families, Qa and Tla (Kappes and 
Stominger 1988). Three non-classical class I genes have 
been described, HLA E, F and G, which express class I 
chains but with limited tissue distributions (Wei and Orr 
1990).
1.2.2. Class II antigens
The HLA class II antigens are membrane bound heterodimers 
made up of a 33-34 KDa a chain and a 28-29 KDa ß chain (see 
Fig 1.1) . The a and ß polypeptides are glycosolated and 
non-covalently associated. Each class II chain has two 
extracellular domains, the polymorphic cell distal domains, 
al and ß l , which contain the antigen binding site, and the 
immunoglobulin-like a2 and ß2 domains. The a and ß chains 
also have transmembrane (TM) and cytoplasmic (CY) domains.
;gest the TM and CY domains are
6not important in the assembly and function of the class II 
molecules, however the removal of as few as six amino acids 
from the CY domain will cause an increase in the rate at 
which the protein moves on the cytoplasmic membrane, which 
implies that the CY domain does interact with cytoplasmic 
proteins (Wade et al 1989).
1.2.3. The antigen binding site
The three dimensional structure of the HLA class I 
molecule has been described from X-ray crystallography 
studies of the HLA-A2 (Bjorkman et al 1987a ) and HLA-Aw68 
antigens (Garret at al 1989). The structurally similar 
cell proximal domains, a3 and ß2 microglobulin, form a 
stalk consisting of two antiparallel /3-pleated sheets, on 
top of which lie the al and a2 domains which together form 
the antigen binding site. The antigen binding site 
consists of an anti-parallel ^-pleated sheet which forms a 
base on which an antigen binding cleft is formed between 
two stretches of a-helix. The al and a2 domains both 
contribute to the slightly curved a-helix regions which 
form the two sides of the cleft.
The binding site is a deep groove approximately 250 nm long 
and up to 100 nm wide. The groove is large enough to bind 
a 20 amino acid a-helix or a nine amino acid extended 
polypeptide chain. It is possible that polypeptides larger 
than this could be accommodated either if they extend up
7from the groove or, since one end of the groove is open, if 
they extend beyond the groove (Bjorkman et al 1987b).
Analysis of the amino acid sequence variation of the al and 
a2 domains in the context of the three dimensional 
structure of the antigen binding site has shown that most 
polymorphic amino acid positions lie within the groove, 
either on the a-helices or on the /3-pleated sheet floor.
Most of the polymorphic sites would be covered when the 
binding site is occupied. Ten highly conserved residues 
also point out from the groove, which probably recognise 
conserved features on the antigenic peptides (Bjorkman et 
al 1987b). The TCR complex recognises conserved amino acid 
residues on the class I membrane proximal domains.
The main function of class I molecules is the presentation 
of immunogenic peptide to T cells. Foreign antigen is 
bound to the antigen binding site, and the class I 
molecule/antigen complex acts as the ligand for the T cell 
receptor which interacts with residues on the al and a2 
domains, while the T cell surface protein, CD8, interacts 
with residues on the a3 domain (Salter et al 1989) .
Brown et al (1988) developed a model of the three 
dimensional structure of the class II antigen binding site 
based on the positions of highly polymorphic and highly 
conserved sites, and the cystein residues involved in 
intra-domain binding. The three dimensional structure of 
the class I and II molecules antigen binding sites appear 
to be very similar. The polymorphic class II domains, al 
and ß l , have similar folding patterns to the class I al and
8ö2 domains, and the class II ql2 and ß2 domains are 
analogous to the class I a3 domain and ß2 microglobulin 
(Brown et al 1988). However an accurate model of the three 
dimensional structure of class II antigens awaits X-ray 
crystallographic analysis.
When polymorphic sites in Class II gene nucleotide 
sequences were analysed it was discovered that in the first 
extracellular domain had a much higher rate of 
nonsynonymous amino acid substitutions (i.e. amino acid 
altering) than other regions of the class II genes (Hughes 
and Nei 1988). Hughes and Nei (1989) suggest that this 
observation is consistent with overdominant selection at 
class II loci. This means rare alleles are selected for 
and are not lost from the population. and provides an 
explanation for the high level and maintenance of allelic 
polymorphism in the HLA region.
1.3. THE INVARIANT CHAIN
During the synthesis and assembly of the class II molecule, 
the class II a and ß chains are associated with a non- 
polymorphic, heavily glycosylated or proteoglycanated 
polypeptide called the gamma or invariant (I) chain (Blum 
and Cresswell 1988), encoded by a gene on the long arm of 
chromosome 5 (Genuardi and Saunders 1988). The I chain is 
cleaved off the class II molecules in the same 
intracellular compartment in which antigen is processed to 
produce immunogenic peptide (Cresswell 1987) . Cells which
9do not express the I chain still express functional class 
II molecules, however, the class II molecules have altered 
conformations shown by monoclonal antibody binding, and 
show an increased ability to present antigen (Paterson and 
Miller, 1990). The I chain is thought to facilitate the 
correct conformation of newly synthesized class II 
molecules and to have some role in the regulation of 
antigenic peptide binding to the class II molecule 
(Hämmerling and Moreno 1990).
1.4. TISSUE DISTRIBUTION OF CLASS II ANTIGENS
The class II antigens are found only on cells capable of 
presenting antigen to T cells (APC). They are 
constitutively expressed on cells such as on B cells, 
macrophages, and dentritic cells. The class II molecules 
can be induced on other cell types such as resting T cells, 
when stimulated by a mitogen, or endothelial cells and 
dermal fibroblasts, when stimulated by gamma interferon 
(Cresswell 1987). Class II antigens are also found on some 
cell types which do not normally have access to T cells, 
such as vascular endothelial cells, thymic epithelium, and 
langerhans cells. Class II antigens are not expressed on 
most other somatic cells.
The three class II isotypes, HLA-DR, -DQ and -DP, are 
differentially expressed. Unstimulated T cells express 
only HLA-DP and upon T cell maturation, first DP then DR 
are expressed (Brown et al 1984), suggesting that DP may
10
have some role in T cell maturation. Class II antigens are 
expressed on the gut epithelium; in the bowel, both HLA-DR 
and HLA-DP are expressed on the apical regions of the villi 
with little or no expression on the immature crypt cells. 
HLA-DQ, however, is not expressed on the epithelium at all, 
and instead is found only on the underlying lamina propria 
along with HLA-DP and -DR (Bland 1988, Kelly et al 1988).
During human foetal development it appears that HLA-DR is 
expressed first and HLA-DP positive cells do not appear 
until the mid second trimester (Oliver et al 1988).
Cultured amniotic fluid cells (fibroblast and epitheliod 
cells) can be induced to express class II molecules by 
gamma interferon, HLA-DR and -DP but not HLA-DQ molecules 
are expressed (Maurer et al 1987).
1.5. FUNCTION
Class I and II molecules have two major functions, the 
presentation of foreign antigen to T cells as part of the 
cellular immune response to infection, and as the major 
allorecognition elements. As part of both functions, the 
class I and II molecules and bound antigenic peptide 
interact with the T cell receptor (TCR), a highly 
polymorphic heterodimeric cell surface receptor expressed
on T cells.
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1.5.1. The T cell receptor
TCR polymorphism is generated by specific gene 
rearrangement of constant, variable, and joining genetic 
domains similar to immunoglobulin genes. The generation of 
TCR diversity allows T cell recognition of a wide range of 
antigenic and allogeneic determinants. The TCR recognises 
polymorphic and non-polymorphic determinants on both HLA 
antigens and on the bound antigenic peptide.
When the TCR interacts with a class I or II molecule, a 
number of physiological changes occur in both antigen 
presenting cells (APC) and T cells. In APC the levels of 
intracellular calcium increases (Roosnek et al 1988), and a 
protein kinase is activated. In the T cell lymphokines 
such as interluekin 2 are expressed, which stimulate the 
immune system, and causes the proliferation of the 
stimulated T cell.
T cell restriction is the ability of the TCR to recognise 
antigenic peptide only when it is bound to particular 
isotypes of class II molecule. However synthetic antigenic 
peptide, when added to APCs, will bind only to certain 
class II alleles, which suggests antigen binding is also 
class II restricted (Guillet et al 1986, Babbit et al 
1985). HLA-DR appears to be the dominant restriction 
element for the TCR, in mouse transgenic cells most 
alloreactive T cells were DR restricted despite all three 
HLA class II molecules being expressed at equal levels 
(Nezu at al 1990).
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1.5.2. Antigen presentation
Class I and II antigens present foreign antigens to 
cytolytic T cells (CD8 positive) and helper (CD4 positive)
T cells respectively. Although the antigen binding site 
can accommodate only small peptide fragments (Bjorkman et 
al 1987a), T cells can discriminate between a very wide 
range of determinants. Both class I and II molecules 
present degradation products of peptide antigen; APCs are 
able to present in vi t ro proteolysed antigen added 
exogenously (Roosnek et al 1988). Murine studies estimate 
that only 210-340 (0.1% of surface I-A molecules) specific 
antigen/class II molecule complexes are needed to stimulate 
T helper cells, which suggests APCs are able to present 
multiple foreign antigens simultaneously (Hardling and 
Unanue, 1990).
Antigen is presented using one of two pathways (Morrison et 
al 1986, Braciale et al 1987, Moore et al 1988). In the 
exogenous pathway, antigens are taken up into peripheral 
endosomal compartments where they are degraded and 
processed for binding to class II antigens. This pathway 
is sensitive to agents, such as chloroquine, which 
neutralise the acidic compartments (Morrison et al 1986) .
Class I antigens present antigen via the endogenous pathway. 
Antigen is derived from protein synthesised intracellularly or 
transported into the cytoplasm. Thus viral translation products 
or mutant gene expression within a cell can be a source of 
antigenic peptide. Brefeldin A (BFA) inhibits the endogenous
13
but not the exogenous pathway by preventing protein transport 
from the rough endoplasmic reticulum to the Golgi apparatus, 
site of class I molecule formation (Nüchtern et al 1989).
Nüchtern et al (1990) report that class II molecules can, 
in at least some cases, present antigen processed by the 
endogenous pathway. This suggests the division of antigen 
presentation strategies are not exclusive and may explain 
some of the findings inconsistent with the two pathway 
model (Sekaly et al 1988).
Lag time experiments suggest that endogenous antigen 
presentation takes approximately one hour (Roosnek et al
1988) , however the exact mechanism by which endogenous 
antigen is degraded to produce antigenic peptide, and then 
transported to the MHC class I or II molecule is unknown, 
and the sequence of events in the processing of endocytosed 
antigen is subject to debate (Guagliardi et al 1990, Peters 
et al 1991). The search is complicated by the fact that 
antigen presentation can differ between different cell 
types (Macchy et al 1987, Chain et al 1988).
Recently genes encoding a ATP binding protein were reported 
in the mouse which is believed to be responsible for 
transporting antigenic peptides across the vesicle membrane 
to class I molecules (Spies et al 1990). This gene is 
found in the class II region in the mouse, and similar 
genes have been reported in the human (Trowsdale et al
1989) and rat (Deverson et al, 1990). The genes were 
located in mutants that were defective in class I molecule
14
function yet expressed normal class I molecules and 
contained no mutations in the class I genes or regulatory 
sequences (Spies et al 1990). Similar mutants involving 
class II expression and function have been reported 
(Mellins et al 1990) implying that there may also be a 
peptide transport protein specific for class II molecules.
1.5.3. Self Peptide
When the three dimensional structure of a class I molecule 
was first presented it was noted that there was an electron 
dense region in the peptide binding site which did not 
correspond to the primary amino acid sequence (Bjorkman et 
al 1987b). It is now postulated that short polypeptides 
derived from intracelullar protein (self peptide) binds to 
the antigen binding site of class I and II molecules 
(Kourilski et al 1987). Antigen binding may be necessary 
for proper class I and II molecule assembly and 
intracellular transport (Townsend et al 1989). Elliot et 
al (1991) showed that peptide binding to newly synthesized 
class I chains induces folding in the chains in the absence 
of /32-microglobulin, and can stabilize class I chain//32- 
microglobulin.
Falk et al (1991) found that the eight or nine amino acid 
long self peptide eluted from human and mouse class I 
molecules contained MHC allele specific amino acid sequence 
motifs. This observation supports the hypothesis that
antigen binding as well as TCR recognition may be HLA 
restricted (see 1.5.1.)*
Self peptide is not normally recognised as being foreign by 
T cells, and may in fact be necessary for proper T cell 
recognition of self-MHC antigens (Heath et al 1989). 
Inappropriate expression of self protein may lead to 
autoimmune disease, or allogenic grafts which present 
different self proteins (including peptides derived from 
class I and II molecules), may contribute to tissue 
rejection process (Termijtelen et al 1990). Self peptide 
presentation may explain the paradox that the TCR can 
recognise both self MHC molecules presenting antigen and 
allogeneic MHC molecules; and that 100-1000 fold more T 
cells are directed towards allogeneic specificities than 
towards antigenic specificities (Matzinger and Bevan 1977).
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1.6. CHROMOSOMAL ORGANIZATION OF THE CLASS II GENES
The HLA gene complex is located on the short arm of 
chromosome 6, between 6p21.1 and 6p21.3 (LePage et al 1984) 
and encompasses about 3.5 million base pairs (Carrol et al 
1987, Dunham et al 1987), the size of the Escherichia coli 
genome. The HLA system consists of three regions, encoding 
class I, II and III genes (Fig 1.2A). The class I and II 
genes code for the class I and II HLA antigens 
respectively. The class III region contains genes encoding 
proteins involved in the complement pathway. The HLA gene 
complex MHC, contains some of the most highly
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polymorphic loci in the genome. The class II, or HLA-D, 
region encodes three class II isotypes, DR, DQ and DP. 
Mapping the region by pulsed field gel electrophoresis 
(PFGE) and Southern blotting shows that the HLA-D region 
covers about 900 kb (Hardy et al 1986). The HLA-D region 
contains at least 11 ß chain genes and six a chain genes, 
but not all are expressed (fig 1.2B).
The intron exon arrangement is essentially the same between 
the A and B genes of the different class II loci with the 
different domains of the a and ß chains being encoded by 
separate exons (Kelly and Trowsdale 1985, Andersson et al 
1987). The A genes contain five exons; the first encoding 
the signal sequence; the second and third encoding the 
first and second extracellular domains respectively, the 
fourth encoding the transmembrane region and the 
ctyoplasmic tail, and the fifth encoding the 3' 
untranslated region. The intron/exon structure of the B 
genes is similar except that the transmembrane region and 
cytoplasmic tail are encoded by separate exons (exons four 
and five) and the 3' untranslated region encoded by exon 
six (Fig 1.3).
1.6.1. The HLA-DR sub-region
The most centromere-distal of the three subregions is DR. 
The DR region has been mapped by overlapping cosmid clones 
(Andersson et al 1987) and covers at least 220 kb. HLA-DR 
typically contains one DRA gene and three DRB genes, DRB2
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being a psuedogene (Spies et al 1985, Tonnelle et al 1985). 
However the number of DRB genes can vary between 
haplotypes. For instance, the DRw8 haplotype encodes only 
one DRB gene while DR4 and DR7 haplotypes have up to four 
DRB genes (Andersson et al 1987). The chromosomal 
arrangement of genes can also vary between haplotypes.
This is demonstrated in DR3 haplotypes where the ß chain 
genes are closer together and have smaller introns than in 
DR4,Dw4 (Andersson et al 1987). The DR region also 
contains numerous relics of its evolutionary history. For 
instance the DR4,Dw4 haplotype contains in addition to two 
functional DRB loci, a single ß chain second exon close to 
DRA and three sets of isolated signal or promoter regions 
lying downstream of the single ß chain exon (Bodmer 1986, 
Andersson et al 1987).
1.6.2. The HLA-DQ sub-region
The central region of the HLA-D region contains the DQ 
genes, which consist of two closely related pairs of a and 
ß chain genes, the DQ1 genes which are expressed and the 
DQ2 genes which are not. The DQA2 and DQB2 genes show a 
high degree of similarity to the DQA1 and DQB1 genes and 
presumably arose by a single duplication event (Jonsson et 
al 1987). There is also evidence for gene conversion events 
occurring between DQ1 and DQ2 (Jonsson et al 1987). 
Seguencing shows the DQA2 and DQB2 genes to be intact 
(Okada et al 1985), and stable DQA2 and DQB2 mRNA 
transcripts have been obtained in transgenic experiments
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where the genes are under control of a constitutive 
promoter. However no DQA2 and DQB2 gene product has been 
observed (Korman et al 1985). Lying between DQA2 and DQB1 
is an isolated ß chain gene exon called DVB (Blanck and 
Strominger 1988).
Between the DQ and DP subregions lie DOB and DNA (Inoko et 
al 1984, Kelly and Trowsdale 1985). These pseudogenes, 
like DQA2 and DQB2, appear to be structurally intact. DOB 
and DNA are transcribed at 10 to 30 times lower than other 
class II loci but are not translated (Blanck and Strominger 
1988, Young and Trowsdale 1990).
It is unlikely that gene products of the DNA and DOB loci 
would form a heterodimer as the genes are at least 200 Kb 
apart, and appear not to be coregulated. HLA-DOB is not 
inducible by gamma interferon, whereas DNA is (Kappes and 
Strominger 1988), and DOB is transcribed only in B cells 
while DNA is expressed as a typical class II gene (Long et 
al 1988). However eguivalent HLA-DNA genes are expressed 
in some species (Young and Trowsdale 1990) The presence of 
unclassified class II proteins have been described 
(Fernandez et al 1988, Pawlec et al 1988), and may be the 
products of the structurally intact A and B chain genes for 
which no product has yet been found, or of as yet
undiscovered loci.
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1.6.3. The HLA-DP sub-region
HLA-DP is the most centromeric class II subregion and was 
mapped by overlapping cosmid clones (Gorski at al 1984, 
Trowsdale et al 1984). It is organised differently than 
the other II subregions. DPA1 and DPB1 are transcribed in 
the tail to tail orientation, whereas at the other loci, 
the genes are transcribed in the head to head orientation 
(Kelly and Trowsdale 1985) . DPA1 and DPB1 genes are 
separated by only 2 Kb and it is believed that the genes 
share some regulatory elements, such as an enhancer (Kappes 
and Strominger 1988). DPA2 and DPB2 have the same 
chromosomal arrangement as the DPA1 and DPB1 genes but are 
pseudogenes with intron/exon splice junction mutations and 
frameshift mutations (Gustafsson et al 1987). DPA2 also 
lacks a recognizable promoter and signal sequences, and 3' 
regulatory regions (Kappes and Strominger 1986).
1.7. HLA CLASS II POLYMORPHISM
Despite the requirement for a high level of polymorphism 
suggested by the function of class II molecules, the extent 
of sequence variation in the class II genes is variable.
The World Health Organisation (WHO) recognises 43 HLA-DRB 
alleles, 8 HLA-DQA alleles, 13 HLA-DQB alleles and 19 HLA- 
DP alleles (WHO Nomenclature Committee, 1989), the DRA1 and 
DPAl genes are almost monomorphic.
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1.7.1. Nucleotide sequence variation
1.7.1.1. HLA-DR locus.
HLA-DRB1 is the most polymorphic class II locus, and on 
some haplotypes is closely linked to a second functional 
DRB locus. DRB3 alleles are carried on DR3, 5 and w6 
haplotypes, DRB4 alleles are carried on DR4, 7 and w9 
haplotypes, while DRB5 alleles are found on DR2 haplotypes 
(Bell et al 1987). The DRB3 and DRB4 loci encode DRw52 and 
w53 respectively, although these molecules are expressed at 
15 to 20 times lower levels than the DR antigens encoded by 
DRA1 and DRB1. (Kappes and Strominger 1988)
Comparison of DRB1 sequences reveal a very complex pattern 
of variation between alleles. The amino acid diversity is 
limited mainly to three hypervariable regions (HVR) at 9- 
13, 25-38 and 67-74 (Reinsmoen and Bach 1990). DRB1
alleles can be closely related to each other with few amino 
acid differences between them, or alleles can share some 
HVRs, but resemble other alleles at other HVRs. It is rare 
to observe allele specific polymorphic regions.
The patchwork of related and unrelated regions between DRB1 
alleles suggests that multiple gene conversion and/or 
reciprocal cross-over events have occurred in addition to 
point mutations. There are numerous reports of putative 
gene conversion events having occurred in the DR region 
(Gregersen et al 1986, Gorski and Mach 1986, Berte et al
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1988, Bontrop et al 1988, Hurley et al 1988a). The 
putative donor sites of the gene conversion events appear 
to be spread out over the HLA-D region, and include a DQB2 
gene (Gregersen et al 1986), and a DRB3 gene (Gorski and 
Mach 1986).
1.7.1.2. HLA-D specificities
The DR locus is also thought to be largely responsible for 
the HLA-D specificities which are defined by the mixed 
lymphocyte reaction (MLR) and can split DR alleles into 
subtypes. Some HLA-D types can be associated with several 
DR genes.
HLA-D types reflect T cell defined epitopes on HLA-DR 
molecules. Reinsmoen and Bach (1990) compared the HLA-D 
types Dw2 and Dw21 on serologically defined DR2 cells with 
DRB sequence variation. They concluded that the second and 
third variable regions explained most (but not all) Dw 
variation. The importance of the second and third HVRs in 
providing epitopes for DR-directed T cells is confirmed by 
Termijtelen (1990). However the reactivity of some T cell 
clones cannot be explained by this model. Termijtelen 
(1990) proposes that some T cell recognition epitopes 
could be masked by bound peptide in the antigen presenting
site.
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1.7.1.3. The HLA-DQ locus
DQA1 is the only class II A gene which exhibits significant 
polymorphism, although it is still less polymorphic than 
DQB1 (Kappes and Strominger, 1988). There is evidence for 
gene conversion events between DQA1 and DQA2, and amino 
acid replacements tend to be clustered between amino acid 
positions 45 and 80 in the first domain (Jonsson et al 
1987). DQB1 has a similar pattern of polymorhpism to DRB1 
with first domain HVRs at amino acid positions 26 - 37, 52 
- 57 and 70 - 74 (Kappes and Strominger 1988). The DQA1 
and DQB1 are in strong linkage disequilibrium with DRB 
alleles (Ryder et al 1981)
1.7.1.4. The HLA-DP locus
The DPB1 second exon contains almost all the HLA-DP allelic 
variation (Bugawan et al 1988, Bugawan et al 1989). When 
comparing the 19 recognised DPB1 allele sequences, the 
polymorphic sites are clustered into six HVRs, however no 
DPB1 allele exhibits allele specific sequence at any one 
hypervariable region. Rather, the alleles appear to be 
generated by the shuffling of a limited number of 
polymorphic sequences at the hypervariable sites (Bugawan 
et al 1990).
The HVRs in DRB1 are believed to encode Dw specificities 
corresponding to the second and fourth HVRs in DPB1 second 
exon sequences, implying that perhaps not every variable
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region in DPB1 encodes TCR recognised epitopes. For DP 
molecules, TCR defined epitopes are established using the 
primed lymphocyte test (PLT). If the amino acid variation 
at the second and fourth HVRs in DPB1 are compared with the 
six PLT defined specificities, each PLT defined specificity 
has a unigue pattern of amino acid seguence. However, at 
the second HVR the alleles DPB1*0201 and *0202 have 
different amino acid sequences, yet PLT is unable to 
discriminate between these alleles (Nomenclature for 
factors of the HLA system, 1984) suggesting that some 
sequence variation may not be functionally significant.
When 10th International Histocompatibility Workshop cell 
lines were PLT typed (Yang et al 1989), some samples typed 
as PLT blank. That is, some cell lines expressed DP 
molecules that were not recognised by the panel of primed 
lymphocytes, inferring that novel DP specificities were 
present. Thus there are more T cell defined DP 
specificities than the six officially recognised.
Alleles that are shown not to be functionally important may 
still prove useful as genetic markers. So while not all 
alleles may be needed to be distinguished from each other 
in the context of tissue typing for transplantation, it is 
still important to be able to discriminate between all 
known alleles for disease, anthropological (Serjeantson 
1987), population and forensic studies (Simons 1990).
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1.7.2. Inappropriate pairing of A and B chains
Extra class II polymorphism can arise from the improper 
pairing of the A and B chains of different isotypes 
(intertypic); or of alleles at the same locus (intratypic).
In transgenic mouse experiments intertypic DRA/DQB 
molecules have been observed but not DQA/DRB (Kappes and 
Strominger 1988) , so that it appears the efficiency of 
intertypic association depends on the loci involved. When 
expression levels of individual A and B genes were raised 
in transgenic experiments, mixed isotype molecules were be 
observed containing the over-expressed chain (Sant and 
Germain 1989). It was postulated that the mechanism by 
which one A chain finds its corresponding B chain appears 
to be a competitive event; each respective A chain having a 
three to five fold preference for its corresponding B chain 
over B chains of other isotypes.
It is possible that significant levels of mixed isotype 
class II molecules are expressed after gamma interferon 
induction, which leads to relatively large concentrations 
of A and B chains being present in the cytosol, and it is 
conceivable that local concentrations of A and B chains may 
differ enough to allow intertypic associations. Such 
associations may have a role in autoimmune disease as T 
cells would not recognise the mixed isotypic molecule. In 
human B cell lines, a DQB1/DRA1 molecule has been detected 
(Lotteau et al 1988).
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The DQA locus is the only class II A locus which exhibits 
significant polymorphism. Thus it is possible that DQA and 
DQB chains from different chromosomes may associate forming 
intratypic, or transcomplementary, HLA-DQ molecules. 
Intratypic DQ molecules have been observed in DQ 
heterozygotes and may have a role in IDDM (Nepom et al 
1987) and celiac disease (Sollid and Thorsby 1990).
1.8. LINKAGE DISEQUILIBRIUM
If the chance of alleles at different HLA loci associating 
with each other was proportional to their individual 
frequencies, there would be over two and a half million 
haplotypes represented in the world's population. However 
in a study of haplotype frequencies in Caucasoids using 
only the HLA-A, -B, -C and -DR loci, only about 90 
haplotypes were seen at any reasonable frequency (Grange et 
al 1984). The lack of certain haplotypes is due to the 
strong linkage disequilibrium found in the HLA region. The 
strongest linkage disequilibrium is between HLA-B and -C, 
due to their close proximity. Between the HLA-A and HLA-B 
loci the recombination frequency is only 1% (Bodmer et al 
1987). There is strong linkage disequilibrium in the class 
II region, where HLA-DR is strongly linked with -DQ (Ryder 
et al 1981) .
Linkage disequilibrium relationships can vary between 
population groups; almost all DR3 positive Caucasoids are 
DQw2 while DR3 in north American Blacks is associated 50%
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of the time with a DQw type not seen in Caucasoids (Hurley 
et al 1988b). Different linkage disequilibrium 
relationships lead to different haplotypes being observed 
in different ethnic groups; A2, B44, DR4 occurs only in 
Caucasoids while A2, B3 5, DR4 only in Mongoloids; A2, B7, 
DR1 occurs in Japanese, and A30, B18, DR3 in Ashkenasi Jews 
(Bodmer et al 1987). Haplotype frequencies will also vary, 
for instance the AI, B8, DR3 haplotype has a frequency of 
10.4% in Northern European populations, in Southern and 
Eastern European populations it is just over 5%, while in 
the Chinese the frequency is only 1.5% (Bodmer et al 1987). 
Patterns of linkage disequilibrium may reflect the genetic 
affinities of different populations, so haplotypes can 
serve as powerful markers for anthropological studies 
(Serjeantson 1985).
Linkage disequilibrium between DR and DP is generally 
considered weak (Termijtelen et al 1983), however in early 
studies the strength of DR/DP linkage disequilibrium 
associations would have been underestimated due to 
undetected allele heterogeniety at both HLA-DR and -DP 
loci. One group reports the crossover frequency is only 
1%, based on analysis of family lineages (Thomsen et al 
1990). Some DR-DP associations have been recognised 
including DR3 being positively associated with DPwl, and 
DR7 being positively associated with a DPw blank (Thomsen 
et al 1990).
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1.9. TRANSPLANTATION
A number of factors can influence the success or failure of 
a tissue transplant. These factors include the disease or 
incident that caused the need for the transplant, the 
relationship between donor and recipient of the graft, the 
number of pre-transplant blood transfusions, post­
transplantation chemotherapy, treatment of the graft pre­
transplantation and even the gender of the donor and 
recipient (Takiff et al 1988). However, the HLA haplotype 
of host and graft is one of the major considerations in 
transplantation.
1.9.1. HLA tissue matching
Long term studies have shown that HLA matching was the most 
dominant effect over time for renal graft survival The 
other factors involved in graft outcome tend to effect 
short term survival only (Morris et al 1987). The positive 
effect of HLA class I on the outcome of renal transplants 
has long been recognised (Morris et al 1968). Other 
studies looking at the role of other HLA loci (Albrechtsen 
et al 1983, van Rood et al 1985) confirm the above results 
and also observe that HLA-C has little or no effect on 
transplant outcome, while the HLA-D region proved to be 
very important. It was found that matching for HLA-DR was 
more important to graft survival than matching for HLA-A or
HLA-B.
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1.9.2. HLA-DP and transplantation
Previously, because of the difficulty of typing the HLA-DP 
locus, and because DP molecules do not stimulate primary 
lymphocyte responses as well as the DR or DQ molecules 
(Trowsdale 1987), HLA-DP has never been considered an 
important factor in transplant outcome. However studies 
looking at the occurrence of severe Graft Versus Host 
Disease (GVHD) in bone marrow transplant cases have shown 
that DP matching as well as DR matching does significantly 
reduce the chance of GVHD developing (Odum et al 1987). 
HLA-DP restricted alloreactive T cell clones have been 
obtained from a graft rejection episode, showing that 
allogeneic HLA DP molecules as well as the other class I 
and II molecules were targets of host T cells (Bonneville 
et al 1988) . Hence there is evidence that HLA-DP matching 
may play a role in tissue transplant outcome.
Even in well matched grafts, up to 25% of the transplants 
can fail, just as up to 40% of the poorly matched grafts 
are successful (van Rood et al 1985). Also, haplo- 
identical grafts between siblings tend to fair better than 
haplo-identical grafts between parents and offspring or 
between unrelated individuals (Albrechtsen 1983, Odum et al 
1987, Bonneville et al 1988). This suggests that factors 
other than the HLA molecules normally typed (HLA-A, -B, - 
DR) are involved in determining graft success. The 
beneficial effect of HLA matching in tissue transplants has 
been reported for most tissues (Volker-Dieban 1989, 
Sanfilippo 1989, Opelz 1989, Honeyman et al 1989)
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1.10. HLA TYPING METHODS
1.10.1. Cellular typing
HLA-D specificities represent functional epitopes 
recognised by the TCR and are typed by the mixed lymphocyte 
reaction (MLR). The MLR consists of looking for a 
proliferative response (blast cell transformation) in a 
mixed culture of lymphocytes (Festenstein and Ollier 1988). 
The test uses homozygous typing cells (HTCs), which are 
cell cultures of lymphocytes that are homozygous for a 
known Dw specificity, and that have been irradiated so that 
they can no longer respond to stimulation, but are still 
able to stimulate non-irradiated or "responder" 
lymphocytes. The HTC or "stimulator" and responder cells 
are cultured together and if no blast cell formation is 
observed (negative MLR), then the responder and stimulator 
cells must share an HLA-D specificity. If blast cells are 
seen, a proliferative response has occurred (positive MLR) 
and the responder and stimulator cells do not share HLA-D 
specificities.
The DP antigens cannot be studied by the MLR as HLA-DP 
molecules are expressed at lower levels that DR and DQ 
(Bodmer et al 1987) and do not stimulate HTCs. DP 
polymorphisms are detected cellularly by PLT, also called 
the secondary mixed lymphocyte reaction. The PLT relies on 
the accelerated secondary response of primed lymphocytes; 
the lymphocytes used to type DP molecules, or responder
32
cells, are produced by culturing with irradiated stimulator 
cells that are identical to the responder cells at every 
locus except at the DP locus. After 10 days culturing the 
responder cells have proliferated in response to a known DP 
type on the stimulator cell. The cells to be typed are 
first irradiated then cultured with the primed responder 
cells. In contrast to the MLR, if a proliferative response 
occurs then the cells being typed share a DP type, and if 
there is no proliferative response, the cells being typed 
do not share a DP specificity with the responder cells 
(Festenstein and Ollier, 1987).
1.10.2. Serologic typing
Lymphocytes can be assayed for class II alleles by using a 
panel of antibodies directed against allele specific 
epitopes. Anti-HLA-class II antibody can be obtained from 
antisera produced by multiparous women, or by individuals 
that received blood transfusions (Bodmer et al 1987).
Due to the low expression of HLA-DP, DP specific sera has 
been difficult to obtain. However, with the advent of 
monoclonal antibody technology, there has been an 
improvement in the availability and specificity of typing 
sera (Bodmer et al 1987). Monoclonal antibodies against 
DPwl and w3 (Nadler et al, 1981) and DPw2 and w4 (Heyes et 
al 1986) have been produced, where DP had been previously 
untypeable by conventional serology. Although serological 
typing is relatively simple to perform, until such time as
there is a complete repertoire of HLA-DP typing antisera 
available, serological typing will not be a method of 
choice.
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1.10.3. Restriction fragment length polymorphism typing
Restriction fragment length polymorphism (RFLP) analysis 
schemes have been presented for the DR (Kohonen-Corish and 
Serjeantson 1986, Riisom et al 1988, Bidwell et al 1988),
DQ (Bidwell et al 1988, Guardiola et al 1988) and DP 
(Easteal et al 1989, Hyldig-Nielsen and Svejgaard 1989, 
Mitsuishi et al 1989) regions. RFLP typing of HLA-DP is 
carried out using three restriction enzymes and two probes 
(Easteal et al 1989) and can distinguish between all PLT 
defined type except DPw3 and DPw6. RFLP analysis is easier 
to perform, faster and more concise than PLT typing, and 
does not rely on expression of the DP molecule. RFLP 
analysis allows better characterization of new variants 
since heterozygotes can be detected. However, RFLP relies 
on complete association between polymorphic restriction 
sites and coding sequence variation. The mutations leading 
to altered RFLP patterns may not be necessarily linked to 
novel DP sequence variation.
1-10.4. Sequence specific oligonucleotide typing
Angelini et al (1989) describe a method of HLA-DP typina
based on the polymerase chain reaction (PCR) . The
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amplified DPB1 second exon PCR product is hybridized with 
sequence-specific oligonucleotides (SSOs) designed to 
hybridize to regions containing the hypervariable 
sequences. The pattern of hybridization of the panel of 
probes to the PCR product allows the assigning of an allele 
to the PCR product. This method is more accurate, 
sensitive and efficient than PLT and RFLP typing and only 
the variation within the polymorphic domain of DPB1 is 
analysed. This method also takes advantage of the fact 
there are only a limited number of sequences at the HVRs, 
and alleles differ in the combination of HVRs rather than 
allele specific sequences. DPB1 typing schemes using this 
strategy have been published (Bugawan et al 1990, 
Fernandez-Vina et al 1991).
1.10.5. Amplified fragment length polymorphism typing
Amplified fragment length polymorphism (AFLP) typing is 
based on restriction site analysis of polymorphic enzyme 
recognition sequences occurring in HVRs. PCR product is 
digested by restriction enzymes and the fragments separated 
by gel electrophoresis and visualised by ethidium bromide 
staining. The development of an AFLP typing scheme for 
DPB1 alleles is the subject of this thesis. During the 
course of this work, AFLP schemes for HLA-DR (Uryu et al
1990) , -DQ (Maeda et al 1989, Uryu et al 1990, Ota et al
1991) and -DP (Maeda et al 1990, Ota et al 1991) loci have 
been published.
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1.11. DISEASE ASSOCIATIONS
In 1967 it was discovered that patients with Hodgkin's 
Lymphoma had higher frequencies of the HLA-B alleles, B5,
B35, B15 and B18, than did healthy controls (Amiel 1967). 
Since then many relationships between HLA and disease have 
been reported, however explanations for the HLA-disease 
associations observed have been rare. There are a number 
of ways in which particular HLA allele or alleles and the 
disease can interact. First, the HLA allele can be directly 
involved in the pathogenesis of the disease. For instance 
congenital adrenal hyperplasia (CAH) is caused by a mutation 
in the class III gene 21 hydroxylase. This causes a 
deficiency of cytochrome p450, and leads to an excess of 
androgens and often failure of salt uptake by renal tubules. 
Research into animal models of insulin dependant diabetes 
mellitus (IDDM) has shown that over expression of a class I 
transgene in the pancreas leads to the development of 
symptoms of IDDM in the mouse (Allison et al 1988). It is 
also possible that the HLA molecule act as a receptor for 
pathogens. A number of viruses have been shown to bind to 
class I molecules including adenovirus type 2 and Semliki 
forest virus (Batchelor and McMicheal et al 1987). Thus it 
is quite possible that different class I alleles may have 
different avidities for a particular virus. Second, the HLA 
gene may be in linkage disequilibrium with the disease 
causing gene. For instance HLA-B47 is linked to the class 
III genotype that causes CAH (Batchelor and McMicheal et al 
1987). Third, there are cases of molecular mimicry where 
pathogens may share antigenic determinants with class I or 
II alleles so that the immune system is unable to recognise
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the pathogen as nonself. Such an event is implicated in 
the etiology of ankylosing spondylitis (AS). It is 
postulated that exposure to Klebsiella infections in 
patients with HLA-B27 leads to the autoimmune disease AS 
because of cross reactivity between HLA-B27 and Klebsiella 
bacterial antigens (Geczy et al 1983).
Sometimes the etiology of the disease is unknown, despite a 
strong HLA association. For example almost all sufferers 
of the sleeping disorder called narcolepsy, have the HLA- 
DR2 allele (Lock et al 1988), yet the cause remains 
unsolved.
In many cases the relationship between HLA alleles and 
disease is very complex. The presence of the disease may 
depend on a combination of loci, only one of which being an 
HLA allele. For example, chronic autoimmune hepatitis is 
associated with an HLA allele and immunoglobulin allotype. 
It has been postulated that the etiology of multiple 
sclerosis (MS) depends on a number of factors including 
some form of infection during adolescence as well as HLA 
region associations (Chataway 1989). The relationship 
between disease and HLA allele may be clouded by the 
disease causing epitopes occurring on different alleles at 
the same locus or at different loci. It has been reported 
that heterodimers of HLA-DQ antigens, where the A and B 
chains are encoded by different chromosomes, have a role in 
celiac disease (Sollid and Thorsby 1990).
Two diseases which have complex relationships with HLA 
genes are multiple sclerosis (MS) and IDDM.
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1.11.1. Insulin dependent diabetes mellitus
IDDM is caused by the immune destruction of the insulin 
producing beta cells in the pancreas, resulting in an 
absolute requirement for exogenous insulin (Eisenbarth 
1986). IDDM patients have circulating antibody to islet 
cells, and T and B cell infiltrates are found in the 
pancreas (Baekkeskov et al 1987). IDDM affects two people 
per thousand in Caucasoids, and is less common in other 
ethnic groups. The median age of onset is 12 years, and 
usually onset of the disease occurs before the age of 20 
(Harris 1986).
IDDM has a genetic component, with concordance rates 
between monozygotic twins being around 35% (Olmos et al 
1988), however the level of concordance can depend on the 
HLA type of the twins. Several HLA genes have been shown to 
be associated with IDDM. HLA-DR3, -DR4, and particularly 
DR3, DR4 heterozygotes have a strong association with the 
disease, while HLA-DR2 is shown to have a protective effect 
(Svejgaard et al 1983, Thomsen 1988). However it was 
suggested that the HLA-DR association is due to linkage 
disequilibrium with HLA-DQ alleles. Amino acid position 57 
of the DQB1 chain has been implicated (Todd et al 1987).
The HLA-DQ alleles shown to have a neutral or protective 
effect on disease risk (e.g. DR2,DQw6) have aspartate at
position 57 (Asp57) on the DQB chain. While HLA types
positively associated with IDDM (e.g. DR4,DQw8, DR3,DQw2,
DR1,DQw5) tend not to have Asp57 (Todd et al 1987).
The ability of DQB Asp57 to determine exclusively 
susceptibility to IDDM has been disputed. Serjeantson and 
Easteal (1989) suggest that position 70 on the DRB chain is 
a better indicator, with glycine at position 70 in the more 
susceptible types, and aspartate in more resistant types, 
while Sheehy et al (1989) found both DRB1 (Dw4) and DQB1 
(DQw8) loci contribute to predisposition to IDDM.
Despite the presence of these susceptibility indicators, 
the relationship between IDDM and HLA is complex. Although 
DR4 is known to be a disease associated allele (DR4,Dw4), 
and has glycine at position 70 on the DRB chain, if DR4 is 
found in conjunction with Dwl4,DQw8 the risk is neutral. 
Also the trans-association between DQA and DQB chains coded 
by different chromosomes may have an affect on disease 
susceptibility. Nepom et al (1986) have shown that hybrid 
DQ molecules do occur in DR3, DR4 heterozygotes.
HLA-DP alleles have also been implicated in IDDM 
susceptibility. Easteal et al (1989) have shown an 
association between IDDM and DPw3 and w6 in IDDM patients 
with late onset of disease. However, the study was 
performed using RFLP analysis which is unable to 
distinguish between DPw3 and w6. Hence it is possible that 
either DPw3 or w6 are involved in IDDM or both alleles have
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a role.
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It is obvious that IDDM susceptibility can be attributed to 
a number of genes, and it is possible that a disease 
causing gene may be linked to HLA class II genes. It is 
therefore important that the relationship between HLA-DP 
alleles and IDDM is explored. Also, if genes linked to 
class II genes are involved, then looking at IDDM 
associations in other ethnic groups is particularly useful.
1.11.2. Multiple sclerosis
MS is a multifactorial disease with an unpredictable 
disease course and unknown etiology. Family studies 
indicate that susceptibility is genetically determined 
(McFarland et al 1984), and experiments in the mouse 
suggest MS is at least in part an autoimmune disease. An 
MS-like disease can be induced in mice and rats, that gives 
very similar symptoms to MS including the characteristic 
sclerotic plaques seen in the brain, called experimental 
autoimmune encephamyelitis (EAE) (Heber-Katz and Acha- 
Orbea, 1989), and is induced by injecting the animal with 
myelin basic protein (MBP), one of the components of the 
oligodendrite sheath. Although in MS, MBP specific T cells 
are observed, they do not occur in ail patients (Chou et al 
1989). Where the MBP immunodominant peptide observed in 
EAE is detected in humans it appears to be HLA-DR 
restricted (Martin et al 1991).
A great variety of factors have been associated with MS.
The well known climate effect where MS is more prevalent in
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the middle latitude temperate regions of the world, however 
this may simply reflect dines in frequency of 
susceptibility alleles. Other factors include; the amount 
of solar radiation (Laborde et al 1988), IgA polymorphism 
(Coyle 1989), Measles Virus (Brahic and Jewell 1989) and T- 
cell receptor alleles (Heber-Katz and Acha-Orbea 1989) .
The risk of contracting MS can be affected by gender 
(Weitkamp 1983) and the presence of affective disorder 
(Schiffer et al 1988).
The HLA region has been studied in detail for associations 
with MS but has provided contradictory results.
In the class region III, a number of loci have been 
studied. Low levels of C2 have been reported in MS 
patients that were Dw2 positive (Betrams et al, 1976). 
However it was later reported that low levels of C2 were 
also found in Dw2 positive healthy controls as the C2 null 
allele is carried on the A25, B18, DR2 haplotype (Nerl et 
al, 1978). Bf has also been associated with MS (Stewart et 
al, 1979). The BfS allele was found to be more prevalent 
in MS patients than in controls, but this was thought to be 
due to linkage with Dw2. A third class III gene, C4, has 
also been implicated (Schroder et al, 1983). A recent 
study (Marcelli-Barge et al 1990), has shown that the C4A 
null allele and the BfS are both associated with MS and are 
both linked with HLA-DR2.
In the class II region, the association between MS and the 
HLA-DR2,Dw2 allele was first reported in 1973 (Jerslid et
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al 1973). As mentioned above, several other genes that 
have been implicated with MS have been linked to DR2. 
However, the DQwl allele of the HLA-DQ loci, which is in 
linkage disequilibrium with DR2, shows a higher association 
with MS than DR2 (Francis et al, 1986). With the advent of 
DNA typing, the HLA-DQ locus has been looked at in more 
detail. It was discovered by Spurkland and co-workers 
(Spurkland et al, 1990) that almost all of the MS patients 
had DQA1 alleles with a glutamine residue at amino acid 
position 34, and shared long polymorphic regions in the 
DQB1 locus. However this result was not confirmed in other 
populations (Swingler et al, 1987).
1.12. AIMS OF THESIS
The recent development of PCR technology has provided a 
means of precise HLA class II typing as allelic nucleotide 
sequence variation, in the exon encoding the polymorphic 
domain of the class II molecule, can be analysed directly. 
Two approaches have become available; SSO typing (Angelini 
et al 1988), and AFLP typing (Maeda et al 1989).
The second exon of DPB1, encoding the polymorphic ß domain, 
and is amenable to restriction site analysis as DPB1 
nucleotide is restricted to HVRs and allelic variation is 
due to the rearrangement of a limited number of polymorphic 
sequences. Therefore only a small number of HVR specific 
restriction enzymes would be necessary to provide allele 
specific AFLP fragment patterns.
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The aim of this thesis is to develop an AFLP typing scheme 
for DPB1 alleles and apply the scheme to the investigation 
of DPB1 allele frequencies to population samples from two 
ethnic groups, and to patients of two diseases groups, IDDM 
and MS.
Chapter 3 presents the development of the AFLP scheme in 
detail. The ability to determine allele identity is 
tested, and the results of the blind typing of 10IHW cell 
line panel DNA samples, that were also typed by PLT, RFLP 
and SSO typing methods, are presented. Deviations of 
observed AFLP patterns from the expected fragment patterns, 
determined from DPB1 second exon sequences, and the 
advantages and disadvantages of the AFLP scheme are 
discussed. This includes an analysis of heterozygote 
typing and an estimate of the relative costs of PCR-based 
typing techniques.
The ability of AFLP typing to separate all 19 DPB1 alleles; 
including the subtypes of DPw2 and DPw4, rare alleles, and 
DPw3 and w6 which are indistinguishable by RFLP analysis; 
has a number of implications. First, linkage 
disequilibrium relationships with other class II loci and 
HLA-DP associations with disease would no longer be masked 
due to the inability to discriminate non-associated DPB1 
alleles. Second, as the 19 DPB1 alleles are typed by 
polymorphic restriction sites in coding regions, the 
assumption of complete association between RFLP pattern and 
HLA-DP allele can be tested. Third, as all six HVRs 
contain recognition sequences for the restriction enzymes
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in the AFLP scheme, novel sequence variants sequences can 
be identified as novel AFLP fragment patterns.
The AFLP typing scheme was used to type healthy control 
groups of two different ethnic groups, White Australian and 
South Indian. The allele distributions are presented in 
Chapter 4 which also includes an analysis of the efficacy 
of RFLP typing in South Indians in the light of the 
relatively high frequency of novel RFLP patterns or 
combinations of patterns observed previously (Easteal et al 
1990). Linkage disequilibrium between HLA-DR types and 
DPB1 alleles are investigated in both populations.
In Chapter 6, the AFLP scheme is applied to three disease 
groups; White Australian and South Indian IDDM patients, 
and White Australian MS patients. Associations between 
DPB1 alleles and IDDM or MS are identified, and discussed 
in terms of linkage disequilibrium with HLA-DR disease 
associated alleles and in terms of amino acid sharing 
between alleles associated with disease susceptibility or 
protection.
A novel AFLP pattern was observed in the 10IHW cell line 
panel typed in Chapter 3. Chapter 6 presents the strategy 
of sequencing one allele in a heterozygote by PCR-based 
direct sequencing. The nucleotide sequence of the new 
allele is presented, and its relationship with to the 19 
recognised alleles discussed.
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Finally implications arising from AFLP DPB1 allele typing 
in the previous three chapters are discussed, including the 
relationship between PLT defined DPw typing and AFLP DPB1 
allelic typing, and the possible role of class II antigen 
variation in disease in the light of DPB1 associations.
Chapter 2
Materials and Methods
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2.1. DNA SAMPLES
2.1.1. 10th International Histocompatibility Workshop cell 
lines
Cell lines were obtained from Dr. B. Dupont (Memorial 
Sloan-Kettering Cancer Centre), chairperson of the 10th 
International Histocompatibility Workshop (10IHW) and 
Conference. The panel of Epstien-Barr virus-transformed 
cell lines was collected from over 28 laboratories 
worldwide, and was selected to be homozygous at HLA-A, -B, 
-C and -DR loci (DuPont 1989). Samples selected for study 
have all PLT defined HLA-DP types except DPw6 represented, 
including cell lines typed as "DPw blank" (Mickleson et al 
1989) to increase the variety of DPB1 alleles present.
2.1.2. South Indians
Blood samples were obtained from a series of IDDM patients 
attending the Madras Veterans Hospital for Diabetes in 
Madras, India and a control series of healthy blood donors 
in the same city (Kirk et al 1985) . The patients were 
selected on the criteria of: having an age of onset less 
than 40 years; being ketosis prone; and having complete 
dependence on exogenous insulin. Immediately after 
collection the samples were centrifuged; buffy coat, plasma 
and packed red cells were separated and frozen. They were 
transported to Canberra in a frozen state.
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2.1.3. White Australian 
2.1.3.1. Controls
Peripheral blood was obtained from healthy Caucasoid 
laboratory workers and other unrelated adults and included 
samples provided by the Red Cross Blood Transfusion 
Service, Canberra.
2.1.3.2. IDDM patients
Peripheral blood samples were collected from Caucasoid IDDM 
patients attending the Royal Southern Memorial Hospital, 
Melbourne, Australia (Kohonen-Corish et al 1987). The 
patients were unrelated and were selected on standard IDDM 
criteria, being nonobese, ketosis prone and idiopathic and 
the median age of onset was 23 years (Easteal et al 1990). 
The samples were transported to Canberra within 2 h of 
collection for HLA-DR serological typing and RFLP typing.
2.1.3.3. MS patients
Blood samples were collected from patients of Anglo Saxon 
ethnic background diagnosed as having MS. Clinical 
assessment of MS was performed by neurologists, and all 
patients had at least a two year history of MS (Stewart et 
al 1981) . Patients were considered to have commenced their
illness with an episode of optic neuritis, and had 
undergone diagnostic testing for MS including visual 
electrophysiological response testing.
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2.2. METHODS
2.2.1. DNA extraction
Genomic DNA was prepared from buffy coat samples. The 
samples were thawed on ice and the red cells removed by 
washing the pellets twice in 20 mM Tris, 5mM EDTA pH 7.5, 
in 10 ml poly-propylene tubes. The pellet was resuspended 
in 4 ml 20 mM Tris, 5 mM EDTA, pH 7.5, to which 200 fll 10% 
SDS (ultrapure) and 400 ßl proteinase K (lmg/ml) was added. 
The samples were incubated overnight at 37°C and the DNA 
extracted by phenol and chloroform (Maniatis et al 1982). 
The DNA was recovered by ethanol precipitation and 
resuspended in 10 mM Tris, 1 mM EDTA pH 7.5 at a 
concentration of approximately 0.3 jLtg/ml. The DNA samples 
were stored at 4°C in sealed 1.5 ml microcentrifuge tubes.
Preparation of cell line DNA was carried out as above 
except only one initial wash in 20 mM Tris, 5mM EDTA pH
7.5, was performed.
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2.2.2. Polymerase chain reaction amplification of DPB1 
second exon
For each DNA sample, the exon II region of DPB1 was 
amplified by PCR from 0.5 to 1.0 fig of genomic DNA in a 100 
111 reaction volume containing 10 mM Tris-HCl, pH 8.3, 50 mM 
KC1, 1.5 mM MgCl2/ 0.001% (w/v) gelatin, 20 mM each dNTP,
0.2 mM each primer and 2.5 units of Taq DNA polymerase 
(Perkin-Elmer, Norwalk, Connecticut) , overlaid with 40 /xl 
mineral oil to prevent evaporation. The reaction was then 
incubated in a Programmable Cyclic Reactor (Ericomp Inc.,
San Diego, California) or an Innovonics Gene Machine 
(Bartlett Industries, Victoria) thermocycler.
Two PCR protocols were developed. In protocol 1 the 
upstream and downstream primers were JDPB5 (5'-CCCTCCCC- 
GCAGAGAATTAC-3') and JDPB3 (5'-TCACTCACCTCGGCGCTGCAG-3') 
respectively. The reactions were incubated for 40 cycles, 
each cycle consisting of 45 s at 95°C, 10 s at 56°C and 45 
s at 72°C. The cycles were preceded by an extended 
denaturation step (5 min) at 95°C and followed by an 
extended primer extension step at 72°C (7 min). This 
protocol produced a 300 bp fragment.
It was observed that some DNA samples did not amplify under 
a variety of conditions using the above primers despite the 
DNA samples being treated to remove contaminants.
Treatments included ethanol precipitation and phenol 
chloroform extraction. To overcome this problem a modified 
protocol, protocol 2, was developed with a different
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upstream primer, JDPU2 (5'-GAGAGTGGCGCCTCCGCTCAT-3'). 
Protocol 2 also included the addition of 10% 
dimethylsulfoxoid (DMSO) to the standard reaction mix. The 
thermocycyling consisted of 30 cycles of 1 min each at 
95°C, 600C and 70°C with no preceding denaturation step and 
no extra extension step following the 30 cycles. It was 
found that this method could reproducibly amplify all DNA 
samples with a minimum of primer dimer formation or non­
specific amplification. The new primer, JDPU2, produced a 
312 bp fragment.
The PCR products were checked by electrophoresis on 2% 
agarose gels. Each set of amplifications was accompanied 
by a negative control which contained all the reaction 
components except genomic DNA. This was done to detect DNA 
contamination of the reaction components that could 
interfere with AFLP typing.
2.2.3. Restriction enzyme digestion of PCR products
For each DNA sample, 10 /xl of PCR product was digested with 
the following restriction endonucleases: Bst UI (4U), Dde I 
(2U), Eco NI (2U), Fok I (1U), Mnl I (2U), Rsa I (2U),
Sac I (2U) and Sau 961 (3U), according to manufacturers' 
instructions (Table 2.1). All digests except Fok I were 
incubated for at least 4 hr (see chapter 3). However only 
Eco NI, Fok I, Mnl I and Rsa I digests were performed 
routinely as these four enzymes are sufficient to 
distinguish all DPB1 alleles (fig 3.17).
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Table 2.1
Restriction endonucleases and digestion conditions used in 
AFLP typing.
Restric- Units
tion Recognition per Reaction
Enzyme"1" Sequence Digest Buffers*
Bst UI CG/CG 3 10 mM Tris, 10 mM MgCl2, 
50 mM NaCl, 1 mM DTT
Dde I C/TNAG 2 50 mM Tris, 10 mM MgCl2, 100 mM NaCl, 1 mM DTT
Eco NI CCTN2/N3AGG 2 20 mM Tris, 10 mM Mg acetate, 50 mM K acetate, 
1 mM DTT
Fok I g g a t gn9/ 1 20 mM Tris, 10 mM Mg 
acetate, 50 mM K acetate, 
1 mM DTT
Mnl I c c t cn7/ 2 12 mM Tris, 12 mM NaCl,50 mM MgCl2, 100 mg/ml BSA
Rsa I GT/AC 2 10 mM Tris, 10 mM MgCl2, 1 mM DTT
Sac I GAGCT/C 2 10 mM Tris, 60 mM NaCl, 
10 mM MgCl2, 10 mM B-ME 
100 mg/ml BSA
Sau 961 G/GNCC 3 20 mM Tris, 10 mM Mg acetate, 50 mM K acetate, 
1 mM DTT
+ All enzymes were purchased from Biolabs except Rsa I 
which was purchased from Boehringer Mannheim.
* All buffers at pH 7.9 at 25 C.
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The restriction fragments, were separated by electrophoresis 
at approximately 8 v/cm for three to four hours on 1.5 mm x 
16 cm 8% polyacrylamide gels except Mnl I digested 
fragments, which were electrophoresed on 12% polyacrylamide 
gels to allow the optimal resolution of the smaller 
restriction fragments produced. The restriction fragments 
were visualised by staining with ethidium bromide and were 
interpreted by reference to the fragment sizes predicted 
from the known DPB1 allele second exon seguences (Begovich 
et al 1989, Bugawan et al 1988, Bugawan et al 1989) (see 
chapter 3).
2.2.4. Southern Blotting
2.2.4.1. Agarose gel electrophoresis
Electrophoresis was performed on 2.0% agarose in TAE buffer 
(40 mM Tris-Acetate, 1 mM EDTA, pH 8.0) using 20 cm x 20 cm
submarine gel apparatus (Pharmacia, GNA-200). Gels were 
run at 20 V overnight, and the gel stained in ethidium 
bromide (2 mg/ml, 30 min) and photographed.
2 . 2 . 4 . 2 .  Southern Transfer
The DNA was transferred onto nylon membrane (GeneScreen 
Plus) by alkaline transfer (Reed and Mann, 1985), however 
no acid depurination was performed as small fragments were 
being transferred. After 16 hours of transfer in the
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presence of 0.4 M NaOH, the membrane Was "removed and washed 
in 0.2 M Tris, 2x SSC, pH 7.5 for 60s and dried.
2 . 2 .  4.  3 .  Ni ck  T r a n s l a t i o n  o f  probe
A cDNA HLA-DP probe, pII-B-7 (Gustafsson et al 1984), was 
labelled with 32P Amersham Nick Translation Kits and (a- 
32P) dCTP. The reaction contained: 10 p i each of dATP, dGTP 
and dTTP mixes, 5 p i DNA polymerase (Klenow fragment, 1.5 
U / p l ) ,  0.2 pq probe DNA, and 1 p i (a-3 2P) dCTP. The 
reaction was made up to 50 p i with sterile double distilled 
H20 and incubated at 15°C for one hour, and stopped by the 
addition of 10 p i 0.5 M EDTA. Labelled probe was separated 
from unincorporated label by passage through an Ultragel 
column (AcA 54, LKB).
2 . 2 .  4 . 4 .  H y b r i d i z a t i o n  o f  membrane
Membranes were incubated at room temperature in a 
prehybridization mixture, prepared by boiling 9.2 ml 
distilled H20 and 100 p i sheared salmon sperm DNA (10 
mg/ml) for 10 min in a 50 ml Corning plastic tube, then 
chilled on ice. To this 10.8 ml Nasmyth's solution (10% 
dextran sulphate, 0.6 M NaCl, 0.18 M Na2P04, 6 mM EDTA, 1% 
sodium lauroyl sarcosine) was added, the solution was mixed 
and added to a plastic bag containing the nylon membrane 
and the bag left unsealed at room temperature for at least
one hour.
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The hybridization mix consisted of the nick translated 
probe added to a prehybridisation mix, boiled 10 min, 
chilled on ice and added to the plastic bag containing the 
membrane. The membrane and probe were incubated at 65°C in 
a shaking water bath for 40 hrs.
2.2 . 4 .5 . Washing of membrane and autoradiography
Membranes were removed from the hybridization solution and 
washed in 2x SSC, 0.1% SDS for 30 min at 65°C. This was 
followed by three subsequent washes with decreasing 
concentrations of SSC (lx, 0.5x and 0.25x). The filters 
were then removed, partially air dried, and wrapped in 
"Glad Wrap" while still damp. The membranes were then 
placed in autoradiography cassettes with Fuji RX x-ray film 
and Du Pont Lightning Plus intensifying screen. The 
cassette was incubated at -70°C for 60 min, after which the 
film was developed.
2.2.5. Data analysis
Associations between class II allele distributions and 
between class II alleles and disease were analysed by log 
linear modeling (Breslow and Day 1980, Adena and Wilson 
1982) with the Glim statistical computer package (Royal 
Stat. Soc. relase no. 3.77, 1986).
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2.2.6. Automated Sequencing
DNA sequencing was by the dideoxy chain termination method 
(Sanger et al 1977) and is based on the random chain 
termination by dideoxy nucleotide incorporation.
Sequencing reactions were primed with the M13 universal 
primer sequence labelled with one of four fluorescent dye 
markers. The sequencing reaction was performed by thermal 
cycling, each cycle producing a strand labelled with a dye 
primer and terminated by a di-deoxy nucleotide. The 
products of the sequencing reaction were then analysed by 
electrophoresis on an Applied Biosystems International 
(ABI) automated sequencer.
2.2.6.1. Preparation of single stranded (ss) DNA
PCR primers tailed with the M13 universal primer sequence, 
JDPB5M13 (5'-TGTAAAACGACGGCCAGTCCCTCCCCGCAGAGAATTA-3') and
JDPB3M13 (5'-TGTAAAACGACGGCCAGTTCACTCACCTCGGCGCTGCA-3') 
were used to produce PCR product labelled with upstream or 
downstream M13 sequence.
Ss DNA was produced by performing PCR with one primer at 
the normal concentration, and the other primer at a 
concentration fifty times lower (asymmetric PCR). To 
obtain ssDNA PCR product tagged with the complement of the 
M13 universal primer sequence, the opposing untailed primer 
was used at the normal concentration. The ss DNA PCR 
contained 2 pi M13 tagged ds DNA product, 200 ng of the
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appropriate untailed primer in a 100 ß1 reaction using 
standard reaction conditions (see above). Thermocycling 
was performed using an Innovonics Gene Machine (Bartlett 
Industries, Victoria) thermocycler for 30 cycles, each 
cycle consisting of 1 min each at 90°C, 56°C and 72°C. The 
success of the PCR was assessed by electrophoresing 5/x 1 of 
product on a 2% agarose gel. The ssDNA PCR product was 
stored at -20°C.
The ssDNA was purified by retention in a centricon 100 
apparatus (Amicon). The centricon apparatus was rinsed in 
absolute ethanol, dried and 1.5 ml of sterile double 
distilled H20 added to the sample reservoir. The ss DNA 
product was added to the sample reservoir, care being taken 
not to transfer mineral oil. The centricon column was 
centrifuged in a Beckman ss34 rotor for 20 min at 6K. The 
filtrate cup was removed, the sample reservoir inverted and 
the retentate cup fitted. The column was then centrifuged 
at 2K for 10 min in a benchtop centrifuge. The retentate 
was transferred to a sterile 1.5 ml eppendorf tube and the 
volume adjusted to at least 48 ßl with sterile double 
distilled H20.
2.2.6.2. Sequencing reactions
The sequencing reactions were carried out using the ABI 
cycle sequencing kit which contained the M13 dye labelled 
primers, deoxy-/dideoxy-ribonucleotide triphosphate (d/dd
56
NTP) mixes, Taq DNA polymerase and 5X sequencing buffer 
(ABI). One reaction mix was performed for each base. The 
"A" reaction mix contained 1 pi each of dye primer Joe (0.4 
pmol/jLtl) , d/ddNTP A mix, 5x sequencing buffer and ss DNA 
template. The Taq DNA polymerse (ABI AmpliTaq) is first 
diluted (4U in 1 pi 5x sequencing buffer and 5.5 pi H20), 
and 1 pi diluted AmpliTaq is added to give a total volume 
of 5 pi. The sequencing reaction mixes for bases C, G and 
T were performed in parallel using M13 Fam, Tmra and Rox 
dye-labelled primers respectively with the corresponding 
d/ddNTP mixes. G and T reactions required twice the volume 
of all ingredients.
The four separate sequencing reactions were overlaid with 
20 pi mineral oil and immediately transferred to a 
Programmable Cyclic Reactor (Ericomp Inc., San Diego, 
California) thermal cycler set to run for 30 cycles as 
follows: 15 cycles of 95°C for 30s, 55°C for 30s and 70°C
for 60s followed by 15 cycles of 95°C for 30s and 70°C for 
60 s.
The completed A, C, G and T reactions were precipitated by 
adding individually to 95% ethanol/0.1M NaAc. and incubated 
at -200C for at least 20 min. The precipitate was isolated 
by spinning in a benchtop microcentrifuge for 15 min, and 
the supernatant removed. The pellet was rinsed in 70% 
ethanol, spun in a benchtop microcentrifuge for a further 
15 min, supernatant was removed and the pellet dried under 
vacuum. All steps were carried out in the dark or in 
reduced light conditions where possible as the dye labelled
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primers are light labile. The precipitate was redissolved 
in 5 ßl deionized formamide, 1 /il 50 mM EDTA, pH 8.0, 
heated at 90°C for 2 min and electrophoresed on a 6% 
polyacrylamide gel using an ABI 370A automated DNA 
sequencer. Version 1.3 software was used to perform 
automatic fluorescence analysis and base calling.
Chapter 3
The AFLP Technique
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3.1. HLA-DP TYPING TECHNIQUES
HLA-DP antigens have traditionally been typed by the primed 
lymphocyte test (PLT)(Shaw et al 1980) and more recently by 
restriction fragment length polymorphism (RFLP) analysis 
(Easteal et al 1989). With the advent of PCR technology 
two new DPB1 typing methods have been described; sequence 
specific oligonucleotide (SSO) typing (Angelini et al 
1989), and amplified fragment length polymorphism (AFLP) 
typing (Maeda et al 1989, Dekker and Easteal 1990).
3.1.1. The Primed Lymphocyte Test
The PLT (described in Chapter 1) detects antigenic 
variation directly by the use of TCR recognition of the 
different HLA-DP antigens, however the technique has a 
number of disadvantages. First, it is technically 
difficult. The generation and handling of lymphocyte 
cultures needs a high level of expertise and few 
laboratories are able to reliably perform PLT. Second, the 
results obtained from PLT are expressed as a continuum of 
radioactivity measurements, and a level is arbitrarily 
chosen, above which a positive reaction is considered to 
have taken place, and below which the proliferative 
response is deemed negative. This arbitrary value is 
often chosen by eye or values expressed as a relative 
response compared to the mean value (Festenstein and Ollier 
1988). Slight proliferative responses can be due to 
responder cells reacting to slight allelic differences
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between other class I and II antigens which could lead to 
false positive reactions in some cases. Third, the 
stimulatory capacity of the typed lymphocytes can vary 
widely between individuals, and can be affected by some 
diseases and the method used to obtain the cells (Odum 
1989). Fourth, although PLT defines HLA-DP alleles at the 
functional level as DP antigens, the range of DP types 
recognised by PLT is limited to the specificities present 
in the panel of primed T cells. PLT will type other 
antigens as blank, so that it is possible that a homozygote 
by PLT is in fact a heterozygote of a recognised allele, 
and an undetected novel allele.
3.1.2. Restriction Fragment Length Polymorphisms
RFLP analysis offers the advantage of being technically 
more simple than PLT; and is DNA based, removing the need 
for the acquisition and maintenance of lymphocytes.
However, RFLPs have a number of drawbacks.
First, it takes a relatively long time to perform.
Analysis requires overnight restriction endonuclease 
digestion of the genomic DNA samples, then overnight 
Southern transfer of the digested fragments, and then 
sequential hybridization and detection of two probes to 
three nitrocellulose filters which may take more than seven 
days to perform (Easteal et al 1989).
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Second, RFLP involves the use of radioactive isotopes which 
require special handling facilities.
Third, DPw3 and w6 cannot be distinguished by RFLP 
analysis, and the discrimination between DPw2 and w4, the 
two most common types in Caucasiods, is prone to error.
DPw2 and w4 can only be differentiated by the results of 
Msp I digestion which requires very low salt conditions and 
digestion is easily inhibited and often unreliable. DPw4 
is associated with a 1.1 kb band while DPw2 is associated 
with a 2.1 kb band lying close to a 1.9 kb band common to 
both types. Both diagnostic bands are relatively faint and 
difficult to distinguish.
Fourth, each analysis requires at least 30 /ig of genomic 
DNA. The relatively large amount of DNA needed may mean 
RFLP analysis is unsuitable in some cases.
Fifth, the DPA1 and DPB1 probes hybridize to regions 
flanking the sequence variation that leads to antigenic 
variation, and depends on the complete association between 
two areas of sequence variation; the coding and non-coding 
regions in an HLA-DP allele. The association between RFLP 
pattern and DPB1 allele may not be complete for two 
reasons. First, non-coding sequences vary independently of 
the coding region sequences, this leads to non­
correspondence between RFLP patterns and alleles in some 
haplotypes. Second, RFLP typing requires that novel 
sequence variation in the coding region giving rise to new 
alleles is reflected as sequence variation in the non-
coding regions which hybridize to the probe DNA, which is 
unlikely to happen in all cases.
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3.1.3. PCR based typing methods
The DPB1 second exon, encoding the ßl domain, contains 
almost all the HLA-DP allelic variation (Bugawan et al 
1988, Begovich et al 1989, Bugawan et al 1989). Comparison 
of the sequences reveals the allelic sequence diversity is 
clustered into six hypervariable regions (HVRs)(Fig. 3.1). 
HVR 1 lies between nucleotides 49 and 59, HVR 2 between 125 
and 135, HVR 3 between 191 and 198, HVR 4 between 220 and 
233, HVR 5 between 253 and 255, and HVR 6 between 277 and 
286. At most HVRs only three or four different sequences 
are represented among the 19 alleles so that the variation 
between alleles appears to be largely due to the 
rearrangement of a limited number of nucleotide positions.
Most of the nucleotide variation is reflected by amino acid 
sequence variation with there being few silent nucleotide 
polymorphisms. Several methods of HLA-DP DNA typing have 
been developed which utilize the limited polymorphism which 
occurs in the HVRs of exon II.
3.1.4. Sequence Specific Oligonucleotide Typing
Some HLA-DP typing protocols use sequence specific 
oligonucleotide (SSO) probes to hybridize to polymorphic
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sequences at the HVRs in PCR amplified second exon 
sequences (Angelini et al 1989, Bugawan et al 1990, 
Fernandez-Vina et al 1991) This method is more accurate, 
sensitive and efficient than PLT and RFLP typing. However, 
many hybridization steps may be required to accurately 
distinguish all the DPB1 alleles now recognized.
The method of Fernandez-Vina et al (1991) requires each 
sample to undergo three PCR reactions. Two "group" 
specific amplifications are performed using primers 
complementary to polymorphic sequences at HVR1 to divide 
the 19 alleles into two groups. A PCR amplification using 
primers that hybridize to all alleles is included to ensure 
the group specific amplifications were successful. The PCR 
products are then hybridized with 16 SSOs, and the pattern 
of SSO hybridization to the PCR products determines the 
identities of the alleles present. Computer analysis of 
the DPB1 second exon sequences suggests a minimum of 18 SSO 
probes are needed without group specific amplification 
(Muller and Eiermann 1991).
3.1.5. Amplified fragment length polymorphism typing
An alternative PCR based method of HLA-DP typing is by 
analysis of amplified fragment length polymorphisms (AFLPs) 
(Maeda et al 1989, Dekker and Easteal 1990). This involves 
the PCR amplification of the DPB1 second exon region, and 
analysis of the amplified fragment by digestion with a 
small number of restriction endonucleases. These
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restriction enzymes have recognition sites at the HVRs 
giving rise to allele specific patterns of restriction 
fragments. The restriction fragments are separated by 
polyacrylamide gel electrophoresis allowing allele specific 
patterns of restriction fragments to be recognized. The 
scheme of Maeda et al (1989) was designed to discriminate 
between 13 alleles using five restriction enzymes; Apa I, 
Sac I, Bst UI, Fok I and Rsa I. The method could not 
distinguish between DPB1*0201 and *0402 which are both 
relatively common alleles in Caucasiods, although Maeda et 
al (1989) did point out that the restriction endonuclease 
Mnl I could discriminate between these alleles, but was not 
included in the scheme as at that time Mnl I was not 
commercially available.
3.2. DEVELOPMENT OF THE AFLP TYPING PROTOCOL FOR DPB1 
ALLELES
3.2.1. PCR Amplification Of HLA-DPB1 Exon II
PCR primers were designed to amplify the DPB1 second exon, 
that span intron exon boundaries, but do not encroach on 
HVRs. In order to demonstrate that the PCR product is the 
DPB1 second exon, a number of experiments were performed. 
First the product was sized by comparison with DNA 
molecular weight markers separated by polyacrylamide gel 
electrophoresis, with the predicted size of the product 
being observed.
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Second, the product was hybridized with a DPB1 cDNA probe, 
pII-b-7 (Gustafsson et al 1984), following Southern 
transfer (Fig 3.2). The results showed that the probe 
hybridized to the product but not to the negative control. 
Some hybridization to the negative control was observed, 
this was due to very slight DNA contaminantion and was not 
observed by ethidium bromide staining.
Third, in order to establish that the DPB1 but not DPB2 was 
being amplified, the restriction map of the pseudogene 
seguence homologous to exon II in the functional gene 
(Gustafsson et al 1987) was examined and two restriction 
enzyme sites were located, one pseudogene (DPB2) specific 
(Hinf I, producing 237 and 75 bp fragments), and the other 
DPB1 specific (Bst UI, producing 178, 76 and 48 bp
fragments) that occurs in a nonpolymorphic region of all 
DPB1 alleles but not in DPB2. PCR product was digested 
with both enzymes and the restriction fragments were 
separated by electrophoresis on an 8% polyacrylamide gel 
(Fig 3.3). The Hinf I digest did not cut the PCR product 
and the Bst UI digest produced 178 and 76 bp bands (the 48 
bp band was too small to be observed), the results were 
consistent with DPB1 second exon specific amplification.
3.2.2. Restriction Enzymes
Variable restriction enzyme sites for the 19 recognised 
DPB1 allelic seguences (Begovich et al 1989, Bugawan et al 
1989, Bugawan et al 1990) were identified. Enzymes were
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Figure 3.2 Autoradiograph of DPB1 specific cDNA probe 
pll-ß-l hybridization: to negative control PCR
product (PCR performed with no template DNA) (Lane 1); 
5 fll protocol 1 PCR product (Lane 2) . Lane M; DNA 
molecular weight marker, pATX digested with Hinf I.
1
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Figure 3.3 Observed band sizes of Hinf I digest products 
(Lane 1) and Bst UI digest products (Lane 2) of PCR 
product produced using protocol 2.
bp 1 2
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chosen that had recognition sites located in HVRs and so 
would digest subsets of DPB1 second exon alleles. At least 
eight enzymes were discovered to give polymorphic 
fragments; Bst UI, Dde I, Eco NI, Fok I, Mnl I, Rsa I,
Sac I and Sau 961. Of these, only four were reguired to 
give allele specific fragment patterns for all 19 alleles; 
Eco NI (Fig 3.4), Fok I (Fig 3.5), Mnl I (Fig 3.6) and 
Rsa I (Fig 3.7).
Due to difficulties in amplification of DNA samples (see 
Chapter 2) protocol 2 was used to produce DPB1 second exon 
product. Restriction digests were performed on PCR product 
produced by both protocols, and it was observed that any 
variation in restriction fragment sizes of protocol 2 PCR 
product could be explained by the use of the new upstream 
primer. The expected restriction digest fragment sizes 
were calculated based on PCR product generated via 
protocol 2 (Fig 3.8).
3 .2.2.2 . Eco NI
Eco NI has an 11 bp recognition seguence, consisting of a 
six bp palindrome separated by a five bp non-specific 
seguence (CCTNN/NNNAGG). The enzyme has recognition 
sequences at the first and fourth HVR (Fig 3.4) and Eco NI 
digestion splits the 19 alleles into five groups (Fig 3.9 
and 3.10). Observation of a 260 bp band is indicative of 
DPB1*0401, *0402 and *0501 alleles; a 174 bp band is
indicative of *0201, *0202, *0801, *1601 and *1901 alleles.
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DPB 1 allele
0 0 0 0 0 0 0 0 0 0 1 1 i
1 2 2 3 4 4 5 6 8 9 0 3 4 5 6 7 8 9
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
E n z .  b p 1 2 2 1 1 1 1 1 i
M n l  I 1 78 ■ ■m i n i 02
■ ■ ■
76
7 6 ‘ ■ ■ ■
73 ■ ■
69 ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■
66» ■ ■ ■
65 ■
54 ■ ■
51 ■ ■ ■ ■ ■ ■ ■
43 ■ ■ ■ ■
36 ■ ■ ■
33 ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■
22 ■ ■ ■
21
19
18
1 1 ■ ■
8 ■
6 ■ ■
5 ■ ■
3 ■ ■ ■ ■ ■ ■ ■ ■ ■ ■
Rsa 1 31 ■ ■ ■
260 ■ ■
199 ■ ■ ■ ■ ■ ■ ■ ■ ■
147 ■
113 m ■
78 ■ ■ ■ ■
69 ■ ■ ■ ■
52 ■ ■ ■ ■ ■ ■ ■
EcoNI  312 ■ ■
260 ■ ■ ■
226 ■ ■ ■ ■
223 ■ ■ ■ ■ ■
174 ■ ■ ■ ■ ■
89 ■ ■ ■ ■
8 6 ! ■ ■ ■ ■ ■ ■ ■ ■ ■ ■
52 ■ ■ ■ ■ ■ ■ ■ ■
3 ■
Fok 1 312 ■ ■
2 6 4 ■ ■ ■
205 ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■
107 ■ ■ ■ ■ ■ ■
59 ■ ■ ■ ■ ■ ■ ■ ■
48 ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■
Figure 3.8 Expected restriction fragment sizes of 
DPB1 second exon PCR products digested with Eco NI 
Fok I, Mnl I and Rsa I.
DPB1
74
Eco NI
312
260
(223/226)789
(223/226)786
174/86
0101,
0401,
0501
0301,
1401,
0601,
1001,
1701
0201,
0801,
1901
1801
0402,
1101,
1501,
0901,
1301,
0202,
1601,
Figure 3.9 Separation of DPB1 alleles on the 
basis of restriction fragments visible on 8% 
polyacrylamide gels following Eco NI digestion of 
PCR amplified DPB1 second exon DNA.
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Figure 3.10 Examples of restriction fragments produced by 
digesting second exon PCR product of DPB1 alleles with Eco NI 
Observed band sizes of Eco NI digest products. Lane 1 = 
DPB1*0401,*0401; Lane 2 = DPB1*0201,*0201; Lane 3 =
DPB1*0801,*0801; Lane 4 = DPB1*0301,*0301; Lane 5 = 
DPB1*0101*0101.
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Alleles which contain 223 or 226 bp bands,
indistinguishable on 8% polyacrylamide gels, can be divided 
into two groups on the basis of 86 or 89 bp bands.
DPB1*0301, *1101, *1401 and *1501 contain 223/6 and 89 bp
bands, while DPB1*0901, *1001 and *1301 contain 223/6 and
86 bp bands. DPB1*0601, because of overlapping Eco NI 
sites (see below) produces both 86 and 89 bp bands in 
conjunction with the 223/6 band. DPB1*0101 and *1801 
remain uncut when digested by Eco NI.
3.2.2 .2 . Fok I
Fok I is an atypical restriction endonuclease in that the 
recognition sequence is non-palindromic and the cutting 
site is nine bp downstream from the recognition site (5'- 
GGATGNg/-3'), with a further four bp overhang on the 
complementary strand (3'-CCTACN13/-5'). Fok I has 
recognition sites in the fourth and fifth HVR (Fig 3.5) and 
digestion divides the alleles into four groups (Fig 3.11 
and 3.12). DPB1*0301 and *1401 do not contain Fok I sites,
while DPB1*0601, *1101 and *1501 give rise to a 264 bp
band. The remaining alleles all contain a 205 bp bands and 
are divided into two groups on the basis of the presence of 
a 107 bp band (DPB1*0101, *0801, *0901, *1001, *1301 and
*1901) or 59 and 48 bp bands (DPB1*0201, *0202, *0401,
*0402, *0501, *1501, *1601, *1701 and *1801).
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DPB1
Fokl
312
264
205/107
205/59
0301, 1401
0601,1101, 
1501
0101,0801, 
0901,1001, 
1301,1901
0201,0202, 
0401,0402, 
0501, 1601, 
1701,1801
Figure 3.11 Separation of DPB1 alleles on the 
basis of restriction fragments visible on 8% 
polyacrylamide gels following Fok I digestion of 
PCR amplified DPB1 second exon DNA.
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Figure 3.12 Examples of restriction fragments produced by 
digesting second exon PCR product of DPB1 alleles with Fok I. 
Lane 1 = DPB1*0401,*0901, Lane 2 = DPB1*0601,*1501; Lane 3 = 
DPB1*0301,*0301.
1 2 3bp
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3.2.2.3. Mnl I
Mnl I, like Fok I, has a non-palindromic recognition 
sequence, with the cutting site seven base downstream 
(CCTCNy/). The DPB1 alleles contain several Mnl I 
restriction sites, at the second, third, fourth and sixth 
HVR and at three non-polymorphic sites in the primer 
regions (Fig 3.6), which give rise to a variety of 
different sized fragments (Fig 3.13 and 3.14).
Mnl I digests give 12 restriction fragment patterns, nine 
of which are allele specific, and can discriminate between 
all six DPB1 alleles described by PLT typing. All alleles 
contain a 76 bp fragment except DPB1*1101 and *1501; these 
two alleles can be discriminated from each other by a 71 bp 
fragment unique to DPB1*1501. DPB1*0101, *0401, and *1301
contain a 102 bp fragment, and can be distinguished from 
each other by the presence of 54 bp, 76 bp doublets and 51 
bp bands respectively. The 76 bp doublet consists of two 
fragments which despite being the same length have 
different electrophoretic mobilities (see 3.5.). The 
doublet is also seen in DPB1*0402 and *1801 in conjunction 
with a 69 bp band. DPB1*0201 and *0202 share a distinct 73 
bp fragment and can be discriminated by the presence of a 
69 bp fragment associated with DPB1*0201 and 66 bp fragment 
associated with DPB1*0202. DPB1*0301, *0601 and *1401 are
predicted from sequence data to contain 69 and 43 bp 
fragments, however due to the interfering effect of 
overlapping Mnl I sites, different fragment patterns are in
Mnl I
DPB1
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Figure 3.13 Separation of DPB1 alleles on the 
basis of restriction fragments visible on 12% 
polyacrylamide gels following Mnl I digestion of 
PCR amplified DPB1 second exon DNA.
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Figure 3.14 Examples of restriction fragments produced by 
digesting second exon PCR product of DPB1 alleles with Mnl I. 
Lane 1 = DPB1*0801,*0801, Lane 2 = DPB1*0501,*0501; Lane 3 = 
DPB1*0101,*0101; Lane 4 = DPB1*0201,*1101 ; Lane 5 =
*0301,*1501; Lane 6 = *0401,*0401; Lane 7 = DPB1*0201,0201; 
Lane 8 = DPB1*0401,*0202.
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fact produced (see section 3.5.)* DPB1*0301 and *1401
contain 69 and 54 bp fragments, while DPB1*0601 contains 69 
and 51 bp fragments makes it indistinguishable from 
DPB1*0801, *0901, *1001, *1601 and *1701.
3.2.2.4 . Rsa I
Rsa I recognises a palindromic four base pair sequence, 
(GT/AC), which occurs at the first, second and third HVRs 
(Fig 3.7). Digestion with Rsa I divides the 19 alleles 
into five groups (Fig 3.15 and 3.16). Rsa will not cut 
DPB1*0901, *1401 and *1701; it has one site in DPB1*0301
and *0601 giving rise to a 264 bp fragment. There is also 
one Rsa I recognition site on DPB1*0201, *0202, *0401,
*0402, *0501, *0801, *1001, *1601 and *1901 giving rise to
199 and 113 bp fragments. DPB1*1801 has two recognition 
sites giving a unique 147 bp fragment in combination with a 
113 bp fragment. The DPB1 alleles *0101, *1101, *1301 and
*1501 all contain the same three Rsa I recognition 
sequences which give rise to 113 and 78 bp fragments.
3.2.3. AFLP Typing Scheme
From the combination of the four enzymes a typing scheme 
can be constructed which allows all 19 alleles to be typed 
(Fig 3.17). As mentioned above, Mnl I digestion gives 
specific patterns for nine alleles, Rsa I digestion can 
discriminate between a further five alleles. The remaining
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Figure 3.15 Separation of DPB1 alleles on the 
basis of restriction fragments visible on 8% 
polyacrylamide gels following Rsa I digestion of 
PCR amplified DPB1 second exon DNA.
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Figure 3.16 Examples of restriction fragments produced by 
digesting second exon PCR product of DPB1 alleles with Rsa I. 
Lane 1 = DPB1*0901,*0901, Lane 2 = DPB1*0401,*New (see chapter 
6) ; Lane 3 = DPB1*0101,*0101; Lane 4 = *0301,*0301; Lane 5 =
*0401,*0401.
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Figure 3.17 Diagram showing AFLP typing scheme used 
to define 19 DPB1 alleles by progressive restriction 
enzyme digests. Numbers refer to expected fragment 
sizes in bp.
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five alleles can be separated by Eco NI and Fok I 
digestion. Only two alleles, DPB1*0801 and *1601, require 
all four enzymes to be distinguished. However all four 
enzymes are needed to type many heterozygote combinations 
(see Appendix 1).
3.3 TYPING OF HETEROZYGOTES
It has been suggested that HLA genotyping by PCR based AFLP 
techniques is unfeasible due to the proportion of 
heterozygote pairs that are indistinguishable from each 
other (Olerup 1990). It is claimed that DPB1 typing by the 
procedure reported by Maeda et al (1989) produced unique 
restriction enzyme digestion patterns for only 65% of 
heterozygote pairs. This has been refuted by Inoko (1990) 
who goes on to point out a number of advantages of AFLP 
typing. The AFLP scheme presented here uses different 
enzymes than the scheme analysed by Olerup (1990) and can 
provide unique restriction enzyme digestion patterns for 
all but one heterozygote pair.
The ability of the AFLP technique to discriminate between 
heterozygotes can be demonstrated by looking at results of 
sequential enzyme digestion (see Appendix 1). Mnl I 
digestion splits the 19 alleles into 12 groups (Fig 3.13) 
and digestion with Mnl I alone will give rise to 41 unique 
restriction fragment patterns out of 190 possible 
homozygote and heterozygote combinations. Three groups of 
alleles cannot be discriminated by Mnl I; DPB1*0301 and
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*1401; DPB1*0402 and *1801; DPB1*0601, *0801, *0901, *1001,
*1601 and *1701. Hence homozygote combinations within 
these groups cannot be discriminated, and pairs of 
heterozygotes involving a particular group with any other 
allele also cannot be discriminated.
Rsa I digestion can give unigue restriction fragment 
patterns to a further 56 genotypes. Rsa I can distinguish 
DPB1*0301 from *1401, and DPB1*0402 from *1801 (Fig 3.16), 
hence most combinations of heterozygotes involving these 
alleles can be separated. Rsa I digestion will split 
DPB1*0601, *0801, *0901, *1001, *1601 and *1701 into three
groups (Fig 3.15). DPB1*0601 has a unigue Rsa I fragment,
but DPB1*0901 and *1701 give the same bands by Rsa I 
digestion, as do DPB1*0801, *1001 and *1601. Eco NI
digestion discriminates a further 21 heterozygotes, and is 
able to split DPB1*1001 from DPB1*0801 and *1601. Fok I 
digestion can split DPB1*0901 from DPB1*1701, and DPB1*0801 
from DPB1*1601 (Fig 3.11) and so can define 71 
heterozygotes.
Thus all homozygote and heterozygote allelic combinations 
give unigue restriction fragments except two pairs of 
heterozygotes; DPB1*0201,*1901 and DPB1*0202,*0801; 
DPB1*0801,*1701 and DPB1*0901,*1601 (see Appendix 1). The 
result was confirmed by analysing the fragment patterns 
using a computer program (kindly supplied by J. Trejaut and 
H. Dunckley, Red Cross Blood Transfusion Service, Sydney). 
DPB1*0801 and *1601 differ only at the fifth HVR region, as
do DPB1*0901 and *1701. DPB1*0801 and *0901 have no Fok I
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site at HVR 5 while *1601 and *1701 do. Hence the 
heterozygote pairs DPB1*0801,*1701 and *0901,*1601 each 
contain the same HVR sequences, differing only as to which 
allele contains the Fok I site at HVR 5. The two pairs 
cannot be distinguished by the use of any other restriction 
enzyme or enzyme combinations, nor by the use of any SSO 
probe.
The pairs can be discriminated between by first performing 
an Rsa I digest, both pairs producing 300, 199, and 113 bp
bands. The 113 bp band originates from the DPB1*0801 or 
*1601 allele, but only *1601 contains the HVR 5 Fok I site 
at nucleotide position 252. The Rsa I digest fragments can 
be separated by electrophoresis on low melting point 
agarose gels, and the 113 band isolated, purified and 
digested with Fok I and the fragments sized by 
electrophoresis. A pattern of a 57 and 48 bp band would 
indicate that the 113 bp band originated from the DPB1*1601 
allele, a 107 bp band would indicate that the band 
originated from DPB1*0801. A sequence specific 
oligonucleotide could also be used to identify the 
polymorphic sequence at HVR 5 on the isolated 113 bp band. 
All four alleles are rare and have a less than one percent 
frequency in Caucasiods, so that a heterozygote containing 
these alleles would be encountered only very rarely.
The second pair of allelic combinations that are 
unresolvable by the scheme presented here are is 
DPB1*0201,*1901 and DPB1*0202,*0801. These allele pairs, 
however, can be discriminated between by Sac I digestion.
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Only DPB1*0202 contains a Sac I site and digestion produces 
181 and 131 bp bands. DPB1*0202, *0801 and *1901 are rare
in Caucasiods, and although DPB1*0201 is relatively common, 
the risk of encountering these heterozygote combinations 
remains low and none was observed in this study.
3.4 WORKSHOP CELL LINE TYPING
The AFLP method was evaluated by applying it to cell lines 
from the panel designed for the Tenth International 
Histocompatibility Workshop (Yang et al. 1989). The DNA 
samples were amplified via protocol 1 (see chapter 2) and 
the identities of the cell lines were obscured to avoid any 
potential bias due to prior knowledge of the typing results 
by other methods. The AFLP typing results and their 
comparison with the results of PLT, RFLP and SSO typing are 
presented in Table 3.1. All the cell lines had previously 
been PLT typed (Yang et al 1989), all but three had been 
RFLP typed (Easteal et al 1989, Hyldig-Nielsen and 
Svejgaard 1989, and Mitsuishi et al 1989) and 22 had been 
typed by SSO (Angelini et al 1989, Fernandez-Vina et al 
1990 ). The cell lines included all of the six recognized 
PLT defined DPw specificities except DPw6, as well as a 
number of "blank" types. AFLP typing agreed with PLT and 
RFLP typing in all but a few cases. There was complete 
agreement between AFLP and SSO typing results.
AFLP typing could recognise rare alleles typed by PLT as 
DPwl-w6 or blank. Cell line 9063 was PLT typed as DPw2,
90
Table 3.1
DPBl assignments determined by AFLP typing compared with 
SSO assignments and RFLP and PLT determined DP types for a 
subset of 10th International Histocompatibility Workshop 
(10IHW) cell lines.
10th IHW PLT1
cell line 
DPw
RFLP2
DPw
SSO3
DPBl
AFLP
DPBl
9023 1 1 *0101 *0101
9058 1 1 *0101 *0101
9021 1 1 *0101,*0402 *0101,*0402
9038 2 2 *0201 *0201
9050 2 2 *0201 *0201
9017 2,4 2,4 *0201,*0401 *0201,*0401
9045 2,4 2,4 *0201 ,*0402 *0201 ,*0402
9074 2,5 2,5 *0201 ,*0501
9020 2 2 *0202 *0202
9019 0 2 *0202 *0202
9018
9079
3
3,4
3/6 *0301 *0301
*0301
9087 3,4 3/6, *0301 ,*0401
9071 3,4 3/6, *0301,*0402
9004 4 4 *0401 *0401
9014 4 4 *0401 *0401
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Table 3.1 continued
10th IHW 
cell line
PLT1
DPw
RFLP2
DPw
SSO3
DPBl
AFLP
DPBl
9075 4 4 *0401 *0401
9031 4 4 *0401 *0401
9051 4 4 *0401 *0401
9035 4 4 *0401
9027 4 4 *0401,*0402 *0401,*0402
9001 4 *0402
9013 0 4 *0402 *0402
9010 0 NEW *0402 *0402
9064 0 NEW *0402
9024 5 *0501
9055 5 NEW *0501 *0501
9077 5 3/6,5 *0501,*NEW
9063 2 NEW *0801 *0801
9048 0 NEW *0901 *0901
9034 0 NEW *1001 *1001
lyang et al. 1989. Consensus from: Easteal et al 1989, 
Hyldig-Nielsen and Svejgaard 1989, and Mitsuishi et al 
1989. 3SSO typed by Angelini et al 1989 and by Fernandez- 
Vina et al 1991.
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and identified as a novel type by RFLPs. However both AFLP 
and SSO type cell line 9063 as DPB1*0801. Workshop cell 
lines 9034, 9048, 9010 and 9064 were all typed as DPw blank
by PLT, however cell lines 9010 and 9064 were typed by 
AFLPs as DPB1*0402. Cell lines 9034 and 9048 were 
identified as having novel RFLP patterns and were typed as 
DPB1*1001 and *0901 respectively by both SSO and AFLPs.
The AFLP technique also identified a novel variant. Cell 
line 9077 was typed as DPw5 by PLT and DPw3/6,5 by RFLP 
typing. AFLP analysis resulted in a unique pattern of 
restriction fragments suggesting a DPB1*0501,*New 
heterozygote. This cell line was not included in the SSO 
typing results.
It is interesting to note that the DPB1 second exon of cell 
line 9021 was sequenced and was reported to contain a 
DPB1*0101 sequence in combination with a novel DPB1 allele, 
lb (Lee et al 1989) . PLT typed cell line 9021 as DPwl and 
the reported sequence of DPB-lb was very similar to 
DPB1*0402 except for a unique sequence in HVR 1. The 
sequence would give rise to a unique restriction fragment 
pattern by AFLP, however the cell line was typed as 
DPB1*0101,*0402. This result was confirmed by SSO typing 
(Fernandez-Vina et al 1991) and the lb allele has been 
independently sequenced and was found to be identical to 
DPB1*0402 (Bugawan 1990).
Thus AFLP typing of 31 workshop cell lines show that AFLP 
typing results are compatible with those obtained by SSO
typing, and that they identify rare alleles not recognised 
by RFLP or PLT typing, and can identify new alleles.
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3.5. AFLP DISCREPANCIES
When comparing observed fragment sizes with those expected 
according to DNA sequence data (Fig 3.8), some 
discrepancies were found. Most were due to overlapping 
Mnl I restriction enzyme sites. Mnl I has a seven bp gap 
between the end of the non-palindromic recognition site and 
the cutting site, and the cut site can be upstream or 
downstream of the recognition site if the site is in the 
forward or reverse orientations respectively. Interference 
between sites can occur if sites overlap or are in close 
proximity.
3.5.1. Mnl I digests of DPB1*0301, *0601 and *1401
Alleles which contain Mnl I restriction sites at nucleotide 
positions 219 and 280, i.e. DPB1*0301, *0601 and *1401, are
expected to produce a 43 bp fragment (Fig 3.8). However, 
in Mnl I digests of DPB1*0301 and *1401, the observed band 
pattern includes a 54 bp fragment; digests of DPB1*0601 
produce a 51 bp fragment (Fig 3.18). This is due to 
overlapping Mnl I sites which include the site at 
nucleotide position 221 (Fig 3.14). DPB1*0301 and *1401
have a second Mnl I site at nucleotide position 226, in the 
opposite orientation to the site at position 221. The
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Figure 3.18
A. Restriction fragments produced by digesting second exon PCR 
product of DPB1*0301*0301 (Lane 1), and DPB1*0401,*0601 (Lane 
2), with Mnl I.
B. Restriction fragments produced by overlapping Mnl I 
recognition sequences (boxed) in DPB1*0301 or *1401 and in 
DPB1*0601.
AB
*0301, 
*1401
219 226 280
:cctcctgi GAGQAGAAGCGG CGAGCTGAC1 GAGGCCG
4 3 bp
54 bp
219 226 229
I I I
IGQCCTCCTG gaggL ggAGCGG
43 bp
51 bp
54 bp
280
I
CGAGCTGAC1 GAGGCCG
- ►
*0601
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interval between recognition sites and cutting sites 
overlap, so that the recognition site of one site is 
disrupted by the cutting site of the other. If the 
position 219 site is recognised, a 43 bp band is produced, 
but if the position 226 site is recognised, a 54 bp band is 
produced. Mnl I digests of DPB1*0301 and *1401 produce 
both the 54 and 43 bp bands, however the 43 bp band is too 
small to be reliably scored on 12% polyacrylamide gels. 
DPB1*0601 contains a third Mnl I site at nucleotide 
position 229, in the same orientation as the position 226 
site (Fig 3.18). A 43 bp band is the result of the enzyme 
binding to the 219 site, but if the position 229 site is 
recognised then a 51 bp band is produced. If the enzyme 
binds to the position 226 site, a 54 bp fragment is 
produced but still contains an intact position 229 site, 
and a 51 bp band is again the final result. If it is 
assumed that each of the sites have an equal chance of 
binding the Mnl enzyme, then the 51 bp band will be the 
outcome in two out of three possible Mnl I binding events. 
Hence the 43 bp band is often not observed because of its 
smaller size, but also represents only one third of the 
product digested.
3.5.2. Mnl I digests of DPB1*1101 and *1501
DPB1*1101 and *1501 contain Mnl I recognition sites at 
nucleotide positions 219, 226 and 231. The latter two
sites are in reverse orientation to the first (Fig 3.19). 
The next Mnl I site downstream in DPB1*1101 is at position
21
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280 and Mnl digestion produces a 43, 49 and 54 bp
fragments, however only a 49 bp is observed (Fig 3.14).
The 54 bp fragment contains an intact position 231 site and 
becomes a 49 bp fragment, so that the 49 bp band on 12% 
polyacrylamide gels becomes twice as intense as the 43 bp 
band. DPB1*1501 has an Mnl I site at position 301 and so 
produces a 71 bp band, a 76 bp band which is further 
digested to produce a second 71 bp band, and a 65 bp band 
which because of its lower intensity relative to the 71 bp 
band is difficult to observe (Fig 3.19). DPB1*1101 and
*1501 are predicted to produce a 178 bp band between Mnl I 
recognition sites at nucleotide positions 30 and 226 (Fig 
3.8). However, the observed fragment patterns include a 
number of discrete bands at the 178 bp region (Fig 3.14). 
This is also due to the overlapping Mnl sites at HVR 4. If 
the Mnl I restriction enzyme binds to the nucleotide 
position 226 site, a 178 bp fragment is produced, if the 
site at position 231 is recognised a 183 bp band is 
produced, and if the site at 219 is recognised a 189 bp 
band is the result. Hence three bands are observed to be 
associated with the expected band of 178 bp.
3.5.3. Mnl I digests of DPB1*1301
DNA sequence data predict that an Mnl I digest of DPB1*1301 
will produce 102, 76 and 51 bp bands (Fig 3.8). However a 
band at approximately 105 bp is observed and is associated 
solely with DPB1*1301 alleles (Fig 3.20). The 102 bp band 
is produced by Mnl I recognition sites at nucleotide
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Figure 3.20
A. Restriction fragments produced by digesting second exon PCR 
product of DPB1*0101*1301 (Lane 1), and DPB1*0801, *1301 (Lane 
2), with Mnl I.
B. Restriction fragments produced by overlapping Mnl I 
recognition sequences (boxed) in DPB1*1301.
AB
bp 2 bp
105
102
1 2 4 2 2 6  2 2 9
I I
* 1 3 0 1  TACAACCGGG£ GGAGTAC
{______
GCCATCCTG
1-4
GAGGAGGAGCGG
102bp -
■ 1 0 5  b p
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positions 124 and 226. An Mnl I recognition site at 
nucleotide position 229 overlaps the site at position 226 
(Fig 3.20). If the position 226 site is recognised Mnl I 
cuts 7 bp upstream at 218, producing a 102 bp fragment, as 
predicted. If the position 229 site is recognised the cut 
site at 221 lies within the 7 bp gap between the 226 
recognition site and cutting site, so disrupting the site 
at position 226 and producing a 105 bp fragment. Other 
DPB1 alleles (DPB1*0201, *0202, *0601, *0801, *0901, *1001,
*1101, *1501, *1601, *1701 and *1901) contain the 226 and
229 recognition sites, however all such alleles, except 
*1101 and *1501 (see section 3.5.2.), contain Mnl I sites 
short distances upstream of the nucleotide position 226 and 
229 sites, producing fragments too small to be reliably 
observed on 12% polyacrylamide gels. DPB1 alleles that 
also produce a 102 bp band by Mnl I digests, DPB1*0101 and 
*0401, do not have the position 229 site.
3.5.4. 102, 69 and 66 bp Mnl I digest pattern
An Mnl I digest pattern was observed which contained 102,
69 and 66 bp bands. The presence of a 69 bp or a 66 bp 
precludes the presence of a 102 bp fragment, as the 
polymorphic Mnl I site responsible for producing the 66 or 
69 bp band lies within the 102 bp band. Several lines of 
enquiry lead to the conclusion that the 102 band was an 
artifact produced by interference between two Mnl I sites 
on different alleles.
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First, band patterns observed for the other restriction 
enzymes did not suggest an allele that included an Mnl I 
102 bp band. If the 102 bp band was ignored, the sample 
typed as DPB1*0201,*0501. Second, a Polynesian population 
was found to contain a high proportion of DPB1*0201 and 
*0501 alleles (S. Easteal pers. comm.), however 
DPB1*0201,*0501 heterozygotes were not observed. Instead, 
a significant proportion of the samples contained the Mnl I 
102, 69 and 66 bp pattern. Third, DPB1*0201 contains an
Mnl I site at nucleotide position 193, as do DPB1*0402, 
*0201, *0301, *0601, *0801, *0901, *1001, *1401, *1601,
*1701 and *1801. DPB1*0501 contains an Mnl I site at
position 190 as do DPB1*0202 and *1901. Combinations of 
these alleles groups have been encountered and all contain 
a an Mnl 102 bp band. Both 102 and 105 bp bands was 
observed in a DPB1*0202,*1601 sample. Both *0202 and *1601 
contain the overlapping Mnl I sites at HVR 5 which lead to 
the 102 and 105 bp bands observed in the *1301 allele.
This led to the hypothesis that the 102 bp bands in these 
heterozygotes was due to heteroduplex formation between 
complementary strands of the different alleles. This was 
tested by mixing aliguots of DPB1*0201 and *0501 homozygote 
PCR product, and prior to addition of Mnl I, the digest was 
incubated at 95 C for 5 min, then cooled at room 
temperature to induce heteroduplex formation. A second 
digest was prepared which contained DPB1*0201 and *0501 PCR 
product, but was not heated. The digestion products were 
electrophoresed on 12% polyacrylamide gels and compared to 
digestions of the homozygote DPB1*0201 and *0501 and
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heterozygote DPB1*0201,*0501 PCR products. The unheated 
homozygote mixture did not produce a 102 bp band whilst the 
heterozygote and the heated homozygote mix did (Fig 3.21), 
demonstrating that the 102 bp fragment is the result of 
heteroduplex formation.
3.5.5. 76 bp doublet Mnl I digest pattern
DPB1*0401, *0402 and *1801 alleles contain two 76 bp Mnl I
fragments (Fig 3.8); the first is between the forward site 
at nucleotide position 30, and reverse site at nucleotide 
position 124 present in all alleles except DPB1*1101 and 
*1501 (Fig 3.6); the second is between two reverse sites at 
nucleotide position 226 and 302. However when the digests 
are electrophoresed on 12% polyacrylamide gels, the two 76 
bp bands do not comigrate (Fig 3.14). The GC content of 
the upstream and downstream fragments is 49% and 65% 
respectively. The slight sequence specific variation in 
the rate of movement through the gel may be responsible for 
the separation of the two identical length fragments as the 
migration of single stranded DNA through polyacrylamide 
gels is dependent on the fragments' sequence as well as 
length (Fischer and Lerman 1983).
3.5.6. Eco NI digest of DPB1*0601
The restriction enzyme Eco NI has a recognition site 
consisting of a six bp palindrome divided in half by an
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Figure 3.21
A. Restriction fragments produced by Mnl I digestion of: 
DPB1*0201, *0501 heterozygote (Lane 1); combined DPB1*0201 
and DPB1*0501 homozygotes (Lane 2); combined DPB1*0201 and 
DPB1*0501 homozygotes treated to produce heteroduplex (Lane 
3); DPB1*0501 homozygote (Lane 4); DPB1*0201 homozygote 
(Lane 5).
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interval of five nonspecific bp which contains the cutting 
site. DPB1*0601 contains two overlapping Eco NI sites at 
HVR 4. The expected outcome of an Eco NI digest of 
DPB1*0601 is an 86 bp fragment, however, both 86 and 89 bp 
fragments are produced since recognition of one of the 
overlapping sites occurs within the five bp segment of the 
other recognition site. Recognition of the position 219 
site produces an 89 bp fragment and disrupts the site at 
nucleotide position 222, recognition of the position 222 
site produces an 86 bp fragment and disrupts the site at 
position 219. Eco NI digestion of DPB1*0601 is not 
important for typing, as DPB1*0601 can be adequately 
discriminated from the other alleles by Rsa I digestion.
Despite these variations between the expected and observed 
outcomes of Mnl I and Eco NI digests, the scheme is still 
able to distinguish between the heterozygote combinations 
predicted by the expected band patterns. Although Mnl I is 
responsible for most of these discrepancies, it remains a 
powerful discriminating enzyme. Mnl I digests can split 
the 19 DPB1 alleles into 12 groups, and have polymorphic 
recognition sites at four of the six HVRs.
3.6. AFLP ADVANTAGES
In comparison to the other typing methods for HLA-DPB1, 
AFLP typing has a number of advantages.
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First, AFLPs are technically simple, involving digestion 
with a small number of restriction endonucleases and no 
hybridization steps or use of radioactive isotopes is 
required. Several SSO protocols (Bugawan et al 1990, 
Fernandez-Vina et al) require two or three PCR 
amplifications, whereas AFLP typing requires a single PCR.
All homozygous alleles and almost all heterozygous allele 
combinations can be typed using three or less restriction 
enzyme digests. Optimisation of conditions could lead to 
AFLP typing taking as little as six to seven hours (Inoko, 
1991). When using AFLP for tissue matching for 
transplantation, typing to determine the alleles present 
would be unnecessary as donor and recipient restriction 
fragment patterns could be compared directly (Inoko, 1991).
Second, as AFLP involves the identification of differences 
in the outcome of an endonuclease digestion, rather than 
the occurrence or non-occurrence of hybridization (as in 
the case of SSOs), experimental failure (i.e. lack of 
digestion) can be readily detected. Where the separation 
of two alleles involves a lack of digestion of one of them, 
as in the case of Fok I digestion of DPB1*0301 and *0601 an 
allele known to contain a restriction site for the enzyme 
can be included in the digestion as a control.
Alternately, it is possible to construct an amplification 
primer with a non-complementary tail containing restriction 
enzyme sites, providing an internal digestion control.
Third, the interpretation of AFLPs is relatively unaffected 
by PCR contamination. The PCR can amplify target DNA from
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several copies to many million fold (/zg quantities) .
Ethidium bromide staining is less sensitive than 
hybridization for detecting DNA as it requires at least 
10 ng of DNA to produce a visible band (Maniatis 1982) 
Hybridization of radio-labelled probes can detect as few as 
several copies of the target sequence, thus ethidium 
bromide staining is less sensitive to low levels of DNA 
contamination. Furthermore, since a PCR product and its 
contaminant are subjected to exactly the same experimental 
regime of PCR amplification and restriction enzyme 
digestion, a contaminant or Taq DNA polymerase error, where 
observed, can be identified by its relatively low 
concentration.
Fourth, the AFLP technique is less affected by PCR "noise". 
Sequence errors can occur during PCR amplification as the 
Taq DNA polymerase has no proof-reading capability. As 
synthetic oligonucleotides used in SSO typing recognise 17 
to 20 bp and are designed to discriminate one bp mismatch, 
and restriction enzymes recognise only four to six bp, AFLP 
typing is less likely to be affected by sequence artifacts 
created by Taq DNA polymerase amplification. For the same 
reason AFLP typing is less likely to be affected by silent 
nucleotide mutations (Inoko 1990).
The AFLP typing strategy can be applied to discriminating 
alleles at any locus (e.g. blood group typing as described 
by Yamamoto et al 1990), and to screen for disease 
associated alleles. Using AFLPs many alleles can be 
separated using relatively few restriction endonucleases,
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making this method particularly useful in HLA typing, where 
most class I and II genes are highly polymorphic. It has 
been applied to other class II loci (Maeda et al 1989, Uryu 
et al 1990, Ota et al 1991). Given the number of 
recognized DPB1 alleles and the limitations of other HLA-DP 
typing techniques, such as serology, PLT, RFLP and SSO 
analysis, AFLP typing should be considered a useful and 
efficient alternative to SSO analysis.
3.7. AFLP PROBLEMS
3.7.1. Partial Digestion
Of the four enzymes used in AFLP, only Mnl I digests all 
DPB1 alleles. Partial digests involving Eco NI, Fok I and 
Rsa I enzymes produce full length fragments
indistinguishable from digestion products of alleles which 
do not contain the enzyme site. The quality of digestion 
can be assessed by comparison between digests performed 
concurrently, or by comparison of band intensity by 
ethidium bromide staining. Partial digestion tends to give 
abnormal band intensities as digested fragments are in 
stochiometric ratios to each other. If novel fragments are 
observed, the digest can easily be repeated; in some cases 
enzymes cut at the same HVRs and can be employed to check 
putative assumed sequence variation. Mnl I produces a 
range of restriction fragments for all alleles and so it is 
obvious when a partial digestion has occurred.
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However the other three enzymes regularly used produce 
limited numbers of fragments and include the non-cutting of 
PCR product as a possible outcome. Fragment patterns which 
include three allelic fragments including full length 
products have been observed and in such cases it is assumed 
the uncut band is due to partial digestion. The results can 
be compared against the results of other restriction enzyme 
digests to ensure a fragment is not due to contamination. 
Typing of homozygotes can be affected by the presence of 
partial bands, again typing results of several enzymes can 
be correlated. No allele remains uncut after digestion 
with Eco NI, Fok I and Rsa I.
Ota et al (1991) presented an AFLP technique that did not 
include uncut product in the typing scheme, each enzyme 
producing two possible outcomes of cleaved product. However 
this strategy reduces the effectiveness of AFLP typing, as 
more digests are required to give sufficient information to 
discriminate between the 19 alleles. Although the use of 
uncut fragments in the scheme is undesirable because of the 
risk of partial or non-digestion being confused with 
complete digestion, the inclusion of uncut fragments 
increases the ability to resolve DPB1 alleles with as few 
enzyme digests as possible.
An internal digestion control can be introduced into AFLP 
typing by including restriction enzyme sites as a non­
complementary tail on PCR primers. The tails do not 
interfere with amplification, and non-digested product
108
could then be distinguished from product containing alleles 
with no exon sites for the particular restriction enzyme.
3.7.2. Assignment of Fragment Sizes.
The interpretation of pairs of fragments with small size 
variations can be difficult, especially when only one of 
the pair is present on a particular gel. For instance the 
Eco NI 86 and 89 bp bands or the Mnl I 54 and 51 bp bands. 
Many of the DNA molecular weight markers do not contain 
bands in this region that would allow accurate 
discrimination between these pairs. The digestion of two 
or more heterozygotes of known DP type should be combined 
to produce a DNA molecular weight ladder consisting of 
allelic fragments for each restriction enzyme. This has 
the advantage of direct comparison between ladder and 
sample lanes and also gives clear identification of novel 
band sizes.
3.7.3. Fok I Digestions
It was discovered that when the same restriction enzyme 
digestion conditions were used for Fok I digests of PCR 
product, the intensity of the 264 and 107 bp bands were 
greatly diminished. The 107 bp band is important for 
discriminating between DPB1*0901 and *1701, and between 
DPB1*0801 and *1601, and is the result of a disrupted Fok I
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due to over digestion, as when the amount of Fok I enzyme 
per digest was reduced to one Unit, and the incubation time 
was restricted to one hour, the problem was resolved.
3.7.4. Speed of Typing
Performing AFLP on large numbers of samples can be 
relatively time consuming when compared to SSO typing. 
Preparation of polyacrylamide gels and restriction enzyme 
digests can become laborious. Mnl I and Rsa I digests can 
discriminate between many alleles, but the digests must be 
performed, results scored and tabulated in order to find 
which alleles reguire further restriction enzyme digestion 
and some samples may have to be handled up to four times. 
However the AFLP technique is open to automation which has 
the potential to considerably increase the speed and 
efficiency of the process. Large numbers of digests can be 
performed in microtitre plates using multi-channel 
pipetters. This greatly increases the speed of preparation 
of restriction enzyme digests, and reduces the usage of 
some materials.
Polyacrylamide gel electrophoresis can be carried out on 
pre-poured gradient gels which have the advantage of being 
fast to run and the gels are of more consistent quality. 
Commercially available rehydratable gels also decrease 
preparation time and are of more uniform quality.
110
Fluorescent dye labelled primers can be used in conjunction 
with electrophoresis imaging systems which allow direct 
computer analysis of results. It is possible to include 
size markers in the same lane as the digested samples, 
which increases the ease of typing fragments. Fluorescent 
dye labelled primers would allow the identification of 
group specific PCR products by electrophoresis and may 
reduce the number of restriction digests required.
Capillary gel electrophoresis allows the very fine 
discrimination of bands, and can detect one base pair 
differences between fragments as well as reliably detecting 
very small fragments. The increase in resolution and 
visibility of bands would allow double or triple digests to 
be performed, and reduce the number of samples that need to 
be electrophoresed, and increase the reliability of 
fragment sizing and identification. Capillary 
electrophoresis has the advantage of being very fast, a 
sample taking as little as 5 min for analysis.
Eco NI, Fok I and Rsa I digests, which produce relatively large 
and well separated restriction fragments, could be visualised by 
agarose gel electrophoresis. Agarose gels are less hazardous to 
prepare and give a faster result than polyacrylamide gel 
electrophoresis. Although agarose gels often give worse band 
resolution than polyacrylamide gels, and at higher gel 
concentrations can become brittle, they could still be used for 
routine AFLP typing. Agarose gels, however, could not be used 
for Mnl I digests as the fragment sizes produced are too small 
to be adequately resolved.
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3.7.5. DPB1 Allele Assignments
SSO results are found by many to be easier to score, as the 
results can only be one of two outcomes. AFLP data is made 
up of several possible fragments for each enzyme digest. 
Although the speed of allocating alleles increases with 
experience, it was found that typing can be a relatively 
time consuming process. The assignment of alleles can be 
automated; fragment patterns could be expressed as a binary 
code and compared to the binary codes for the expected 
allele combinations by computer. The binary code could 
also be converted to a decimal, giving every allele 
combination a unique address that can easily be checked 
against predicted typing results.
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3.8. COMPARATIVE COST ANALYSIS
The estimated cost of the AFLP technique, in Australian 
dollars (A$), was compared to two SSO typing protocols 
practised in the laboratory; the 11th International 
Histocompatibility Workshop (11IHW) protocol and the method 
suggested by Fernandez-Vina et al (1990).
Typing by AFLP costs approximately A$4.70 per sample. This 
includes the cost of Taq DNA polymerase, amplification 
primers, the four restriction endonucleases, the 
polyacrylamide gel and the photographic film used to record 
the results. The actual cost maybe slightly less as all 
four enzymes are not necessary in most samples. PCR 
amplification costs approximately A$0.70 per sample, and 
will be considered the same cost in each protocol. The 
biggest proportion of the cost per sample of AFLP typing is 
the price of Mnl I, which is almost A$2.90 per sample. As 
Mnl I has only recently become commercially available, it 
is probable that the price will be reduced if demand 
increases or more manufacturers produce the enzyme.
The 11IHW SSO consists of 96 amplified products spotted 
onto five duplicate 12 x 8 cm nylon membranes.
Approximately 60 ng of each of the 25 oligonucleotides is 
labelled with 60 /xCi of radioisotope P^2r and hybridized to 
the membrane in plastic bags. The membranes are washed and 
exposed to X-ray film. The cost, based on the price of PCR 
amplification per sample, the SSOs, nylon membranes, 
radioactive label and X-ray film, is approximately A$4.20
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per sample. The largest component of this estimate is the 
amount of P-^2 radioisotope, as the labelling of 25 SSOs 
requires 1.5 mCi p32.
The Fernandez-Vina method requires three PCR 
amplifications, two group specific, and one generic.
Again, 96 samples (i.e. 32 individuals) are bound to 16 
duplicate 5x7 cm nylon membranes by Southern transfer, and 
probed with 16 SSOs in 10 ml screw top tubes, incubated in 
a rotary incubator. The SSOs are labelled with 30 ßCi P^ 2, 
and reused once so that each probe is hybridized to 192 
samples. The cost per sample in this case is approximately 
A$4.40. The biggest component of the cost is the three PCR 
amplifications required, which accounts for almost half of 
the cost per sample.
Although both SSO typing methods are marginally cheaper per 
sample than the AFLP typing method, it must be noted that 
the production of the oligonucleotides is expensive. It 
costs approximately A$125 for 500 fiq and so to produce 25 
SSO probes costs over A$3000, and 16 SSO probes costs 
A$2000. As each SSO probe requires only 60 ng of DNA, 
enough oligonucleotide is produced for over 8000 labelling 
reactions and thus the cost of the SSO per sample becomes 
negligible. To purchase one set of the four enzymes used 
in AFLP typing costs just over A$1100, and the enzymes may 
also be used for other purposes not connected with DPB1 
AFLP typing, however the use of the SSO probe DNA is 
restricted to DPB1 typing because of their specificity.
The use of SSO probes is cheap so long as most of the
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oligonucleotide produced is used, however many laboratories 
will not type 8000 individuals. If the cost per sample of 
typing 1000 samples is considered, that is, if the cost of 
SSOs or enzyme is distributed over 1000 individuals, then 
AFLP typing costs approximately A$4.90, by the 11IHW 
protocol the cost is A$7.80, and by the Fernandez-Vina the 
cost is A$5.40 per sample. Thus large numbers of 
individuals need to be typed to justify the outlay of 
producing the required SSOs. The AFLP technique is more 
cost effective for small to medium scale use.
3.9. CONCLUSIONS
AFLP is a simple yet reliable technique for the typing of 
DPB1 alleles. It is capable of typing all homozygote and 
heterozygote combinations except DPB1*1701,0801 from 
DPB1*1601,*0901 which cannot be discriminated by other DP 
typing techniques.
Performing the AFLP technique on large numbers of samples 
can be cumbersome, the AFLP technique is perhaps more 
suited to the typing of relatively small numbers of 
individuals or in situations where HLA-DPB1 typing is not 
routinely performed. The only oligonucleotides that need 
to be synthesized are the amplification primers, and the 
restriction enzymes can be bought in small quantities or 
used for other purposes. This avoids the expense of 
manufacturing a panel of SSOs, which is expensive in time 
and resources if sufficient use is not guaranteed. For
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rapid clinical results the AFLP technique may be the method 
of choice, as it is not only quick to perform but is an 
efficient use of resources when only a few samples need to 
be typed. Similarly AFLPs may be useful in forensic 
applications.
Chapter 4
AFLP Typing of DPB1 
Two Ethnic Groups
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4.1. INTRODUCTION
The HLA system is one of the most polymorphic regions in 
the human genome, and apart from its relevence in 
histocompatibility typing, HLA loci are useful as genetic 
markers. The detection of HLA alleles and haplotypes have 
a number of applications, including specimen identification 
(forensic), population markers in anthropoplogy and disease 
associations, which make it important to be able to 
accurately define all alleles present.
This chapter extends HLA-DPB1 typing to White Australian 
and South Indian population samples. Many of the White 
Australian samples have been examined by serology and RFLPs 
for HLA-DR and -DQ and HLA-DP typed by RFLPs (Easteal et al 
1989). The South Indian series has been previously 
examined by RFLP analysis for HLA-DR and -DQ (Serjeantson 
et al 1987) and for HLA-DP (Easteal et al 1990). This has 
provided population comparisons of HLA-DPB1 allele 
distributions and the opportunity to test for population- 
specific HLA-DR and -DP linkage disequilibrium 
relationships. As DPB1-RFLP typing protocols have been 
based on an essentially Caucasoid cell-panel from the 10th 
International Histocompatibility Workshop (DuPont 1989, 
Easteal et al 1989), the comparison of AFLP and RFLP typing 
results in South Indians provides assessment of the 
efficacy of the RFLP protocol in a different ethnic group.
RFLP-typing relies on strong linkage disequilibrium between 
the region of interest and restriction enzyme sites in
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flanking regions. Often no polymorphic restriction sites 
occur in the region of interest as DNA fragments less than 
0.5 kb in size are not readily visualized. However AFLP 
typing looks directly at the variable nucleotide sequences 
under study. RFLP-typing at HLA-DP is based not only on 
sequences flanking HLA-DPB1, but also on those flanking 
DPA1, so that any recombinant DPA1, DPB1 haplotypes could 
potentially give rise to erroneous DPB1 typing results.
RFLP-typing protocols for other genetic systems that have 
been based on Caucasoid phenotypes and RFLP genotypes have 
shown differing efficacy in different populations. For 
instance, the HLA-DR RFLP-typing procedure based on the 
hybridization of DRB, DQA, and DQB probes to Taq I digested 
DNA (Kohonen-Corish and Serjeantson, 1986) correlated well 
with HLA-DR serology in different ethnic groups, 
demonstratd in Southern Chinese where the only discrepancy 
involved a novel DR5-related RFLP (since shown to be 
DRB1*1202, X. Gao, personal communication) which was typed 
serologically as DRw6 (Kohonen-Corish et al 1987).
However, the HLA-DR RFLP protocol does not hold in 
Australian Aborigines, where a novel DRw6 type would be 
typed as DR3 (Davies et al 1990).
RFLP-typing of Gm allotypes shows an excellent correlation 
between Pvu II and Taq I RFLPs and Gm allotypes in 
Caucasoids (Jazwinska et al 1988), but due to different 
linkage disequilibrium relationships in different 
populations, the protocol does not hold in all ethnic 
groups; for instance, Micronesians (Propert et al 1991).
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Population-specific linkage disequilibrium may also be 
expected with respect to HLA-DP and -DR alleles.
Termijtelen et al (1983) suggests the presence of a 
recombination hotspot, lying between HLA-DR, -DQ and HLA- 
DP, which is responsible for the lack of linkage 
disequilibrium between HLA-DP alleles and the rest of the 
HLA. However some examples of DR alleles positively or 
negatively associated with HLA-DP antigens or alleles have 
been reported. Matsui et al (1985) reported linkage 
disequilibrium between DR3 and DPwl, and DR4 and DPw4. The 
linkage disequilibrium between DR3 and DPwl has been 
observed in several studies (Rosenberg et al 1989, Hall et 
al 1990, Thomsen et al 1990, Gao et al 1991). Thomsen et 
al (1990) also report that DR3 is negatively associated 
with the remaining DPw types, as well as a number of other 
associations; DR7 appears to be positively associated with 
non-DPwl to w6 alleles whilst DR4 is rarely associated with 
non-DPwl to w6 antigens. A possible association between 
DR4(Dwl4) and DPw6 is also reported (Thomsen et al 1990). 
However, other studies have failed to find any evidence of 
linkage disequilibrium between HLA-DP and -DR (Olerup et al 
1990).
The apparent lack of linkage disequilibrium between HLA-DP 
PLT types and HLA-DR types in early studies may simply 
reflect the underlying allelic heterogeneity at both loci. 
The consistent reports of linkage disequilibrium between 
DR3 and DPwl (Matsui et al 1985; Rosenberg et al 1989, Hall 
et al 1990, Thomsen et al 1990, Gao et al 1991) indicate
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the lack of heterogeneity in DRwl7 (DR3). Thus it is 
perhaps no accident that DR3, rather than heterogeneous 
antigens, such as DR4 or DRw6, shows linkage disequilibrium 
with HLA-DP. A similar situation was observed in earlier 
studies of HLA-B and HLA-DR linkage arrangements, where DR3 
was strongly linked with B8 (Bodmer et al 1987) but other 
DR alleles were less strongly associated with HLA-B 
alleles. It is now known that the lack of association was 
masking HLA-DR heterogeneity and when RFLP-defined HLA-DR 
subtypes were correlated with HLA-B antigens, there was 
marked disequilibrium between DR2,DRw6 and DR7 RFLP types 
and HLA-B (Serjeantson et al., 1986).
When HLA-DRB1 and -DPB1 alleles were defined by SSOs in a 
Northern Chinese population, Gao et al (1991) found linkage 
disequilibrium between DR4(Dw4) and DPB1*0601. Possible 
associations reported by Gao et al (1991) include: DR5
with DPB1*0201; DRw8 with DPB1*0202; and DR7 with 
DPB1*04 02.
AFLP typing has provided the opportunity to re-examine the 
apparent lack of linkage disequilibrium between HLA-DP and 
-DR antigens, by correlating HLA-DP alleles with RFLP- 
defined HLA-DR types in Causasoids and South Indians.
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4.2. AFLP TYPING OF WHITE AUSTRALIAN AND SOUTH INDIAN 
SAMPLES.
DPB1 AFLP typing was performed on 89 White Australian and 
64 South Indian samples. White Australian DNA samples were 
obtained from healthy individuals from two sources, the Red 
Cross Blood Transfusion Service, Canberra, and healthy 
individuals associated with this laboratory. South Indian 
DNA samples were obtained from Madras (Serjeantsen et al 
1987). All samples were typed using all four enzymes to 
increase the likelihood of observing novel alleles (Table 
4.1) .
The observed allele frequencies in both population samples 
are consistant with Hardy-Wienberg expectations. The 
results show the two populations share similar features. In 
both cases DPB1*0401 is the most common allele and the 
majority of chromosomes contain at least one of the six PLT 
defined alleles. Approximately 10% of chromosomes in the 
White Australian and 15% in the South Indian population 
samples are non-PLT defined DPwl to Dw6 types (DPB1*0801- 
*1901). Five significant differences between the South 
Indian and White Australian population samples are 
observed; DPB1*0201 in the South Indian sample is 25.8%, 
almost twice that observed in the White Australian which 
has a frequency of 14.0%. DPB1*0301 and *0402 frequencies
appear to be slightly reduced in South Indians with respect 
to White Australians. While DPB1*0901 and *1301 are 
increased in South Indians. DPB1*1301, comprises under 2%
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Table 4.1
Frequencies of DPBl alleles in White Australian and 
Southern Indian population samples.
DPBl
White
n
Australians
frequency 
% S.E.
South
n
Indians
frequency 
% S.E.
*0101 9 5.1 1.6 8 6.3 2.1*0201 25 14.0 2.6 33 25.8 3.9*0202 1 0.6 0.6 0 -*0301 16 9.0 2.1 4 3.1 1.5*0401 79 44.4 3.7 47 36.7 4.2*0402 26 14.6 2.6 9 7.0 2.3*0501 3 1.7 1.0 0 -*0601 3 1.7 1.0 0 -*0801 0 - 1 0.8 0.8*0901 0 - 4 3.1 1.5*1001 3 1.7 1.0 2 1.6 1.1*1101 5 2.8 1.2 0 -*1301 3 1.7 1.0 14 10.9 2.8*1401 0 - 3 2.3 1.3*1501 1 0.6 0.6 1 0.8 0.8*1601 1 0.6 0.6 0 -*1701 2 1.1 0.8 1 0.8 0.8*1801 0 - 1 0.8 0.8
*1901 1
178
0.6
100
0.6 0
128 100
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in the European sample but accounts for over 10% of alleles 
in South Indian sample.
Between the two groups all 19 recognised alleles are 
represented, and no novel alleles were detected. The 
European sample contains 15 different alleles, the South 
Indian sample contains 13, so each group shows significant 
allelic variation, and shows the allelic diversity missed 
by previous typing techniques.
4.2.1. Comparison of AFLP and RFLP typing results
Some of the South Indian and White Australian samples had 
been previously typed by RFLP. In the White Australian 
population sample (Table 4.2) there is general agreement 
between AFLP and RFLP typing results. RFLP typing is 
unable to distinguish between the subtypes of DPw4, as two 
samples typed by AFLP as DPB1*0101,*0401 and 
DPB1*0101,*0402 both typed as DPwl,w4 by RFLP. Similarly 
RFLP typing was unable to discrminate DPB1*0601 from 
DPB1*0301. DPB1*1001, *1101 and *1301 alleles typed by 
AFLP correlate with a novel RFLP pattern designated for 
both DPA1 and DPB1 probes called "B". Two samples typed by 
RFLP as 4,- and 4,B were typed by AFLP as DPB1*0401,*0501 
and DPB1*0401,*0401. There was one sample where there was 
diagreement between DPA1 and DPB1 probe results; the DPA1 
probe produced a DPw2 and "B" fragnent pattern while the
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Table 4.2
Comparisons between DPB1 typing White Australian population samples by 
AFLPs and RFLPs (Easteal et al 1990).
RFLP associated 
DPA1/DPB1 genotype 
combinations
DPAl DPBl n AFLP type n
1,4 1,4 4 *0101 ,*0401 2
*0101,*0402 2
2,3 2,3 1 *0201,*0601 1
2,4 2,4 3 *0201,*0401 3
2 , B 2 , B 1 *0201 ,*1001 1
2 , B 3,5 1 *0202,*1701 1
4,- 4,- 6 *0401 ,*0401 4
*0401 ,*0402 1
*0401,*0501 1
4, B 4 , B 4 *0401 ,*0401 1
*0401,*1101 1
*0401 ,*1301 2
124
DPB1 probe gave a DPw2 and DPw3 or DPw5 associated RFLP 
pattern. AFLP typed this "recombinant" sample as 
*0202,*1701 which would be consistant with the DPA1 
associated RFLP pattern. These discrepancies may be due to 
experimental error or may be examples of non-association 
between RFLP patterns and DPB1 allele.
In the South Indian population sample (Table 4.3), most 
AFLP types correspond to the RFLP typing results. As seen 
in the White Australian series, the DPA1 gnd DPB1 RFLP 
pattern "B" is associated with non-DPBl*0801 to *1901 
alleles, with the exception of DPB1*1501 which appears to 
be associated with a novel DPA1 probe RFLP pattern, 
designated "A".
There are several examples of disagreement betwen the 
results of AFLP and RFLP typing methods; an RFLP-typed 
DPw2,3 heterozygote is typed by AFLP as a DPB1*0201 
homozygote; an RFLP-typed DPwl chromosome typed as 
DPB1*0301 by AFLP typing; and two examples of DPA1 probe 
RFLP pattern "B" samples being typed as DPB1*0101 by AFLP. 
There are also two DPB1*0201,*0401 heterozygotes which were 
typed by RFLP as DPw4 homozygotes. This may reflect the 
difficulty in separating DPw2 and DPw4 associated RFLP 
patterns (see Chapter 3).
RFLP typing of the South Indian population sample revealed 
12 samples with "recombinant" RFLP patterns were typed by 
AFLP (Table 4.3) and the results show that in each case 
theDPBl allele did agree with one of the RFLP patterns, but
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Table 4.3
Comparisons between DPB1 typing South Indian population samples by 
AFLPs and RFLPs (Easteal et al 1990).
R F L P  a s s o c i a t e d  
D P A l / D P B l  g e n o t y p e  
c o m b i n a t i o n s
D P A l  D P B l  n A F L P  t y p e n
1,4 1,4 1 * 0 1 0 1 , * 0 4 0 1 1
1, B 1, B 2 * 0 1 0 1 , * 1 3 0 1 1
* 0 3 0 1 , * 1 3 0 1 1
2,- 2,5 1 * 0 2 0 1 , * 0 2 0 1 1
2,3 2,3 1 * 0 2 0 1 , * 0 2 0 1 1
2,4 2,4 6 * 0 2 0 1 , * 0 4 0 1 6
2,4 4,- 1 * 0 2 0 1 , * 0 4 0 1 1
2,5 2,4 1 * 0 2 0 1 , * 0 4 0 1 1
2, B B,- 2 * 0 8 0 1 , * 1 3 0 1
* 0 2 0 1 , * 1 3 0 1 1
3 , B 3,- 1 * 0 3 0 1 , * 1 3 0 1 1
4,- 4,- 6 * 0 4 0 1  , * 0 4 0 1 1
* 0 4 0 1  , * 0 4 0 2 3
* 0 2 0 1 , * 0 4 0 1 2
4,- 4 , B 1 * 0 2 0 1 , * 1 0 0 1 1
4, B 1,4 2 * 0 1 0 1 , * 0 4 0 1 1
* 0 1 0 1  , * 0 4 0 2 1
4 , B 2,4 1 * 0 2 0 1 , * 0 4 0 1 1
4, B 4,- 1 * 0 4 0 1 , * 0 9 0 1 1
4 , B 4 , 3 / 5  1 * 0 4 0 1 , * 0 9 0 1 1
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Table 4.3 continued
RFLP associated 
DPAl/DPBl genotype 
combinations
DPAl DPBl n AFLP type n
4,5 4,B 2 *0401 ,*1301 1*0401, *1401 1
5,A 4,B 1 *1301,*1501 1
5 , B 4 , B 1 *0401,*1401 1
B,- B,- 1 *0901,*1301 1
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did not consistantly agree with either the DPA1 or DPB1 
probe RFLP pattern. This demonstrates that recombination 
events occur which affect the flanking polymorphic 
restriction enzyme sites but not the DPB1 second exon, so 
that the association between DPB1 allele and RFLP pattern 
may not always be complete.
Apart from the discrepancies due to the inability of RFLP 
to discriminate DPw4 suptypes, DPw2 subtypes, DPw3 from 
DPw6, and between "B" DPA1 and DPB1 probe RFLP patterns, of 
the 20 White Australian samples typed by both RFLPs and 
AFLPs, only three samples gave discordant RFLP and AFLP 
results, including one example of a "recombinant" RFLP 
pattern. However, of the 32 South Indian population 
samples typed by both methods, including "recombinant" RFLP 
patterns, This suggests that the associations between 
flanking polymorphic restriction sites and DP alleles 
utilized by RFLP typing in Europeans may not be as strong 
in other ethnic groups.
4.2.2. DPB1 typing in different ethnic groups
White Australian and South Indian DPB1 antigen frequencies 
were calculated in order to compare these results with 
published antigen frequencies for other populations.
Antigen frequencies were found by dividing the number of 
individuals homozygous or heterozygous for an allele by the 
total number of inidividuals. Comparison of the antigen 
frequencies obtained in this study by AFLP typing with
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Table 4.4
DPBl antigen frequencies in five different ethnic groups.
DPBl
Allele WA NA No SI BM NB NC
*0101 10 9 14 13 11 45 1*0201 25 29 19 45 30 23 35*0202 1 3 1 0 2 0 6*0301 17 9 20 5 17 3 15*0401 67 52 71 64 52 32 24*0402 23 34 27 13 37 29 21*0501 3 9 4 0 4 0 60*0601 3 5 2 0 4 0 1*0801 0 1 2 2 0 0 0*0901 0 4 3 6 2 3 1*1001 3 6 3 3 4 0 0*1101 5 1 5 0 2 0 0*1301 5 2 1 20 4 0 1*1401 0 0 1 5 4 3 5*1501 1 2 0 2 0 0 0*1601 1 0 0 0 0 0 0*1701 2 2 0 2 7 0 13*1801 0 2 1 2 0 22 0*1901 1 0 2 1 2 3 0New 0 0 0 0 2 3 0
167 170 176 183 184 166 183
WA = White Australians (see Table 4.1)
NA = North American Caucasoids (Ferandez-Vina et al 1991) 
No = Norwegians (Ronningen et al 1990)
SI = South Indians (see Table 4.1)
BM = Brazilian Mestizos (Fernandez-Vina et al 1991)
NB = North American Blacks (Fernandez-Vina et al 1991)
NC = North Chinese (Gao et al 1991)
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those of other ethnic groups typed by SSOs (fig 4.4) show 
that, even between widely separated ethnic groups, the DPB1 
alleles corresponding to the DPwl to w6 PLT defined 
genotypes have the highest frequencies. However most of 
the non-European groups contain relatively high frequencies 
of DPB1 alleles considered rare in the other ethnic groups. 
For instance the antigen frequency of DPB1*1301 is 20% in 
South Indians, but is no greater than 5% in any of the 
other ethnic groups. Similarly DPB1*1801 is relatively 
common in North American Blacks at 22% (Fernandez-Vina et 
al 1991) and DPB1*1701 is relatively common in North 
Chinese at 13% (Gao et al 1991). Very few novel alleles 
were found, suggesting that most of the major sequence 
variation in DPB1 has been observed.
4.2.3. HLA-DP typing of European population samples
The antigen frequencies of the three European samples, from 
Australia (present study), North America (Fernandez-Vina et 
al 1991) and Norway (Ronningen et al 1990) exhibit quite 
different frequencies for some alleles, for instance 
DPB1*0401 has an antigen frequency of 71% in Norwegians but 
only 52% in North American Caucasoids, the difference 
approaching significance (x2 = 3.6, d.f. = 1, p > 0.05). 
However the three European Caucasoid groups are still more 
closely related to each other than to the other ethnic 
groups. The variation within the White European samples 
may be due to slight differences in antigen frequencies 
between different European populations. The comparitive
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ratios of European populations in such countries as North 
America and Australia may differ enough for the 
differentimmigration patterns to be reflected in the DPB1 
antigen frequency results.
The results obtained by AFLPs can be compared to HLA-DP 
antigen frequencies generated by RFLPs (containing some 
samples also typed by AFLPs) and PLT typing (Table 4.5). 
Although RFLP and PLT typing cannot distinguish DPw2 and w4 
subtypes, the combined frequencies of DPB1*0401 and *0402; 
and DPB1*0201 and *0202 are comparable to the results 
obtained for DPw4 and w2. The frequencies of DPB1*0101 or 
DPwl are similar by all three typing methods as are the 
frequencies of DPB1*0301 and DPw3. The DPw5 frequency by 
PLT typing agrees with the frequency of DPB1*0501 typed by 
AFLPs, however the frequency of DPw5 by RFLP is 
approximately four-fold higher. This may be due to random 
variation between samples, or to alleles other than DPw5 
being associated with the DPw5 RFLP pattern. The frequency 
of blank alleles by PLT typing is 31%, which is much higher 
than the combined frequency of MA" and "B" DPA1 and DPB1 
probe RFLP patterns, 10.6%, or the combined frequency of 
DPB1*0801-*1901 alleles, 9.1%. When it is remembered that 
PLT "blank" alleles are not detected when in heterozygous 
combination with recognised alleles, then the frequency of 
blank alleles may be higher.
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Table 4.5
AFLP typing of White Australian population sample compared 
to RFLP (Easteal et al 1989) and PLT (Pawlec et al 1982) 
typing of European Caucasoid populations.
AFLP
D P B l : % DP:
RFLP
%
PLT
DP: %
*0101 5.1 wl 6.6 wl 6*0201 14.0 w2 9.2 w2 17*0202 0.6*0301 9.0 w3/6 6.6 w3 8*0401 44.4 w4 59.2 w4 36*0402 14.6*0501 1.7 w5 7.9 w5 2*0601 1.7*0801 0 A 5.3 Blank 31*0901 0 B 5.3*1001 1.7*1101 2.8*1301 1.7*1401 0*1501 0.6*1601 0.6*1701 1.1*1801 0
*1901 VO•o
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4.2.4. HLA-DR and -DP linkage disequilibrium
The HLA-DR types of 57 of the White Australian and 58 South 
Indian samples also DPB1 typed by AFLPs were obtained and 
were analysed by log-linear modelling techniques, using the 
GLIM (release 3.77) computer package, to find evidence of 
linkage disequilibrium between HLA-DP and DR.
In the White Australian sample no linkage disequilibrium 
between DR3 and DPB1*0101 was observed (Table 4.6).
However positive association between DR7 and non-DPwl to w6 
(DPB1*0801 - *1901) alleles (X2 = 14.9, d.f. = 4, p < 
0.005). There was no evidence for association between DR4 
and DPB1*0101 to *0601 alleles. A positive association was 
observed between DR2 and DPB1*0401 (X2 = 14.3, d.f.= 4, p < 
0.01). If DPB1*0401 and *0402 are combined with DR2 no 
association is observed; hence this relationship would not 
be observed if the subtypes of DPw4 could not be 
discriminated. There was a trend towards linkage 
disequilibrium between DR4 and DPB1*0401, but it was not 
significant (x2 = 8.7, d.f. = 4, p > 0.05).
Linkage disequilibrium analysis in the South Indian 
population sample did not show any evidence for linkage 
disequilibrium between HLA-DR and -DP reported for 
Europeans, or observed in the White Australian sample 
(Table 4.7). However a positive association between 
DR6(Dwl3) and DPB1*1301 (x2 = 9.6, d.f. = 4, p < 0.05) was 
found and was not observed in the White Australian sample. 
This may be due to the relatively low frequency of
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Table 4.6
Selection of linkage disequilibrium analysis results from 
the White Australian population sample.
DR
type
DPBl
allele X ts.)
3 *0101 CO•
2 *0401 11.8+
2 *0402 3.1
2 *0401,*0402 5.3
4 *0401 00 •
4 *0402 4.8
4 *0401,*0402 2.8
4 *0301 6.7
3 *0301 0.0
7 *0801-*1901 14.9 *
4 *0101-*0601 1.8
+ p > 0.05 (d.f. = 4)
# p > 0.005 (d.f. = 4)
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Table 4.9
Selection of linkage disequilibrium analysis results from 
the South Indian population sample.
DR
type DPBlallele X2
3 *0101 0.5
2 *0401 6.3
4 *0301 1.7
3 *0301 1.1
2 *1301 5.1
6(Dwl3) *1301 9.6+
7 *1301 1.7
7 *0801-*1901 6.0
4 *0101-*0601 4.3
6 (Dwl4 ) *0201 2.6
+ p < 0.05 (d.f. = 4)
DPB1*13 01 in the White Australian sample; however niether 
of the two samples which contain DPB1*1301 has a DR6(wl3) 
allele.
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4.3. CONCLUSIONS
Two Caucasoid populations were DPB1 typed by AFLP. Despite 
similarities in the distribution of allele frequencies, the 
White Australian sample more closely resembled the DPB1 
antigen frequencies of other European population samples 
than did the South Indian samples. The major difference in 
the frequency distribution of alleles between White 
Australians and South Indians is the relatively high 
frequency of DPB*1301 in South Indians. Examples of 
population associated non-DPwl to w6 alleles are observed 
in several other populations.
The comparison of AFLP and RFLP typing results show that 
the DPA1 and DPB1 probe RFLP patterns "A" and "B" are 
associated with DPB1*0801 to *1901 alleles. Although most 
of these rare alleles exhibit the same RFLP pattern, 
further investigation into RFLPs using additional 
restriction enzymes may reveal allele specific RFLP 
patterns for non-DPwl to w6 alleles.
Less agreement was observed between RFLP and AFLP typing 
results in South Indian samples than in White Australian 
samples. This implies that the HLA-DP RFLP technique, 
devised using mainly European DNA samples, may be
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unsuitable for other ethnic groups. The RFLP technique to 
type Indian samples may have to be modified to use 
different restriction enzymes in order to take advantage of 
possible population specific associations between HLA-DP 
genotypes and flanking polymorphic restriction sites. 
Examples of possible linkage disequilibrium were observed 
in both populations. Although the most widely reported 
association between HLA-DR and -DP, DR3 and DPB1*0101, was 
not observed, two other previously reported observations 
were found; DR4 with DPB1*0401, and DR7 with DPB1 alleles 
corresponding to non-DPwl to w6 types. A previously 
unreported association was also found between DR2 and 
DPB1*0401. In the South Indian sample, the only 
significant association was between DR6(Dwl3) and DPB1*1301 
rare DPB1 allele *1501, an association not observed in the 
White Australian sample.
The linkage disequilibrium analysis method is frequency 
dependent so that low frequency alleles in linkage 
disequilibrium may not be apparent unless the association 
is strong. Increasing sample size is an obvious way of 
improving the likelihood of observing linkage 
disequilibrium.
The detection of linkage disequilibrium between HLA-DR and 
-DP will also be improved by more accurate typing of DRB 
alleles. It is likely that the significance of some 
associations will improve and new associations observed as 
methods of typing DRB1 alleles become more widely used. 
RFLP typing is often unable to distinguish between
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genotypic subtypes. For instance, HLA-DR4 has eight 
recognised nucleotide variants (Bodmer et al 1990), and a 
positive association between one DR4 allelic variant and a 
DP allele may be masked by the other seven DR4 alleles. 
Thus the association between DR4 and DPB1*0401 reported by 
Matsui et al (1985), which approaches significance in this 
study may be improved by DR4 allelic typing. The improved 
likelihood of observing linkage disequilibrium by being 
able to discriminate alleles is demonstrated in allelic 
typing of DPB1, as the association between DR2 and 
DPB1*0401 is not observed if DPB1*0402 samples are
included.
Chapter 5
AFLP Typing of DPB1 in IDDM 
and MS Patients
138
5.1. INTRODUCTION
The diseases insulin-dependent diabetes mellitus (IDDM) and 
multiple sclerosis (MS) both have complicated etiologies 
with genetic as well as environmental factors implicated in 
the disease process. IDDM is a chronic disease affecting 
about three per thousand individuals under 20 years in 
Caucasoids, and is caused by the immune destruction of 
pancreatic B cells, while MS can be either chronic or acute 
and involves the immune destruction of neural 
oligodentritic sheaths in the brain (see Chapter 1).
This chapter extends HLA-DPB1 typing to two IDDM patient 
groups and one MS patient group. The White Australian and 
South Indian IDDM patient groups have been examined by 
serology and RFLPs for HLA-DR and -DQ (Kohonen et al 1987, 
Serjeantson et al 1987, Easteal et al 1990a) and HLA-DP 
typed by RFLPs (Easteal et al 1990a, Easteal et al 1990b). 
The MS patient group has been DR typed by serology (Stewart 
et al 1981) and by RFLPs..
5.1.1 HLA-DP and IDDM associations
Due to the earlier difficulties in typing HLA-DP, its 
relationship to IDDM has not been studied in great detail. 
By PLT typing, no association between DPw types and IDDM 
were detected in European Caucasoids (De Jongh et al 1984), 
while RFLP studies have shown an association between DPw3 
and/or DPw6 and IDDM in White Australians (Easteal et al
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1990b). RFLP typing cannot discriminate between DPw3 and 
w6, and so the level of association could not be accurately 
determined as an IDDM association with one allele may be 
masked by the inclusion of the other allele. The study did 
not discern any linkage disequilibrium between DPw3/w6, and 
DR types associated with IDDM.
Some preliminary results using the more precise PCR based 
typing methods have been described for European Caucasoid 
IDDM patients, however the sample sizes have been small. 
Bugawan et al (1988), typing by the SSO method, reported an 
association between a DPB1 allele (not identified) and IDDM 
in DR3 positive patients, but was later suggested to be due 
to linkage disequilibrium between HLA-DR and -DP (Todd et 
al 1990). Erlich (1990) SSO typed European controls and 
detected five individuals with the B18,DR3 haplotype, which 
is associated with IDDM. Three of these individuals also 
contained the rare allele DPB1*0202, indicating possible 
linkage disequilibrium. Three individuals from the patient 
group were typed as having the B18,DR3 haplotypes, however, 
none was DPB1*0202 positive, but two were DPB1*1301 
positive, another rare DPB1 allele. This implies that for 
B18,DR3 haplotypes, the DPB1*0202 allele may possibly have 
a protective effect, while the DPB1*1301 may be associated 
with IDDM susceptibility.
South Indian IDDM patient and control groups have been used 
in previous studies (Kirk et al 1984, Serjeantson et al 
1987, Easteal et al 1990a) and were found to exhibit 
different patterns of linkage disequilibrium than observed
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in White Australians; for instance DR2, DR4 and DRw6 had 
different DQA1 and DQB1 associated RFLP patterns. An HLA- 
DQB1 associated RFLP pattern, observed in IDDM susceptible 
DR1 haplotypes in European Caucasoids, was detected in 
DRwlO,DRwl4 haplotypes in South Indians, and was associated 
with IDDM (Serjeantson et al 1987).
Typing of HLA-DP by RFLP analysis of the South Indian 
sample revealed no positive associations with IDDM, 
although a marginally significant rise in the frequency of 
DPw2 associated RFLPs in controls compared with patients 
was reported (Easteal et al 1990a). Novel DPA1 and DPB1 
probe RFLP patterns, called "B", were found to be 
negatively associated with IDDM.
5.1.2. HLA-DP and MS associations
Genetic analysis of occurrence of MS in family pedigrees 
suggest that two loci are related to the disease, one in 
the HLA region and the other elsewhere (Tiwari et al 1981, 
Ho et al 1985). Although HLA-DR2,Dw2 and more recently 
DQwl have been positively associated with MS (Tiwari and 
Terasaki 1985, Spurkland et al 1991), there have been 
reports that different aspects of the disease may be 
associated with different HLA loci. Stendahl-Brodin et al 
(1979) observed that Dw2 was more strongly associated with 
a progressive form of MS (severe or moderate disability 
within five years of onset). Walker et al (1982) report 
that DR2 positive MS patients have a higher mean age of
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onset; 32.5 years in DR2 positive patients, 25.0 years in 
DR2 negative patients. In some MS affected families, DR2 
is not detected (Tiwari and Terasaki et al 1985). One 
study, typing HLA-B, and -DR antigens in pedigrees 
containing MS affected individuals found no HLA association 
with MS (Poskanzer et al 1980). This suggests that other 
HLA or HLA-linked loci are involved.
The evidence for an association between HLA-DP has been 
contradictory. Moen et al (1984) PLT typed 36 Norwegian MS 
patients. Only DPwl to w4 were detected, however a 
positive association between DPw4 and MS with a relative 
risk of 2.1, and a non-significant negative association 
between DPwl and MS were observed. The study confirmed the 
association between MS and DR2. Odum et al (1988) also 
found an increase in the frequency of the DPw4 antigen in 
45 Swedish MS sufferers (relative risk 5.4). Odum et al 
(1990) found that although HLA-DR2 and DPw4 were 
independent, haplotypes containing both DR2 and DPw4 were 
associated with a higher risk.
However, the relationship between DPw4 and MS has been 
disputed. Tremijtelen et al (1985) detected linkage 
disequilibrium between DPw4 and DR2 and several studies 
have found no relationship between MS and DPB1 alleles 
(Begovich et al 1990, Fugger et al 1990, Spurkland et al 
1990) or DPw antigens (Olerup et al 1990) .
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5.2. RESULTS AND DISCUSSION
5.2.1 IDDM
5.2.1.1. DPB1 allele associations with IDDM patients
The DPB1 types of 55 White Australian IDDM patients were 
obtained by the AFLP technique. Table 5.1 compares the 
allele and antigen frequencies in IDDM patients and healthy 
controls. Relative risk values for each allele and antigen 
were calculated by 2 x 2 contingency tables (Table 5.1).
The allele frequency of DPB1*0301 is 9.0% in healthy White 
Australian controls and 17.2% in IDDM patients and is 
associated with IDDM with a relative risk of 2.3 (95% 
confidence interval (Cl) = 1.1 - 4.6, x2 = 4.3, d.f. = 1, p 
< 0.05). This is in agreement with Easteal et al (1990b) 
who reported a relative risk of 4.5 associated with the 
DPw3 or w6 antigen. Although the same population sample 
was used in each study, the relative risks are different as 
the IDDM patient DNA sample series was augmented in the 
AFLP study, a different control series was used, and it was 
possible to discriminate DPB1*0301 and *0601. The 
difference between patients and controls for the DPB1*0301 
antigen frequencies, as distinct from allele frequencies, 
was not significant, suggesting that the association 
between DPB1*0301 and IDDM may be weak.
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Table 5.1
Frequencies and relative risks of DPBl alleles (all.) and 
antigens (ag.) in White Australian patients and healthy 
controls.
Patients Controls Relative risk
DPBl
Allele % %
n all. ag. n all. ag. all. x 2 ag. X2
*0101 7 6.4 11 9 5.1 10 1.3 0.2 1.1 0.0*0201 17 15.5 24 25 14.0 25 1.1 0.1 1.0 0.0*0202 1 0.9 2 1 0.6 1 1.6 0.6 1.7 0.1*0301 20 18.2 27 16 9.0 17 2.3 4.3+ 1.8 2.4*0401 40 36.6 55 79 44.4 67 0.7 1.8 0.7 0.9*0402 11 10.0 15 26 14.6 23 0.7 1.3 0.6 1.1*0501 1 0.9 2 3 1.7 3 0.5 0.3 0.6 0.3*0601 3 2.7 7 3 1.7 3 1.6 0.1 2.2 1.2*0801 0 0 0 0 0 0 _ - - _*0901 1 0.9 2 0 0 0 - _ - -*1001 1 0.9 2 3 1.7 3 0.5 1.9 0.6 0.3*1101 1 0.9 2 5 2.8 5 0.3 1.2 0.3 1.1*1301 4 3.6 7 3 1.7 3 2.2 1.1 2.3 1.2*1401 0 0 0 0 0 0 - - - -*1501 2 1.8 4 1 0.6 1 3.3 1.0 3.4 1.1*1601 0 0 0 1 0.6 1 - - - -*1701 0 0 0 2 1.1 2 - - - -*1801 0 0 0 0 0 1 - - - -*1901 1
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0.9 2 1
178
0.6 1 1.6 0.6 1.7 0.1
+ p < 0.05, d.f 1
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AFLP typing revealed DPB1*0601 had an allele frequency of 
2.7% in patients and 1.7% in controls, which was not 
significant, implying that the association observed by the 
RFLP method was due to the presence of the DPw3 antigen.
No evidence of linkage disequilibrium was observed between 
DR3 or DR4 and DPB1*0301 in either the White Australian 
control or patient groups.
The DPB1 genotypes of 74 South Indian IDDM patients were 
identified by AFLP typing and compared to a control sample 
(see chapter 4) and the relative risk of IDDM was 
calculated for DPB1 alleles and antigens (Table 5.2).
No significant positive association was observed between 
DPB1 alleles and IDDM in South Indians. However one 
allele, DPB1*1301, was negatively associated with IDDM, 
having a frequency of 10.9% in healthy South Indian 
controls, and 0.7% on IDDM patients, resulting in a 
relative risk of 0.06 (95% Cl = 0.04 - 0.37). This 
association is highly significant with a x2 value of 16.4 
(d.f. = 1, p < 0.001). DPB1*1301 was not in linkage
disequilibrium with DR2, an allele associated with a low 
relative risk in South Indians (Easteal et al 1990a), and 
there was no evidence for interactive effects between the 
protective alleles at the HLA-DP and -DR loci.
Table 5.2 145
Frequencies and relative risks of DPB1 alleles (all.) and antigens (ag.) in 
South Indian patients and healthy controls.
D 5  ^n ^ r**. u ca co controls Relative risk
DPBl
Allele
% %
n all. ag. n all. a g . all. X2 ag. X2
*0101 3 2.2 4 8 6.3 13 0.3 3.3 0.4 1.9*0201 49 35.6 58 33 25.8 45 1.4 1.8 1.4 1.6*0202 1 0.7 1 0 0 0
*0301 10 7.2 13 4 3 .1 5 2.3 1.9 3.0 2.8*0401 53 38.4 68 47 36.7 64 1.0 0.0 1.1 0.2*0402 6 4.3 9 9 7.0 3 0.6 1.2 0.7 0.4*0501 0 0 0 0 0 0 _ -*0601 0 0 0 0 0 0 - • _*0801 0 0 0 1 0.8 2 _ _*0901 6 4.3 9 4 3 .1 6 1.3 0.2 1.4 0.3*1001 0 0 0 2 1 .6 3 - _ _*1101 0 0 0 0 0 0 - - _ _*1301 1 0.7 1 14 10.9 20 0.1 16.4+ 0.1 11.7+*1401 5 3.6 7 3 2.3 5 1.5 0.3 1.6 0.4*1501 4 2.9 4 1 0 .8 2 3.5 1.5 2.8 0.9*1601 0 0 0 0 0 0 - _ - _*1701 0 0 0 1 0 .8 2 - _ - -*1801 0 0 0 1 0 .8 2 - - _ _*1901 0
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0 0 0
128
0 0
&
+ p < 0.001, d . f . = 1
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5.2.1.2. Putative epitope associations with IDDM
Reinsmoen and Bach (1990) suggested that two hypervariable 
regions on the DRB molecule encoded the T cell defined 
epitopes. These regions correspond to the second and 
fourth HVRs on DPB1. By combining allele frequencies based 
on HVR similarities, associations of putative epitopes 
shared by different DPB1 alleles can be assessed. This 
approach has been used for other HLA loci. Neutral amino 
acid residues at amino acid position 57 in DQB1 alleles are 
associated with IDDM susceptibility, whereas acidic amino 
acid residues are associated with IDDM resistance (Todd et 
al 1987). Amino acid position 70 in DRB alleles also shows 
associations between amino acid and IDDM; neutral and basic 
amino acids are observed more often on IDDM susceptible 
alleles, while resistant alleles are more likely to contain 
acidic residues at this site (Serjeantson and Easteal 
1989).
Amino acid position 57 in DQB1 corresponds with the 
polymorphic amino acid position 56 in site in DPB1; 
DPB1*0101, *0202, *0401, *0501, *1101, *1301, *1501 and 
*1901 contain a neutral alanine residue, while DPB1*0201, 
*0301, *0402, *0601, *0801, *0901, *1001, *1401, *1601, 
*1701, and *1801 contain an acidic glutamic acid residue. 
Analysis of the association between IDDM and the DPB1 
second exon amino acid position 56 in the White Australian 
patient group revealed no significant associations with
IDDM.
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Allele combinations based on the amino acid at position 56 
did show significant associations with IDDM in South Indian 
patients. The neutral alanine residue has a negative 
association IDDM (relative risk = 0.6, 95% Cl = 0.4 - 0.9,
X2 = 5.0, d.f. = 1, p < 0.025), while the acidic aspartic 
acid is positively associated with IDDM (relative risk =
1.7, 95% Cl = 1.0 - 2.7, X2 = 4.5, p < 0.05).
Amino acid position 70 in DRB1 corresponds with polymorphic 
amino acid position 69 DPB1 and lies within HVR 4.
DPB1*0101, *0301, *0401, *0402, *0501, *1401 and *1801 all
contain a basic lysine residue at amino acid position 69, 
While DPB1*0201, *0202, *0601, *0801, *0901, *1001, *1601,
*1701 and *1901 contain an acidic glutamic acid residue.
The remaining alleles, DPB1*1101 and *1501, contain the 
basic arginine residue. However the combinations of 
alleles based on the amino acid at position 69 do not show 
significant positive or negative association with IDDM in 
either White Australian or South Indian patient groups.
An amino position associated with IDDM was located in 
DPB1*0301, *0601, *1101, *1401 and *1501 which all contain 
a leucine residue at amino acid position 65 (Leu65) in HVR 
4. All remaining alleles contain an isoleucine residue 
(Ile65).
In White Australians, the combined frequency of Leu65 
alleles has a relative risk of 2.0 (95% Cl = l.i - 3.7, x2 
= 5.0, d.f. = 1, p < 0.05), whereas no association is 
observed between IDDM and Ile65 alleles. Combining the
148
frequencies of alleles sharing the DPB1*0301 HVR2 sequence 
does not lead to a significant association with IDDM. When 
the analysis of Leu65 alleles is repeated excluding 
DPB1*03 01, there is no evidence of association. This 
suggests that the association between HLA-DP and IDDM in 
the White Australian patient group may be due to DPB1*0301 
alone.
No single allele was positively associated with IDDM in the 
South Indian sample. However the Leu65 group of alleles, 
have a combined frequency of 6.2% in controls and 12.9% in 
IDDM patients. This group of alleles has a relative risk 
of 2.6 (95% Cl = 1.0 - 6.4, X2 = 4.4, d.f. = 1, p <0.05), 
and is independent of the presence of DR3 or DR4.
DPB1*0601 and *1101 alleles were not observed in either the 
control or patient group, hence the relative risk is 
associated with DPB1*0301, *1401 and *1501, and is higher 
than the relative risk observed for an glutamic acid 
residue at position 56.
DPB1*1301 and DPB1*0101 share the same unique nucleotide 
sequence at HVR 2 and in South Indians DPB1*0101 also tends 
to occur less frequently in patients (2.0%) than in 
controls (6.0%)(x2 = 3.2, d.f. = 1, p < 0.1). If the 
DPB1*1301 and *0101 allele frequencies in South Indians are 
combined, the negative association with IDDM is increased
(relative risk = 0.12, 95% Cl = 0.04 - 0.37, x2 = 20.9,
d.f. = 1, p < 0.001). The protective effect of DPB1*1301
and *0101 is stronger than that observed for alleles
containing an alanine at position 57. This leads to the
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speculation that the epitope including the amino acid motif 
Glu-Glu-Tyr-Ala encoded by the HVR 2, may have a protective 
effect against IDDM in South Indians, however it is likely 
that other factors are involved as the effect of the 
DPB1*1301/*0101 HVR 2 sequence is not observed in the White 
Australian sample.
5.2.1.3. Linkage disequilibrium between HLA-DR and -DP in 
IDDM patient groups.
Linkage disequilibrium analysis was performed on both the 
White Australian and South Indian IDDM patient samples.
The White Australian group did not show any evidence for 
association between HLA-DR and -DP, including between the 
DR IDDM susceptibility types, DR3 and DR4, and the DPB1 
alleles associated with MS in this study; DPB1*0301 and 
Leu65 alleles (Table 5.3).
Linkage disequilibrium analysis in South IDDM patients 
(Table 5.4) reveal one significant association between DR4 
and DPB1*1501 (X2 = 10.6, p < 0.05, d.f. = 4). This 
association is based on the presence of four DPB1*1501 
alleles all present on DR4 haplotypes, and includes one 
sample that is homozygous for both DPB1*1501 and DR4. No
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Table 5.3.
Some results of analysis for linkage disequilibrium 
between HLA-DR and -DP from White Australian IDDM 
patients.
DR
type DPBlallele(s) X2
3 *0101 3.7
3 *0301 1.1
3 *0301,*0601,*1101 
*1401,*1501
3.7
4 *0301 2.4
4 *0301,*0601,*1101 
*1401,*1501
2.8
4 *0101 - *0601 1.9
7 *0801 - *1901 2.1
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Table 5.4
Some results of analysis for linkage disequilibrium 
between HLA-DR and -DP from South Indian IDDM patients.
DR
type
DPBl
allele(s) X2
3 *0301 2.1
3 *0301,*0601,*1101 
*1401,*1501
6.0
4 *0301 1.4
4 *0301,*0601,*1101 
*1401,*1501
3.7
4 *1501 10.6+
4 *0101 - *0601 6.3
7 *0801 - *1601 7.9
7 *1301 0.5
7 *0101 0.0
2 *1301 0.1
2 *0101 0.0
+ p < 0.05, d.f. = 4
association was observed between DR4 and *0301, and Leu65 
alleles present in the patient group (DPB1*0301, *1401,
*1501).
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5.2.1.4. Homozygosity
Both the European and South Indian IDDM patient groups have 
a greater proportion of DPB1 homozygotes than do their 
respective controls; 41.8% of the European IDDM patient 
group were homozygotes compared to 32.6% in European 
controls, while in the South Indian patient and control 
groups the percentage of DPB1 homozygotes are 35.5% and 
21.1% respectively. However the differences were not 
significant.
5.2.2. MS
In order to investigate possible heterogeneity of HLA 
association with MS two groups of MS patients, 25 DR2 
positive and 15 DR2 negative, were HLA-DPB1 typed by AFLPs. 
The MS groups were compared to DR2 positive and negative 
controls (table 5.5). The controls were the White 
Australian population sample described in chapter 4, and 
were split into DR2 positive or negative groups on the 
basis of RFLP analysis.
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Table 5.5
Numbers and frequency of DPB1 alleles in DR2 positive (DR2+) and DR2 
negative (DR2-) MS patients and controls.
DPBl
Allele
*0101
*0201
*0202
*0301
*0401
*0402
*0501
*0601
*0801
*0901
*1001
*1101
*1301
*1401
*1501
*1601
*1701
*1801
*1901
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5.2.2.1. HLA-DR2 positive and negative controls
Comparison of allele and antigen distributions in HLA-DR2 
positive and negative controls reveal no significant 
differences (table 5.6). The frequency of HLA-DPB1*0401 
alleles is 54.3% in HLA-DR2 positive controls, and 36.8% in
DR2-negative controls, and the difference approaches 
significance (x2 = 3.4, p > 0.05, d.f. = 1). Linkage 
disequilibrium analysis (see chapter 4) shows there is a 
positive association between HLA-DR2 and HLA-DPB1*0401 
accounting for the increase in the frequency of DPB1*0401 
in the DR2-positive control group. The association between 
DR2 and DPB1*0401 may also explain the association between 
DPw4 and MS observed in earlier studies (Moen et al 1984, 
Odum et al 1988). Because these studies used the PLT to 
type DP antigens, the subtypes of DPw4 (DPB1*0401 and 
*0402) cannot be discriminated, and the association between 
DPB1*0401 and DR2 could have been masked by the inclusion 
of DPB1*0402 frequencies. If linkage disequilibrium 
analysis is performed on the combined DPw4 subtypes and DR2 
no association is observed (see chapter 4).
5.2.2.2. HLA-DR2 positive MS patients and controls
Comparison between the DPB1 allele distributions in DR2- 
positive MS patients and controls (Table 5.7) reveal no 
significant variation. DPB1*0401 occurs in 54% of DR2
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Table 5.6
Comparison of DPB1 allele (all.) and antigen (ag.) distribution in 
DR2 positive (DR2+) and DR2 negative (DR2-) controls.
D R 2 + D R 2 -
D P B l
A l l e l e
% % *2
n all. a g . n all. a g . all. ag.
* 0 1 0 1 4 1 0.9 4 4 4.4 4 1.7 0.8
* 0 2 0 1 4 8.7 4 9 1 4 . 7 8 0.9 0.0
* 0 2 0 2 0 0 0 1 1.5 1 - -
*03 0 1 4 8.7 4 8 1 1 . 8 7 0.3 0.0
* 0 401 26 54.3 17 25 36.8 23 3.4 1.4
* 0 4 0 2 2 8.7 2 13 1 6 . 2 10 1.4 2.2
* 0 5 0 1 1 0 1 0 1.5 0 - -
*06 0 1 1 4.3 1 2 1.5 2
00•o oo
* 0 801 0 0 0 0 0 0 - -
* 0 901 0 0 0 0 0 0 - -
* 1 0 0 1 0 0 0 1 1.5 1 - -
* 1 101 1 2.2 1 2 2.9 2 0.1 0.0
* 1 3 0 1 1 2.2 1 1 1.5 1 0.1 0.2
* 1 4 0 1 0 0 0 0 0 0 - -
* 1 5 0 1 0 0 0 1 1.5 1 - -
* 1 601 0 0 0 1 1.5 1 - -
* 1 701 0 0 0 1 1.5 1 - -
* 1 801 0 0 0 0 0 0 - -
*19 0 1 0
44
0 0
35
1
70
1.5 1
63
Table 5.7
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Frequency of DPB1 alleles (all.) and antigens (ag.) in DR2 positive MS 
patients and controls.
Patients Controls Relative risk
DPBl
Allele
% %
n all. ag. n all. ag. all. X2 ag. x2
*0101 1 2.0 1 4 9.1 4 0.2 2.3 0.2 2.3
*0201 5 10.0 5 4 9.1 4 1.1 0.0 1.1 0.0
*0202 1 2.0 1 0 0 0 - - - -
*0301 3 6.0 2 4 9.1 4 0.5 0.5 0.4 1.0
*0401 27 54.0 17 26 59.1 17 0.7 0.1 0.8 0.1
*0402 5 10.0 5 2 4.5 2 2.3 1.0 2.4 1.1
*0501 0 0 0 1 2.3 1 - - - -
*0601 3 6.0 3 1 2.3 1 to -o
CO•o 2.8 0.8
*0801 0 0 0 0 0 0 - - - -
*0901 0 0 0 0 0 0 - - - -
*1001 2 4.0 2 0 0 0 - - - -
*1101 0 0 0 0 1 2.3 1 - - - -
*1301 0 0 0 1 2.3 1 - - - -
*1401 1 2.0 1 0 0 0 - - - -
*1501 1 2.0 1 0 0 0 - - - -
*1601 1 2.0 0 0 0 0 - - - -
*1701 0 0 0 0 0 0 - - - -
*1801 0 0 0 0 0 0 - - - -
*1901 0
50
0 0
39
0
44
0 0
29
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positive MS patients and 59.1% in DR2 positive controls, 
and so agrees with the results of Begovich et al (1990), 
Fugger et al (1990), and Spurkland et al (1990). Moen et 
al (1984) suggested that DPB1*0101 could be protective 
against MS. In this group, only one DPB1*0101 allele is 
detected (2.0%) in MS patients and four (9.1%) in controls, 
giving a relative risk of 0.2 (95% Cl = 0.1 - 5.5),
however this result is not significant.
5.2.2.3. HLA-DR2 negative MS patients and controls
In contrast to the DR2 positive groups, significant allele 
frequency differences are observed between DR2 negative MS 
patients and controls (Table 5.8). The DPB1*0301 allele 
occurs in 33.3% of DR2 negative MS patients and 11.4% in 
DR2 negative controls (relative risk = 3.3, 95% Cl = 1.1 - 
9.9, = 5.1, p < 0.025, d.f. = 1). This association is
not observed in DR2 positive MS patients and controls where 
the allele frequency of DPB1*0301 is 6.0% and 9.1% 
respectively (x^  = 0.5) (Table 5.7). DR2 and DPB1*0301 do 
not show evidence of being in linkage disequilibrium in the 
control groups (see chapter 4). DPB1*1701 is over
represented in DR2 negative MS patients as two DPB1*1701 
alleles (8.3%) were detected in the patient group, and one 
in the controls (1.4%). However this is not significant 
(95% Cl = 0.4 - 59.5).
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Table 5.8
Frequency and re la tive  r isk  of DPB1 a lle les  ( a l l . )  and antigens (ag.) in 
DR2 negative MS patients and controls.
D P B l
A l l e l e
p a t i e n t s
%
n all. ag.
C o n t r o l s
%
n all. ag. all.
R e l a t i v e  risk
2 2 v z ag.
*0101 1 4.2 1 4 5.7 4 0.6 0.3 0.5 0.3
*0201 2 8.3 2 9 12.9 8 0.5 0.8 0.5 0.7
*0202 1 0 1 1 1.4 1 2.4 °-4 * 2.2 0.3*0301 9 33.3 9 8 11.4 7 3.3 5 .1 # 3.6 5 .5*
*0401 11 37.5 10 25 35.7 23 0.0 0.0 0.9 0.0
*0402 2 8.3 2 13 18.5 10 0.3 1.6 0.4 1.4
*0501 0 0 0 0 0 0 - - _ -
*0601 1 0 1 2 1.4 2 1.2 oo 1.1 o•o
*0801 0 0 0 0 0 0 _ _ -
*0901 0 0 0 0 0 0 _ _ _ -
*1001 0 0 0 1 1.4 1 _ _ _ -
*1101 0 0 0 2 2.9 2 - - _ -
*1301 0 0 0 1 1.4 1 _ _ _ _
*1401 1 0 1 0 0 0 - _ - -
*1501 0 0 0 1 1.4 1 _ _ _ -
*1601 0 0 0 1 1.4 1 - - - -
*1701 2 8.3 2 1 1.4 1 5.0 2.0 4.6 1.8
*1801 0 0 0 0 0 0 _ _ _ -
*1901 0 0 0 1 1.4 1 - - - -
30 29 70 63
# p < 0.025, d . f . = 1
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5.2.2.4. HLA-DR2 positive and negative MS patients
Comparison of the two MS patient groups (Table 5.9) confirm 
the observation of a significantly higher frequency of 
DPB1*0301 alleles in DR2-negative patients over DR2 
positive patients (30.0% compared with 6.0% respectively;
= 8.5, p < 0.005, d.f. = 1). The frequency of DPB1*0401 
in DR2 positive MS patients is higher than in DR2 negative 
patients, 54.0% and 36.7% respectively, but this difference 
was not significant (x^  = 2.3).
5.3. CONCLUSIONS
The AFLP typing of White Australian and South Indian IDDM 
patients support a conclusion of Easteal et al (1990b) that 
the DPB1 associations with IDDM are different between the 
two ethnic groups, and that DPB1*0301 was positively 
associated with IDDM in White Australians. However the 
association is weak, as the relative risk is only 2.3, and 
the association is not observed when DPB1 antigen 
frequencies are analysed (Table 5.1).
The DPB1 allele and antigen distribution in South Indian 
IDDM patients did not show positive association with IDDM 
unless the Leu65 alleles, DPB1*0301, *1401 and *1501 were 
combined. This group of alleles showed no interaction with 
DR3 and DR4 alleles, however DPB1*1501 is in linkage 
disequilibrium with DR4 (Table 5.4). DPB1*0301 and *1401
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Table 5.9
Comparison of DPB1 allele (all.) and antigen (ag.) distribution in 
DR2 positive (DR2+) and DR2 negative (DR2-) MS patients.
DR2+ DR2-
DPBl
Allele
% % X2
n all. ag. n all. ag. all. a g .
*0101 1 2.0 1 1 3.3 1 0.1 0.1
*0201 5 10.0 5 2 6.7 2 0.3 0.6
*0202 1 2.0 1 1 3.3 1 0.1 0.1
*0301 3 6.0 2 9 30.0 9 8.5# 8.2#
*0401 27 54.0 17 11 36.7 10 2.3 0.6
*0402 5 10.0 5 2 6.7 2 0.3 0.6
*0501 0 0 0 0 0 0 - _
*0601 3 6.0 3 1 3.3 1 0.3 0.5
*0801 0 0 0 0 0 0 - _
*0901 0 0 0 0 0 0 _ -
*1001 2 4.0 2 0 0 0 - -
*1101 0 0 0 0 0 0 _ _
*1301 0 0 0 0 0 0 ~ -
*1401 1 2.0 1 1 3.3 1 0.1 0.1
*1501 1 2.0 1 0 0 0 - -
*1601 1 2.0 1 0 0 0 - -
*1701 0 0 0 2 6.7 2 - -
*1801 0 0 0 0 0 0 - -
*1901 0
50
0 0
39
0
30
0
29
# p < 0.005, d.f. = 1
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do not show positive associations with either DR3 or DR4, 
and it is only when the allele frequency of DPB1*1501 is 
combined with those of DPB1*0301 and /*1401 that an 
association with IDDM is observed. As only low numbers of 
DPB1*1401 and *1501 positive samples are involved in this 
analysis, a clearer picture may be obtained with the typing 
of more IDDM patients.
A strong negative association was observed between IDDM and 
DPB1*1301 alleles and antigens only in South Indians and 
the significance of the association was strengthened by the 
inclusion of DPB1*0101 allele frequencies. This 
combination suggests the involvement of an HVR 2 sequence 
encoded epitope rather than a single amino acid site. The 
protective effect of these alleles were not observed in 
White Australians. This may be due to the low frequency of 
DPB1*1301 in White Australians compared to South Indians 
(1.7% and 10.9% respectively), however DPB1*0101 is 
relatively common in both populations (5.1% in White 
Australian controls and 6.3% in South Indian controls) and 
shows marginal negative association with IDDM only in South 
Indians.
It was observed that in both White Australian and South 
Indian IDDM patients amino acid position 65 was more 
diagnostic than amino acid position 69 (position 70 in DRB1 
alleles) or amino acid position 56 (position 57 in DQB1 
alleles). Leucine and isoleucine are both nonpolar amino 
acids of roughly the same size, the only difference being
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in the branching of the carbon side-chain, this suggests 
there would be little difference in the putative epitopes.
By referring to the putative structure of the class II 
antigen binding site (Brown et al 1988), position 65 lies 
on the outward edge of the ß chain alpha-helix, pointing 
away from the antigen binding cleft but presumably 
accessible to the TCR. If amino acid position 65 is part 
of a TCR directed epitope then it is possible that the 
apparently small conformational change between leucine and 
isoleucine may be significant. The HVR 2 region encodes a 
region at the extreme end of the alpha helix, and again 
appears to have little involvement in the antigen binding 
site but is accessible to the TCR.
In the White Australian MS patients the results suggest 
that the disputed association between MS and DPw4 may be 
due to weak linkage disequilibrium between DPB1*0401 and 
DR2. A protective effect assigned to DPB1*0101 was not 
observed although a non-significant negative association 
with MS was observed in DR2 positive MS patient and control 
groups.
The DPB1*0301 allele is associated with MS only in DR2 
negative MS patients, and analysis using antigen 
frequencies also reveals a significant association with MS 
(Table 5.1). A non-significant association between DPw3/w6 
and MS has been reported previously (Olerup et al 1990), 
the study typed two MS patient groups by RFLP; those with 
the progressive form of MS and those with a slower
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progressing disease (slight or moderate disability at least 
10 years post-onset). In the group of 82 individuals with 
the less severe form of the disease, the DPw3 and w6 
antigens had an antigen frequency of 52% compared to 37% in 
controls, which was not significant after multiple 
comparisons were taken into account (Olerup et al 1990).
Interestingly Walker et al (1982) observed that DR2 was 
associated with a higher progression coefficient, this 
implies that DPB1*0301 may be associated with the less 
progressive disease. This is supported by the observation 
of a strong negative interactive effect between DR2 and 
DPB1*0301 when the results are combined.
In MS patient groups not split on the criteria of being DR2 
positive or DR2 negative it is likely that any association 
between DPB1*0301 and MS would be obscured by the presence 
of DR2 positive haplotypes. Further typing of MS DR2- 
negative patients would also allow analysis of the 
association between MS and HVR sequence. It would also be 
interesting to split an MS patient group on the basis of 
disease course rather than on the presence or absence of 
DR2. This could lead to better definition of clinical
subsets in MS.
Chapter 6
Novel DPB1 Sequence Variant
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6.1 INTRODUCTION
One important feature of an HLA allele typing protocol 
must be the ability to detect novel sequence variation.
PLT utilizes TCR mediated recognition of HLA-DP molecule 
epitopes. As the T cells are generated to be stimulated 
only by particular DP epitopes, a novel sequence variant 
presenting a new epitope will not be recognised by the 
panel of T lymphocytes. Thus novel antigens remain 
undetected by PLT unless the antigens are found as 
homozygotes or in combination with other novel antigens.
As novel antigens are rare, they are most likely to be 
found in combination with recognised alleles and so masked 
by the that allele. Similarly, serology can detect 
recognised epitopes but the presence of novel epitopes can 
be detected only in homozygotes. Reliable typing by these 
methods depends on foreknowledge of the epitopes expected 
to be encountered.
Although novel alleles may give rise to distinct RFLP 
patterns detectable by Southern blotting, this is not 
always the case. Detection of alleles by RFLPs generally 
relies on polymorphic restriction sites outside the coding 
sequence of the gene. A new allele arising by gene 
conversion or point mutation is thus unlikely to result in 
a novel RFLP pattern.
SSO and AFLP typing methods detect sequence variation 
directly, and are designed to specifically target 
variation in the HVRs. It is observed that DPB1 allelic
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variation is restricted to the HVRs, and new alleles have 
arisen by novel rearrangements of HVR sequences (Bugawan 
et al 1990).
Although several novel DPB1 alleles have recently been 
reported, no new DPB1 allele sequences have been published 
since the 19 DPB1 alleles were recognised by the WHO 
Nomenclature Committee (1990). Ando et al (1986) 
described a DPB1 second exon amino acid sequence that 
contained amino acid polymorphisms outside the HVRs, 
however DNA sequencing revealed that the allele was in 
fact identical to DPB1*0901 (Bugawan et al 1990).
Lee et al (1989) presented the nucleotide sequence of a 
novel allele, which they referred to as DPBl-lb, 
discovered in combination with DPB1*0101 in the 10IHW cell 
line 9021. They reported the sequence of DPB-lb as 
identical to that of DPB1*0402 except for a unique HVR1 
sequence. When Bugawan et al (1990) sequenced the cell 
line, however, they found that the allele was in fact 
DPB1*04 02, a result which agrees with AFLP typing (see 
chapter 3).
Several novel alleles have been detected by SSO typing. 
Fernandez-Vina et al (1990) located three unique SSO 
hybridization patterns, one in each of Brazilian Mestizos, 
North American Blacks and North American Caucasoid 
populations sampled. Another unique SSO pattern has been 
described in a Brazilian Mestizo population sample (Moraes 
et al, in press). Gao et al (1991) also report a novel
SSO pattem in a North Chinese population sample. The 
DPB1 second exon sequences associated with these novel SSO 
patterns have not yet been published.
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6.2. RESULTS
6.2.1. Novel AFLP pattern
During DPB1 typing of 10IHW cell lines by AFLPs, a novel 
restriction AFLP pattern was observed. Typing revealed 
that cell line 9077 (T7527) was a heterozygote, and most -
likely contained a DPB1*0501 allele in combination with a 
new allele that did not conform to recognised fragment 
patterns (Table 6.1). The Mnl I fragment pattern, 76, 66, 
54 and 51 bp fragments, suggested a DPB1*0501,*1901 
heterozygote. However, Rsa I digestion resulted in 199 
and 113 bp fragments, consistent with a DPB1*0501,1901 
heterozygote, but also a 147 bp fragment, associated only 
with DPB1*1801 alleles. The Mnl I fragment pattern was 
inconsistent with DPB1*1801 which produces 76 bp doublet 
and 69 bp bands, neither of which were observed for cell 
line 9077. Eco NI digestion confirmed the presence of a 
DPB1*0501 allele with a 260 bp band being observed. The 
presence of the 223/6 and 86 bp band was inconsistent with 
either a *1801 or *1901 DPB1 allele. The results of Fok I 
digestion of cell line 9077 PCR product is also consistent 
with the presence of a *0501 allele. Although the 
combined restriction fragment patterns suggest the
Figure 6.1
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Restriction enzyme fragments observed for 10IHW cell line 9077 DNA, 
and DPB1 allele associated with restriction fragment pattern for each 
enzyme.
Enzyme
Restriction 
fragments (bp) Associated DPBl alleles
Mnl 76, 66, 54 
76, 66, 51
*0501
*1901
Rsa I 199, 113 
147, 113
*0201, *0202, *0401, *0402, *0501, 
*0801, *1001, *1601, *1901
*1801
Eco NI 260
223/226, 86
*0401, *0401, *0501
*0601, *0901, *1001, *1301, *1701
Fok I 205, 59 *0201, *0202, *0401, *0402, *0501, 
*1601, *1701, *1801
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presence of a DPB1*0501 allele, an alternative 
interpretation is that both alleles are novel; thus the 
260 bp band produced by Eco NI digestion could be from the 
chromosome that produced the Mnl I digestion fragments 76, 
66 and 51 bp. However, as novel alleles have a low 
frequency, this is unlikely.
Restriction mapping based on Eco NI, Fok I, Mnl I and Rsa 
I digests suggested: An HVR 1 sequence as found in
DPB1*03 01, *0601, *1101 and
*1501 alleles; an HVR 2 sequence as found in DPB1*0201 and 
*0202 alleles; an HVR 3 sequence as found in DPB1*0202, 
*0501 and *1901 alleles; an HVR4 and HVR 5 sequence as 
found in a number of alleles including DPB1*0201 and 
*0202; and an HVR 6 sequence as found in all alleles 
except DPB1*0201, *0202, *0401, *0402, *1501 and *1801.
6.2.2. Sequencing of 10IHW cell line 9077 heterozygote 
6.2.2.1. Direct Sequencing
The use of the thermostable Taq DNA polymerase in 
sequencing by the Sanger dideoxynucleotide chain 
termination method (Innis et al 1988) has improved the 
sequencing technique by removing several time-consuming 
procedures. The usual method of sequencing heterozygotes 
is to clone both alleles into a vector, transform the
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vector into a suitable host, and by clonal expansion 
isolate copies of individual alleles. Vectors from 
different clones can be analysed to obtain copies of both 
alleles in either orientation to allow sequencing of the 
forward and reverse strands of each allele.
PCR amplification removes the need for subcloning DNA into 
an M13 sequencing vector. Single stranded (ss) DNA 
suitable for sequencing can be produced by limiting the 
concentration of the primers (asymmetric PCR) in a PCR 
amplification. Ss DNA produced in this way can then 
bepurified and used as a template in a PCR sequencing 
reaction, which contains only one sequencing primer 
(unilateral PCR) and the deoxy/dideoxy-nucleotide mix 
described by the Sanger method. Asymmetric PCR can be 
used to produce ss DNA product of both strands by limiting 
the concentration of each amplification primer in turn, 
thus removing the need for complementation experiments to 
ensure cloned material of both orientations is used in 
sequencing reactions.
Taq DNA polymerase lacks 3' to 5' exonuclease activity 
important for "proofreading" so that any nucleotides 
misincorporated into the extending PCR product will not be 
removed (Innis and Gelfrand 1990). Estimates of the error 
rate range between 0.25% (Paabo and Wilson 1988) and 2.8% 
(Dunning et al 1988), and depends on a number of factors 
including nucleotide concentrations and the number of 
cycles (Innis and Gelfrand 1990). A 2.8% error rate 
applied to the 312 bp DPB1 second exon PCR product means
0.8 nucleotide bases are misincorporated, per 312, bp per 
cycle (almost 4 bp per 312 bp per 5 cycles).
Direct sequencing reduces the problem of point mutations 
due to PCR. The sequencing template used in direct 
sequencing is not a single PCR product, but a sample of 
the entire population of PCR products produced in a 
reaction, so that errors occurring in individual strands 
will be averaged out. As the genomic DNA sample used in 
the production of the double stranded PCR product contains 
several copies of the HLA-DPB1 gene, an error occurring 
even in the first cycle is unlikely to affect the fidelity 
of the entire PCR product.
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6.2.2.2. Direct sequencing of cell line 9077
The automated sequencing system (ABI) presents sequencing 
data as a graph consisting of a series of peaks 
corresponding to a particular nucleotides. A polymorphic 
site contains two different nucleotides at the same 
position, and are indicated by the presence of two 
superimposed peaks, each half the height of the 
surrounding peaks. Although this approach is not accurate 
enough to allow definite identification of polymorphic 
nucleotides, it does allow some inferences to be made as 
to the identity of the new allele sequence.
At least four sequencing reactions (WT7-3A6R, WT7-3A7R, 
WT7-21M3R and WT7-30A4F) produced appreciable sequences of
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the cell line 9077 DPB1 heterozygote. Comparison of the 
four sequences to the DPB1*0401 sequence (Fig. 6.1) showed 
that most differences were due to sequencing reaction 
artifacts that led to uncertain base calling, indicated by 
an "N" (Fig 6.1). Other variation did occur, several at 
polymorphic nucleotides within HVRs; for instance at 
position 191, all four sequencing results contained an 
adenosine nucleotide (found in DPB1*0501), where DPB1*0401 
contained a cytidine nucleotide.
6.2 .3 . Direct sequencing of the new al lele  
6.2.3.1. Allele specific primer design
HVR 1 sequences from the results of several direct 
sequencing reactions were examined and positions where two 
peaks were superimposed and reduced in size with respect 
to surrounding peaks were noted. The sequences were 
compared with the HVR 1 sequence of DPB1*0501 and from 
this comparison a putative new allele HVR 1 sequence was 
inferred (Fig 6.2). This putative HVR 1 sequence, along 
with the sequence suggested by the AFLP results were used 
to generate an HVR 1 sequence specific primer that would 
selectively amplify the new allele but not DPB1*0501. The 
new allele specific primer, JDPU3 (5'-
TGTAAAACGACGGCCAGTCGCAGAGAATTACGTGTACCAGTT-3'), contains 
an M13 universal primer sequence to facilitate the binding 
of primers in the sequencing reaction at the 5' end, and
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HVR 1
49 54 59
1 1 1
Automated sequence 
identifcation
C T tT T C C A G tT WT7-3A7R
cT® TTCCAG^T WT7-3A6R
CT® CCAG^T WT7-21M3R
GCfTACNAGff WT7-30A4F
CTTTTCCAGGG DPB1*0501
GTGTACCAGTT - Putative
new allele
Figure 6.2 Alignment of cell line 9077 DPB1 second exon 
HVR 1 nucleotide sequences obtained using JDPU2 and JDPB3 
primers, compared with nucleotide sequence of DPB1*0501 
second exon HVR 1 (Bugawan et al 1988).
the polymorphic double thymidine nucleotides which occur 
at nucleotide positions 58 and 59 in some alleles at the 
3' end.
When used in PCR, JDPU3 failed to amplify DPB1 alleles 
that do not contain the two thymidine residues at 
positions 58 and 59. Cell line 9077 PCR product, produced 
using JDPU3, was digested with Rsa I and was found to 
produce only the 147 and 113 bp fragments, attributed to 
the new allele. These results confirmed that the JDPU3 
primer selectively amplified only the new allele in the 
cell line 9077 DPB1 heterozygote. JDPU3 was then used to 
produce single stranded DNA for automated direct 
sequencing.
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6.2.3.2. Sequence of new allele
An example of the output of the automated sequencing 
system (WTN-13M3F) (Fig. 6.3) shows the sequence of the 
new allele. The sequence was confirmed by other direct 
sequencing results (WTN-2M3F and WTN-13M2R), with each 
sequencing template being the product of different double 
stranded PCR amplifications. The new allele appears to 
have been produced by the of shuffling of polymorphic 
sequences present in other alleles (Fig 6.4). HVR 1 and 
HVR 6 sequences are found in a number of alleles, for 
instance DPB1*0301, while the remainder of the sequence, 
HVR 2 to 5, is similar to the DPB1*0202 allele, as 
suggested by Table 6.2.
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Figure 6.3 Automated sequencing result of WTN-13M3F 
produced using JDPU3 and JDPB3 amplification primers 
(arrowed), and showing the positions of the HVRs (shaded). 
Nucleotides: adenosine; green, cytidine; blue, guanosine; 
black, thymidine; red.
G 
G 
.< 
G 
G 
A 
G
176
O +  Q
1111
Table 6.2
Alleles containing HVR sequences observed in the new allele.
H V R S e q u e n c e D B P l  A l l e l e s
1# G T G T A C C A G T T * 0 1 0 1 ,  * 0 3 0 1 ,  * 0 6 0 1 ,  * 1 1 0 1 ,  
* 1 3 0 1 ,  * 1 5 0 1
2 G A G G A G C T C G T * 0 2 0 2 ,  * 0 5 0 1
3 A G G C G G A G * 0 2 0 2 ,  * 0 5 0 1
4 A T C C T G G A G G A G G A * 0 2 0 1 ,  * 0 2 0 2
5 A T G * 0 2 0 1 ,  * 0 2 0 2 ,  * 0 4 0 1 ,  * 0 4 0 2 , 
* 0 5 0 1 ,  * 0 6 0 1 ,  * 1 1 0 1 ,  * 1 5 0 1 ,  
* 1 6 0 1 ,  * 1 7 0 1 ,  * 1 8 0 1
6 A C G A G G C C G * 0 1 0 1 ,  * 0 3 0 1 ,  * 0 5 0 1 ,  * 0 6 0 1 ,  
* 0 8 0 1 ,  * 0 9 0 1 ,  *100 1 ,  * 1 1 0 1 ,  
* 1 3 0 1 ,  * 1 4 0 1 ,  * 1 6 0 1 ,  * 1 7 0 1 , 
* 1 8 0 1 ,  * 1 9 0 1
# Inferred HVR 1 sequence (see text).
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It is interesting to speculate about the origin of this 
novel allele. The sequence appears to have arisen from a 
gene conversion event involving a DPB1*0301 like allele, 
with the central portion of a DPB1*0202 allele acting as 
the sequence donor. Wu et al (1986) report the presence 
of recombination hotspot associated sequences (5'- 
GCTGG(T/G)G-3'), called X“sec3uences / being present in HLA- 
DR genes. The X“sec3uence was found in X-phage and 
E s c h e r i c h i a  col i and is thought to promote recombination 
events. A number of x~like sequences have been located, 
including in the human immunoglobulin switching region. 
Possible x~like sequences, GCTGGTGG, have been observed in 
HLA-DPB1 sequences at nucleotide positions 177 and 273 
(Bugawan et al 1990) which occurs just upstream of HVR 3 
and HVR 6 respectively. If these sequences did act as 
recombination hotspots, the sequence of the new allele 
might be the result of a recombination event between 
DPB1*0301 and DPB1*0202. However the cytidine nucleotide 
at nucleotide position 130 in HVR 2 is found only in 
DPB1*0201 and *0202, and which occurs outside the region 
spanned by the two x_Ü k e  sequences.
6.2.4. AFLP typing of the new allele
Comparison of the new allele sequence with the other 19 
recognised allele sequences (Fig 6.5) shows that the new 
allele sequence conforms to the pattern seen in the other 
alleles in that the new allele is a unique combination of 
HVR sequences rather than containing unique sequences.
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Despite the fact that JDPU3 covers the HVR 1 sequence, the 
sequence of HVR 1 in the new allele can be inferred from 
the heterozygote sequence and AFLP data.
The new allele can be added to the AFLP typing scheme (Fig 
6.6). The Mnl I digest of the new allele gives the same 
restriction fragment pattern as DPB1*1901, however the new 
allele can be discriminated by digestion with Rsa I. This 
produces 147 and 113 bp bands in the new allele and 199 
and 113 bands in DPB1*1901. The alleles can also be 
separated by the other enzymes, Eco NI and Fok I.
DPB1*1801, the only other allele to produce a 147 bp band 
by Rsa I digestion produces a different fragment pattern 
from the new allele after digestion with Mnl I, and Eco 
NI. This means the inclusion of the new allele in the 
AFLP typing scheme does not lead to any combinations of 
heterozygotes unresolvable with the four enzymes.
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6.2.5. Occurrence of the new allele
Cell line 9077 is one of the cell lines collected together 
for the panel used in the 10th international 
histocompatibility workshop (Yang et al 1989) and is of 
Chinese (Hong Kong) origin. The AFLP pattern associated 
with the new allele has been observed a number of times in 
a Southern Chinese population sample (Jacobsen and 
Serjeantson, personal communication) and in an Indonesian 
sample from the island of Java (Easteal, personal 
communication).
Mnl I
DPB1
102/76/54
76/73/69
76/73/66
76/69/54
Rsa i
260
102/76/76
76/76/69
76/66/54
312
Rsa I
199/113
147/113
Rsa I
260
76/69/51 199/113
113/78
Fokl
205/107
Eco Nl
174/86
226/86
205/59/48
205/107
205/59/48
178/54
105/102/76/51
178/71
76/66/51
Rsa I
199/113
147/113
0101
0201
0202
0301
1401
0401
0402 
1801
0501
0601
.0801 
-1001 
. 1601
-0901
1701 
-1101
-1301
-1501
-1901
- NEW
Figure 6.6 Typing scheme used to define 19 DPB1 
alleles and the new allele, by progressive 
restriction enzyme digests. Numbers refer to 
expected fragment sizes in bp.
6.3. CONCLUSIONS
The AFLP technique is able to identify novel DPB1 
variants. Direct sequencing revealed an allele with the 
characteristic pattern of the variation limited to HVRs, 
and can be explained in terms of shuffling of HVR 
sequences. The new allele could be distinguished by 
several existing SSO protocols (Angelini et al 1989, 
Bugawan et al 1990, Fernadez-Vina et al 1990) but the 
predicted SSO pattern does not correspond to any other 
novel SSO patterns yet reported (Fernandez-Vina et al 
1990). The AFLP pattern produced by the new allele has 
been observed in two populations, so that the new allele 
may represent an Asian ethnic group associated DPB1
allele.
Chapter 7
Final Discussion
183
7.1. FINAL DISCUSSION
The PCR is a powerful technique that has revolutionized 
many aspects of molecular biology, and is central to the 
AFLP technique. PCR can rapidly amplify specific regions 
of DNA which allows the analysis of fig quantities of a 
particular region of DNA, removing the need to clone, 
transform, and extract material using conventional 
techniques. The ability to analyse regions of polymorphic 
DNA directly is especially useful when defining different 
alleles at the HLA-DP locus.
HLA-DP was the last expressed class II loci located (Shaw 
et al 1980, Shaw et al 1981). Because HLA-DP molecules 
represent only 10% of class II molecules on B cells, the 
standard cellular typing technique for class II antigens, 
the MLR, cannot be applied to HLA-DP. The PLT typing 
technique was developed, but was hampered by the 
requirement for samples homozygous for HLA-DP to produce 
typing reagents. This meant that reagents for typing rare 
alleles were hard to come by as rare alleles are most 
likely to be observed as heterozygotes.
Discovery of Southern transfer techniques led to the development 
of HLA-DP RFLP typing (Hyldig Nielsen and Svejgaard 1989). Rare
alleles in heterozygotes could be observed by as novel RFLP 
patterns. Although this technique analysed HLA-DP DNA 
rather than the HLA-DP molecule, it still relied on
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polymorphic restriction sites in regions flanking coding 
seguence variation.
The PCR technigue is used to amplify the exon which encodes 
the polymorphic ßl domain of the HLA-DP molecule to allow 
direct analysis of the nucleotide seguence variation. Two 
main methods of polymorphic seguence detection, SSO 
(Angelini at al 1989, Fernandez-Vina et al 1990) and AFLP 
(Maeda et al 1989, Dekker and Easteal 1990) have been 
developed, and both offer accurate and rapid means of DPB1 
allelic typing.
The development of AFLP typing means that there is a viable 
PCR based alternative to SSO typing. AFLP is cheaper to 
perform than SSOs on low to moderate numbers of samples, 
and the technique is comparable in terms of speed and 
accuracy (see Chapter 3). AFLP typing can be performed 
with a minimum of equipment, the most expensive items being 
a thermocycler and a polyacrylamide electrophoresis system.
The disadvantage of AFLP typing is that for inexperienced 
operators interpretation of fragment patterns can be time 
consuming. Also, the use of restriction endonucleases 
brings with it inherent problems. If the enzymes are not 
stored properly or the digests are performed in less than 
optimal conditions, the efficiency of digestion can be 
variable. The expected digest results using three of the 
restriction enzymes in the AFLP typing scheme, Eco NI, Fok 
I and Rsa I include uncut PCR product as diagnostic 
fragments. Although the failure of an enzyme digest can be
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detected by comparing the results of several restriction enzymes, 
it is possible that if the minimum number of enzymes are used 
then errors may occur. The AFLP scheme devised by Ota et al 
(1991) uses restriction enzymes with at least one restriction 
site in all alleles, so that digestion failure can be easily 
identified. The strategy could be applied to this AFLP typing 
protocol by adding short nucleotide tails containing restriction 
sites to the amplification primers. This would allow non­
digestion to be controlled for and still allow the use of 
restriction enzymes which produce a number of possible outcomes 
rather than just two as in the Ota et al (1991) scheme (see 
Chapter 3.7.1). Examples of over-digestion and partial digestion 
have been encountered. Fok I is particularly prone to 
over-digestion which leads to the diminishing of some bands on 
polyacrylamide gels. However this may be avoided by ensuring the 
enzyme concentration and incubation times are kept to a minimum. 
Partial digestion is usually obvious due to the variation in band 
intensities or extra bands being present.
There are some deviations between the expected and observed 
restriction fragment patterns, and most are the result of 
interference between overlapping Mnl I sites. These 
discrepancies are consistent so that the non-predicted 
fragments can still diagnostic for particular alleles or 
allele combinations.
Restriction enzymes with novel recognition sequences are 
still being released commercially so that the AFLP 
technique can be modified to incorporate a new restriction 
enzyme. This may led to the replacement of more than one
of the existing enzymes used in the scheme, making the 
typing protocol more efficient.
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AFLP typing is amenable to use of high technology. In recent 
years there has been remarkable growth in the detection of DNA 
by electrophoretic systems and computer analysis. The best 
conceivable scenario would involve a fast PCR that would need to 
amplify a relatively small amount of product, a double or triple 
enzyme digest followed by electrophoresis on a system capable of 
detecting small fragments (e.g. capillary electrophoresis) with 
the results being output directly into a computer for analysis 
and allele identification. The addition of multiple restriction 
enzymes in a single digest may improve typing efficiency by 
reducing the time needed to set up single restriction enzyme 
digests and by possibly producing a wider range of allele 
specific fragments. Thus AFLP typing could be utilised by both 
the small individual laboratory as well as a large facility with 
access to larger resources.
The ability to type all 19 DPB1 alleles does not 
necessarily provide information as to whether or not the 
allelic variation detected is of functional significance. 
For instance DPB1*0301 and *1401 differ by only one amino 
acid in HVR 1, but it is unknown whether or not the amino 
acid variation is reflected in functional variation, in 
terms of HLA-DP serology or T cell recognition.
As PLT typing is based on TCR recognition of HLA-DP 
molecules (Shaw et al 1981), it gives a direct indication 
of the significance of epitope differences between DPB1
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alleles. However PLT is disadvantaged in that it is unable 
to recognise new HLA-DP antigens. As AFLP is able to type 
all recognised alleles as well as screen for novel 
nucleotide sequence variation, AFLP can be used to identify 
individuals homozygous for alleles that correspond to non- 
DPwl to w6 types. Lymphocytes from these individuals can 
be tested to see if PLT typing reagents recognise the DPB1 
allele, to determine whether or not the allelic variation 
is functionally significant. However if the PLT reagents 
do not recognise the DPB1 allele, then it would suggest 
that the variation has altered the T cell recognition site.
Several 10IHW cell line DNA samples typed by PLT as "blank" 
(Yang et al 1989), have been typed by AFLP (Table 3.1). 
DPB1*0901 and *1001 homozygotes type as PLT blank, however 
a DPB1*0801 homozygote was typed by PLT as DPw2. This 
would argue that DPB1*0901 and *1001 alleles do represent 
functional allelic variants, and that DPB1*0801 does not. 
DPB1*0801 differs from DPB1*0201 only at HVR 5 and HVR 6.
If DPB1*0801 alleles are functionally indistinct from DPw2 
antigens, it would imply that the last two HVRs do not 
contribute significantly to TCR recognised epitopes.
The relatively high frequency of DPB1*1301 in South Indians 
is no guarantee that the allele is functionally distinct 
from PLT DPwl to w6 antigens. Most of the PLT typing 
reagents were generated using non DR7 or DRw6 cells 
(Hartzman et al 1984) and non DPwl to w6 antigens 
(DPB1*0801 - *1901 alleles) are in linkage disequilibrium 
with DR7 in White Australians (see Chapter 4), so that it
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is unlikely that PLT reagents specific for these alleles 
would have been produced. It is therefore likely that 
additional PLT specificities exist. DPB1*1301 is similar 
to DPB1*0101 except for HVRs 4, 5 and 6. Although it
appears that HVR 5 and 6 variation is not enough to 
generate functionally significant variation, HVR 4 does 
appear to be an important region as DPB1*0202 and DPB1*0501 
which can be discriminated by PLT differ only at HVR 4.
This would suggest that DPB1*1301 does encode a unique TCR 
defined antigen.
A DPB1 homozygote typing as PLT "blank" could be used to 
generate PLT reagents capable of typing that allele. The 
DPB1 typing of other ethnic groups has the advantage that 
an allele represented at a low frequency in one ethnic 
group may be relatively common in another. For example, 
DPB1*13 01 is rare in White Australians, and the likelihood 
of locating a DPB1*1301 homozygote to develop PLT typing is 
low. However DPB1*1301 has a frequency of 10.9% in South 
Indians (see Table 4.1) and so this population may provide 
a source of DPB1*1301 homozygotes.
As most of the development of DP typing protocols and 
allele sequencing has been performed on Europeans, existing 
protocols assume that alleles are preserved across ethnic 
boundaries. This is important as both AFLP and SSO typing 
look at only small portions of the second exon. The 
sequencing here of a new allele found in Southern Chinese 
and Indonesians revealed that the nucleotide sequences of 
the constant regions of the exon were identical to
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sequences of European alleles; no unique HVR sequences were 
observed.
It appears that the frequency of DPB1 alleles is relatively 
homogeneous across ethnic boundaries when compared with, 
for example the HLA-B locus. At the HLA-DP locus, 
DPB1*0101, *0201, *0301, *0401 and *0501 alleles are
represented in all populations so far examined, which is 
similar to the universal distribution of HLA-A2 and A24. 
Ethnic group-specific DPB1 alleles are not observed, 
although some instances of ethnic group-associated alleles 
are observed. For instance DPB1*1801 in North American 
Blacks (Fernandez-Vina et al 1991), DPB1*1701 in Northern 
Chinese (Gao et al 1991) and DPB1*1301 in South Indians 
(this study). These alleles, however, are not unique to a 
particular ethnic group but tend to have low frequencies in 
other ethnic groups. This is in contrast to the 
frequencies of DRB1 alleles where some ethnic group 
specific variants are exclusive; for instance there is 
virtually no overlap between DRB1 alleles in Australian 
Aborigines and Caucasoids (Davies et al 1990). Population 
specific alleles are common at the HLA-B locus, for example 
B8, B14, B37 and Bw41 are essentially confined to 
Caucasoids; Bw54, Bw67 and Bw59 to Northern Mongoloids;
Bw46 to Chinese: and Bw46 and Bw48 to Oceania (Serjeantson 
1989).
The formation of new alleles, in terms of shuffling HVRs, 
is clearly permissible, but rare alleles have not 
flourished in the same way as rare alleles at HLA-B and
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DRB1 loci. It could be argued that the high frequency DPB1 
alleles have some selective advantage common across ethnic 
boundaries. Or, it could also be possible that the 
selective advantages attributed to some rare DRB1 alleles 
are not operating at the DPB1 locus.
As rare DPB1 alleles do not contain unique HVR sequences 
but are rather the unique combination of HVR sequences 
present in other alleles (Bugawan et al 1990), there may be 
additional constraints in the generation of diversity at 
DPB1. The new allele sequenced here is no exception to the 
shuffling of HVRs, with the first and last HVR sequences 
also found in DPB1*0301, *0601 and *1101, and the central
four HVR sequences also found in DPB1*0202.
DPB1*03 01 is associated with IDDM and MS (in DR2 negative 
patients) in White Australians, and is one of the group of 
alleles, based on the presence of a leucine residue at 
position 65, associated with IDDM in South Indians. The 
frequencies of DPB1*0301 in other Caucasoid groups (Table 
4.5) are not significantly different, so the association of 
DPB1*0301 observed in the disease groups is not due to 
abnormal control group allele distributions. IDDM and MS 
are similar in that their etiologies are complex and 
involve the cooperation of a number loci as well as 
environmental factors. It is perhaps possible DPB1*0301 is 
linked to both IDDM and MS susceptible loci independently, 
or that the allele is associated with a general 
susceptibility to certain forms of autoimmune disease.
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DPB1*0301 is only associated with MS in DR2 negative 
patients. DR2 has been positively associated with a 
progressive form of MS, and so it possible that DPB1*0301 
is associated with the less progressive, remitting disease. 
This implies that MS is a heterogeneous condition, and 
could be considered as at least two closely related 
diseases with similar pathologies, but different genetic 
backgrounds giving rise to different etiologies. A similar 
situation may apply with respect to IDDM. The patient 
series characterised here had an unusually late age of 
onset (median age = 23 yrs)(Easteal et al 1989) and the 
observed DPB1*0301 association may be enhanced or absent in 
IDDM patients with a younger age of onset. In Chinese 
there is a marked positive association between DR3,DR9 
heterozygotes in early onset patients from Singapore (Chan 
1985) and Hong Kong (Hawkins et al 1987). This association 
is not observed in patients who present with the disease in 
adolescence or adulthood. Thus further studies of DPB1 
allele distributions should be carried out in IDDM patients 
with lower ages of onset than those examined here.
Both amino acid position 70 in DRB (Serjeantson and Easteal 
1989) and position 57 in DQB1 (Todd et al 1987) are 
polymorphic sites which are associated with IDDM. The 
corresponding positions are also polymorphic in DPB1, and 
both encode amino acids that differ in charge. However the 
site with the strongest association to IDDM in both ethnic 
groups at HLA-DP is amino acid position 65. This position 
encodes only two possible amino acids, leucine and 
isoleucine, which are both non-polar, neutral amino acids
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differing only in the branching of their carbon side 
chains. It is difficult to see how a change such as this, 
if it were functional, would have the same effect on the 
tertiary structure of the antigen binding site as would the 
change from an acid to a basic or neutral amino acid.
DPB1*1301 is negatively associated with IDDM in South 
Indians but not White Australians. The protective effect 
is enhanced by the addition of DPB1*0101 allele frequencies 
in patients and controls. In this case the best 
association at the amino acid sequence level is not due to 
a single residue but to the four amino acids which are 
encoded by HVR 2.
These two findings raise questions as to the significance 
of disease association to single amino acid positions. The 
protective effect of the DPB1*1301 and *0101 in South 
Indians suggests that if DPB1 polymorphism does have a 
direct role in the pathogenesis of IDDM, then it is due to 
an epitope including the entire HVR 2, and not just to a 
single amino acid. Similarly the association of IDDM with 
position 65 would perhaps suggest the difference in carbon 
side chains is enough to alter the conformation of an 
antigen binding pocket.
The amino acid polymorphism and a disease related gene may be in
linkage disequilibrium due to particular mutational event.
This scenario suggests that an amino acid substitution from 
an isoleucine to a leucine at amino acid position 65 became
associated with an IDDM related locus. Because of the 
similarity of the amino acids, the change was not
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disruptive. Subsequent mutations resulted in the formation 
of the alleles observed today, and have remained in linkage 
disequilibrium with the disease associated gene.
The progression of HLA-DP typing techniques has led to a 
broadening of the scope of applications. One major impact 
of these techniques is on tissue typing for 
transplantation. PLT, serology and RFLPs cannot type at 
the same level of definition so that is possible to obtain 
an exact match between transplant donor and recipient for 
HLA-DP alleles. This has implications for tissue 
transplants from unrelated donors, where it has been shown 
HLA-DP disparity is associated with tissue rejection of 
otherwise haploidentical grafts (Odum et al 1987)
PLT and serology require live, intact cells for typing 
which restrict these techniques to a clinical laboratory. 
RFLP analysis is DNA based so that DNA or blood samples can 
be obtained from anywhere in the world, and stored for long 
periods of time if necessary. PCR-based methods offer the 
same advantages of mobility, but they have the added 
advantage of requiring only small quantities of DNA. This 
means non invasive methods of sample collection can be 
employed, for example, the ability to amplify DNA obtained 
from as little as a single hair root (Higuchi et al 1988) 
has meant samples can be obtained from very remote 
locations, with little or no sample preparation required 
prior to PCR amplification. This feature has benefited 
genetic reconstruction of prehistory in anthropological 
studies as well as forensic and clinical disciplines.
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In summary, the AFLP technique may be widely used in 
laboratories anxious to avoid radioactive and recombinant 
DNA techniques, and where to low or moderate turnover of 
samples does not justify the large-scale production of 
SSOs. Further, the AFLP technique, originally developed by 
Maeda et al 1989, with respect to DQA1 typing, has 
widespread applicability to almost any polymorphic locus. 
This has been amply demonstrated in this analysis of HLA- 
DPB1 allelic variation.
195
Appendix 1.
Expected fragment patterns obtained by digestion of homozygote and 
heterozygote combinations of 19 DPBl alleles with the four enzymes 
in the AFLP scheme, ordered in descending fragment sizes.
RESTRICTION FRAGMENTS (bp)
Mnl I Fok IRsa I Eco NI
DPBl
genotype
*0401:*1501
*0401:*1101
*0101:*1501
*1301:*1501
*1101:*1301
* 0101:*1101
*0402:*1501
*1501:*1801
*0402:*1101
*1101:*1801
*0201:*1501
*0202:*1501
* 0201:*1101
* 0202:*1101
*1401:*1501
*0301:*1501
*0901:*1501
*1501:*1701
*0601:*1501
*0801:*1501
*1501:*1601
*1001:*1501
*0501:*1501
196
Appendix 1 continued.
Mnl I
DPBl
genotype
*1501:*1901 
*0901: *1101 
*1101: *1701 
*0601:*1101 
*0801: *1101 
*1101: *1601 
*1001: *1101 
*1401: *1101 
*0301 : *1101 
*1101: *1901 
*0501 : *1101 
*1101: *1501 
*1501 : *1501 
*1101: *1101 
*0201 : *0401 
*0202:*0401 
*0401 : *1401 
*0301 : *0401 
*0101:*0402 
*0101:*1801 
*0401:*0901 
*0401: *1701 
*0401:*0601 
*0401 : *1301 
*0401 : *1001 
*0401:*0801 
*0401:*1601 
*1301: *1801
1 1  . 3 2 1 1 1
7 0 7 7 7 7 6 6 5  5 . 1 6 9 4 1 7  
8 2 6 6 3 1 9 6 4  1.2 0 9 7 3 8
RESTRICTION FRAGMENTS (bp)
Rsa I . Eco NI . Fok I
3 2 2 1  . 3 2 2 1
1 6 2  7 8 8.1 6 0 0 5
2 03/64 9 6.2 4 5 7 9
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Appendix 1 continued.
Mnl I
DPBl
genotype
1 1
RESTRICTION FRAGMENTS (bp) 
Rsa I . Eco NI
0 7 7 7 7 6 6 5 5
2 6 6 3 1 9 6 4 1
3 2 1 1 1
1 6 9 4 1 7
2 0 9 7 3 8
3 2 2 1
1 6 2 7 8 8
2 03/64 9 6
Fok I
3 2 2 1
1 6 0 0 5
2 4 5 7 9
*0401:*1801 
*0401:*0402 
*0401:*0501 
*0401:*1901 
*0101:*0401 
*0401:*1301 
*0401:*0401
X X X  X
X X X  X
X X X  
X X
X X X
X X X
X X X
X X X
X X X
X X 
X X 
X
X
*0101:*0201 X X X X X
*0201:*1301 X X X X X
*0101:*0202 X X X X X
*0202:*1301 X X X X X
*0101:*1701 X X X X X X X X.X X X X X
*0101:*0901 X X X X X X X X X X X X X
*1301:*1401 X X X X X X X X X X
*0101:*0601 X X X X X X X X X X X
*1301:*0301 X X X X X X X X X X X
*0101:*1601 X X X X X X X X X X X X X
*0101:*0801 X X X X X X X X X X X X X
*0101:*1001 X X X X X X X X X X X
*0101:*1401 X X X X X X X
*0101:*0301 X X X X X X X
*1301:*1701 X X X X X X X X X X
*1301:*0901 X X X X X X X X X X
*1301:*0601 X X X X X X X ♦
*1301:*1601 X X X X X X X X X X X X
*1301:*0801 X X X X X X X• X X X X X
*1301:*1001 X X X X X X X X X •
1 9 8
A p p e n d i x  1 c o n t i n u e d .
Mnl  I
DPBl
g e n o t y p e
RESTRI CTI ON FRAGMENTS ( b p )
Rs a  I . E c o  NI  . Fo k  I
1 1
7 0 7 7 7 7 6 6 5 5  
8 2 6 6 3 1 9 6 4 1
3 2 1 1 1
1 6 9 4 1 7
2 0 9 7 3 8
3 2 2 1 
1 6_2  7 8 8
2 0 ' / 6 4 9 6
2 2 1 
6 0 0 5 
4 5 7 9
* 0 5 0 1 : * 1 3 0 1  
* 0 1 0 1 : * 1 9 0 1  
* 0 1 0 1 : * 0 5 0 1  
* 1 3 0 1 : * 1 9 0 1  
* 0 1 0 1 : * 1 3 0 1  
* 0 1 0 1 : * 0 1 0 1  
* 1 3 0 1 : * 1 3 0 1  
* 0 2 0 2 : * 1 8 0 1  
* 0 2 0 2 : * 0 4 0 2  
* 0 2 0 1 : * 1 8 0 1  
*0 2 0 1 : * 0 4 0 2  
* 0 5 0 1 : * 1 8 0 1  
* 0 5 0 1 : * 0 4 0 2  
* 1 9 0 1 : * 1 8 0 1  
* 1 9 0 1 : * 0 4 0 2  
* 1 4 0 1 : * 1 8 0 1  
* 1 4 0 1 : * 0 4 0 2  
*0 3 0 1 : * 1 8 0 1  
* 0 3 0 1 : * 0 4 0 2  
* 1 8 0 1 : * 0 9 0 1  
* 1 8 0 1 : * 1 7 0 1  
* 0 4 0 2 : * 0 9 0 1  
* 0 4 0 2 : * 1 7 0 1  
* 1 8 0 1 : * 0 6 0 1  
* 0 4 0 2 : * 0 6 0 1  
* 1 8 0 1 : * 1 0 0 1  
*1 8 0 1 : * 0 8 0 1  
* 1 8 0 1 : * 1 6 0 1
X X 
X X
X X 
X X 
X X 
X X 
X X
X X X
X X X
X X X
X X X
X X 
X X
X X 
X X
X X 
X X 
X X 
X X
X X 
X X 
X X 
X X 
X X 
X X 
X X 
X X 
X X
X X X
X X X
X X X
X X X
X X 
X X 
X X 
X
X
X X 
X X
X X X
X X X
X X 
X X
X X
X X
X X
X X
X X X  
X X
X X X  
X X
X X X  
X X
X X X  
X X
X X X  
X X
X X X X 
X X  X
X
X
X
X
X
X
X
X
X
X . X  X X X  X X
X . X  X X X  X X
X . X  X X  X X
X . X  X X  X X
X X X X 
X X  X
X X X  
X X X  . X 
X X X  X
X X X
X
X X X
X
X X X
X
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Appendix 1 continued.
DPBl
genotype
*0402:*1001 
*0402:*0801 
*0402: *1601 
*0402: *1801 
*0402:*0402 
*1801:*1801 
*0202:*1401 
*0202:*0301 
*0201:*0501 
*0202:*0901 
*0202:*1701 
*0202:*0601 
*0202:*1001 
*0202:*0801 
*0201:*1901 
*0202:*1601 
*0201 : *0202 
*0201:*1401 
*0201:*0301 
*0201 : *0901 
*0201:*1701 
*0201 : *0601 
*0201:*1001 
*0201 : *0801 
*0201:*1601 
*0201:*0201
Mnl I
1 1
7 0 7 7 7 7 6 6
8 2 6 6 3 1 9 6
RESTRICTION FRAGMENTS (bp)
Rsa I . Eco NI . Fok I
3 2 1 1 1
1 6 9 4 1 7
2 0 9 7 3 8
3 2 2 1
1 6 2 7 8 8
2 03/64 9 6
3 2 2 1
1 6 0 0 5
2 4 5 7 9
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Appendix 1 continued.
DPBl
genotype
*0202: *0501 
*0202:*1901 
*0202: *0202 
*0501:*0901 
*0501:*1701 
*0501:*0601 
*0301 : *1901 
*0501: *1001 
*0501:*0801 
*0501:*1601 
*1401 : *1901 
*0501:*1401 
*0501:*0301 
*1901:*1701 
*1901:*0901 
*1901 : *0601 
*1901: *1601 
*1901:*0801 
*1901:*1001 
*1401:*0601 
*0301:*0901 
*0301: *1701 
*1401:*0801 
*1401:*1601 
*1401:*1001 
*1401 : *0901 
*1401: *1701
RESTRICTION FRAGMENTS (bp)
Rsa I . Eco NI . Fok I
3 2 2 1
1 6 0 0 5
2 4 5 7 9
X X X  
X X
X X X  
X X
X X X  
X X
X X X
X
X X
X X 
X
X X 
X
X X 
X
201
Appendix 1 continued.
DPBl
genotype
*0301:*0801 
*0301:*1601 
*0301:*1001 
*0301:*0601 
*0301:*1401 
*1401:*1401 
*0301 :*03 01 
*0601:*0901 
*0601:*1701 
*0901:*1601 
*0801:*1701 
*0801:*0901 
*1601:*1701 
*1001:*1701 
*0901:*1001 
*0901:*1701 
*0901:*0901 
*1701:*1701 
*0601:*0801 
*0601:*1601 
*0601:*1001 
*0601:*0601 
*1001:*1601 
*0801:*1001 
*1001:*1001 
*0801:*1601 
*0801:*0801 
*1601:*1601
Mnl I
1 1
7 0 7 7 7 7
8 2 6 6 3 1
RESTRICTION FRAGMENTS (bp)
Rsa I . ECO NI
3 2 1 1 1  . 3 2 2 1
1 6 9 4 1 7.1 6 2  7 8 8
Fok I
202
Appendix 1 continued.
DPBl
genotype
RESTRICTION FRAGMENTS (bp)
Rsa I . Eco NI . Fok I
203
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